US20020062146A1 - Methods and apparatus for transmyocardial direct coronary revascularization - Google Patents

Methods and apparatus for transmyocardial direct coronary revascularization Download PDF

Info

Publication number
US20020062146A1
US20020062146A1 US09/994,222 US99422201A US2002062146A1 US 20020062146 A1 US20020062146 A1 US 20020062146A1 US 99422201 A US99422201 A US 99422201A US 2002062146 A1 US2002062146 A1 US 2002062146A1
Authority
US
United States
Prior art keywords
passageway
coronary
transmyocardial
blood
vein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/994,222
Inventor
Joshua Makower
J. Flaherty
Timothy Machold
Jason Whitt
Margaret Tumas
Theodore Lamson
Marc Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Vascular Inc
Original Assignee
Joshua Makower
Flaherty J. Christopher
Machold Timothy R.
Whitt Jason Brian
Tumas Margaret W.
Lamson Theodore C.
Marc Jensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/730,496 external-priority patent/US5830222A/en
Priority claimed from US08/730,327 external-priority patent/US6190353B1/en
Application filed by Joshua Makower, Flaherty J. Christopher, Machold Timothy R., Whitt Jason Brian, Tumas Margaret W., Lamson Theodore C., Marc Jensen filed Critical Joshua Makower
Priority to US09/994,222 priority Critical patent/US20020062146A1/en
Priority to US10/150,306 priority patent/US6929009B2/en
Publication of US20020062146A1 publication Critical patent/US20020062146A1/en
Assigned to MEDTRONIC VASCULAR, INC. reassignment MEDTRONIC VASCULAR, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TRANSVASCULAR, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/11Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/1204Type of occlusion temporary occlusion
    • A61B17/12045Type of occlusion temporary occlusion double occlusion, e.g. during anastomosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136Balloons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • A61B17/12172Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34Trocars; Puncturing needles
    • A61B17/3417Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2421Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with non-pivoting rigid closure members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2493Transmyocardial revascularisation [TMR] devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/94Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00491Surgical glue applicators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/064Surgical staples, i.e. penetrating the tissue
    • A61B17/0643Surgical staples, i.e. penetrating the tissue with separate closing member, e.g. for interlocking with staple
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1477Needle-like probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1492Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • A61B2017/00247Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • A61B2017/00247Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • A61B2017/00252Making holes in the wall of the heart, e.g. laser Myocardial revascularization for by-pass connections, i.e. connections from heart chamber to blood vessel or from blood vessel to blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00491Surgical glue applicators
    • A61B2017/00504Tissue welding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/11Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
    • A61B2017/1107Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis for blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/11Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
    • A61B2017/1135End-to-side connections, e.g. T- or Y-connections
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/11Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
    • A61B2017/1139Side-to-side connections, e.g. shunt or X-connections
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/12127Double occlusion, e.g. for creating blood-free anastomosis site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/30Surgical pincettes without pivotal connections
    • A61B2017/306Surgical pincettes without pivotal connections holding by means of suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34Trocars; Puncturing needles
    • A61B2017/347Locking means, e.g. for locking instrument in cannula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345Vascular system
    • A61B2018/00351Heart
    • A61B2018/00392Transmyocardial revascularisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B2018/1405Electrodes having a specific shape
    • A61B2018/1425Needle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/40Apparatus fixed or close to patients specially adapted for providing an aseptic surgical environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418Scaffolds therefor, e.g. support stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2475Venous valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30079Properties of materials and coating materials magnetic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/009Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof magnetic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008Fixation appliances for connecting prostheses to the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0074Dynamic characteristics of the catheter tip, e.g. openable, closable, expandable or deformable
    • A61M25/0075Valve means
    • A61M2025/0076Unidirectional valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/1052Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22Valves or arrangement of valves
    • A61M39/24Check- or non-return valves

Definitions

  • the present invention pertains generally to medical treatment methods and devices, and more particularly to methods and devices for transluminal direct coronary revascularization.
  • Coronary artery disease continues to be one of the leading causes of morbidity and mortality, throughout the world.
  • the typical etiology of coronary artery disease is characterized by the build-up of atherosclerotic plaque within the coronary arteries. Such deposits of atherosclerotic plaque tend to fully or partially block the flow of blood through the affected coronary arteries, and if untreated can result in myocardial ischemia, infarction and death.
  • balloon angioplasty One alternative to traditional coronary artery bypass surgery is balloon angioplasty.
  • a flexible guide catheter is percutaneously inserted into a peripheral artery (e.g., the femoral artery) and is transluminally advanced through the vasculature until the distal tip of the catheter is within an obstructed coronary artery.
  • a balloon catheter is passed through the guide catheter and into the obstructive lesion.
  • the balloon of the balloon catheter is inflated one or more times to dilate coronary artery in the region of the obstructive lesion.
  • restenosis has generally been attributed to either a) an increase in the mass of the artery wall (e.g., neointima formation), b) a thickening of the artery wall without substantial change in it's mass (e.g., vascular remodeling) and/or c) radial contraction of the balloon-dilated artery wall upon healing of cracks and fissures that have been created by the balloon dilation process.
  • an increase in the mass of the artery wall e.g., neointima formation
  • a thickening of the artery wall without substantial change in it's mass e.g., vascular remodeling
  • c radial contraction of the balloon-dilated artery wall upon healing of cracks and fissures that have been created by the balloon dilation process.
  • transluminal atherectomy or ablation of the obstructive matter within the coronary artery Another alternative to traditional coronary artery bypass surgery is transluminal atherectomy or ablation of the obstructive matter within the coronary artery. These transluminal atherectomy or ablation procedures are performed by passing a catheter-mounted ablation apparatus through the vasculature to the site of the coronary obstruction. the catheter-mounted ablative apparatus is then utilized to cut, shave, sonicate, pulverize or otherwise ablate the obstructive matter from the lumen of the coronary artery. These atherectomy or ablative procedures must be performed with caution to avoid abrasion or damage to the artery wall, as such abrasion or damage can result in excessive scaring and subsequent reclusion of the artery lumen.
  • Atherectomy or ablative procedures may, in some cases at least, be confounded by the need to meticulously contain and remove the severed fragments of obstructive matter in order to prevent such fragments of obstructive matter from escaping into the patient's circulatory system.
  • Examples of such atherectomy catheters and other catheter-mounted ablative apparatus are described in U.S. Pat. No. 3,433,226 (Boyd), U.S. Pat. No. 3,823,717 (Pohlman, et al.), U.S. Pat. No. 4,808,153 (Parisi), U.S. Pat. No. 4,936,281 (Stasz), U.S. Pat. No.
  • TMR transmyocardial revascularization
  • a tissue-boring device such as a laser
  • TMDCR Transmyocardial Direct Coronary Revascularization
  • a stent or valving apparatus is required to be positioned within the transmyocardial passageway to perform a one-way valving function (i.e., to open and close the transmyocardial passageway in accordance with changes in the systolic-diastolic cardiac cycle).
  • TMDCR methods previously described in U.S. Pat. No. 5 , 287 , 861 (Wilk), U.S. Pat. No. 5,409,019 (Wilk) and U.S. Pat. No. 5,429,114 (Wilk), may be difficult or impossible to perform in patients who suffer from total or near total obstructions of a coronary artery, because of the necessary for advancing the catheter through the coronary artery obstruction to accomplish creation of the transmyocardial passageway at a location which is downstream of the coronary obstruction.
  • any stent which is positioned solely within the transmyocardial passageway may be subject to repetitive flexing and/or stressing as the myocardium undergoes its normal contraction and relaxation. Such repeated flexing and/or stressing of the intramyocardial stent may lead to unwanted migration, dislodgement or damage of the stent.
  • ICSO intermittent coronary sinus occlusion
  • the inflatable balloon is placed in the coronary sinus and is attached to a mechanical pump.
  • the mechanical pump operates to intermittently inflate and deflate the balloon so as to intermittently occlude the coronary sinus.
  • Such intermittent inflation and deflation of the balloon may be linked to the coronary sinus pressure so as to optimize the retroperfusion of the ischemic myocardium.
  • Specific ICSO procedures have been described in Belamy, R. F: (et al.) Effect of Coronary Sinus Occlusion on Coronary Pressure - Flow Relations , Am. J. Physiol.
  • the coronary sinus balloon is typically mounted on a percutaneously inserted catheter and is connected to an extracorporeally located pumping system
  • the clinical usefulness of these ICSO procedures is presently limited to temporary applications intended to minimize heart muscle damage following infarction or during acute periods of myocardial ischemia.
  • the general concept of these ICSO procedures could be applicable for the long-term treatment of chronic myocardial ischemia if a totally indwelling system could be devised which would eliminate the need for continued coronary sinus catheterization and/or the deployment of an extracorporeal pumping apparatus connected to such catheter.
  • the human circulatory system functions to send oxygenated blood from the aorta to the heart muscle (myocardium) via the left and right coronary arteries (small and large arteries).
  • the venous system returns the de-oxygenated blood via the epicardial veins (large and small veins).
  • a small fraction of the de-oxygenated blood returns through a set of small vessels which empty directly into the chambers of the heart called the Thebesian veins. Support exists in clinical literature that these Thebesian vessels can carry as much as 90 percent of the total coronary inflow back into the chambers of the heart.
  • Thebesian vessels connect to both the venous and arterial beds in an interface at the capillary level.
  • occluding the venous system e.g. blocking the coronary sinus or other large vein
  • ICSO pressure-controlled intermittent coronary sinus occlusion
  • EP0230996 European Patent Application No. EP0230996 to Mohl.
  • This PICSO procedure is typically performed in a hospital setting, during a coronary catheterization procedure.
  • This PICSO procedure has been shown to elevate the pressure in the venous bed, providing a therapeutic benefit.
  • angiogenesis a stimulation of the endothelial cells lining the internal walls of vessels to form new blood vessels, may be stimulated as a compensatory mechanism in response to the disruption of normal venous blood flow, thereby providing additional myocardial perfusion through newly created blood flow conduits.
  • the present invention provides new TMDCR methods, as well as certain valving devices which are usable in conjunction with these TMDCR methods.
  • a transmyocardial passageway is formed between a chamber of the heart (e.g., left ventricle) and a coronary vein.
  • blood may pass from the cardiac chamber, through the transmyocardial passageway, and into the coronary vein for the purpose of improving blood flow to the myocardium and/or to equalize or normalize pressures within the coronary venous vasculature by draining blood from the vein into the cardiac chamber.
  • the coronary vein of this embodiment may be situated next to an obstructed coronary artery, and one or more secondary blood flow passageways may be created between the coronary vein and the adjacent artery, at site(s) which is/are downstream of the coronary artery obstruction.
  • the lumen(s) of the coronary vein and/or adjacent coronary artery may be blocked or embolized at appropriate positions to facilitate the flow of blood in the desired direction (s) through the man-made blood flow passageway (s), the coronary vein and/or the coronary artery.
  • one or more valving apparatus may be positioned within the coronary vein and/or within the cardiac chamber, to control or intermittently block the flow of blood through the transmyocardial passageway.
  • TMDCR procedures wherein a transmyocardial passageway-forming catheter is initially advanced into a coronary vein which lies adjacent to an obstructed coronary artery.
  • the passageway forming catheter is advanced through the coronary vein until the distal end of the catheter is adjacent a location on the coronary artery which is downstream of the coronary artery obstruction.
  • the passageway-forming catheter is utilized to form an arterio-venous passageway which extends from the coronary vein wherein the catheter is located into the coronary artery, at a site downstream of the obstruction.
  • the passageway-forming catheter is advanced through the arterio-venous passageway and into the coronary artery.
  • the passageway- forming catheter is then oriented such that the tissue- penetrating element of the catheter will pass out of the catheter, through the wall of the artery and into a chamber of the heart (e.g., left ventricle). Thereafter, the tissue-penetrating catheter is removed and the arterio-venous passageway, which had been initially formed to allow the passageway-forming catheter to enter the coronary artery downstream of the obstruction, is closed by way of an occlusion apparatus, sutures, cautery, adhesive, or any other suitable tissue closure method or apparatus.
  • a transmyocardial passageway is formed between a chamber of the heart (e.g., left ventricle) and an obstructed coronary artery, at a site downstream of the coronary artery obstruction, without the need for advancing any guidewire, catheter or other apparatus through the obstruction located within the coronary artery.
  • a chamber of the heart e.g., left ventricle
  • an obstructed coronary artery at a site downstream of the coronary artery obstruction
  • the temporary arteriovenous fistula created in this procedure may also be used for other purposes, such as to perform an atherectomy within the lumen of the occluded vessel, or to place a guidance/aiming apparatus (e.g., a target or signal-emitting apparatus) within the lumen of the occluded artery downstream of the obstruction to facilitate formation of a transmyocardial or interstitial passageway into the occluded blood vessel, downstream of the obstruction.
  • a guidance/aiming apparatus e.g., a target or signal-emitting apparatus
  • This aspect of the invention will be particularly useful in patients in whom the obstruction is sufficiently complete as to prevent a catheter from being passed through the obstruction, but in whom it is desirable to catheterize the distal portion of the occluded blood vessel downstream of the obstruction to accomplish a therapeutic procedure (e.g., atherectomy, ablation of the occlusive matter, placement of a target, etc.)
  • a therapeutic procedure e.g., atherectomy, ablation of the occlusive matter, placement of a target, etc.
  • a temporary arterio-venous fistula of the above-described type may be utilized to facilitate the performance of other therapeutic or interventional procedures within the lumen of a blood vessel, downstream of an occlusion.
  • This aspect of the invention will be particularly applicable in patients who have total or near total occlusions of an artery, and in whom it would be difficult or impossible to advance a catheter through the total or near total occlusion.
  • the types of interventional or therapeutic procedures which may be performed through the temporary arterio-venous fistula include, but ar not necessarily limited to, balloon angioplasty, atherectomy, stenting, thrombolysis, full or partial ablation or removal of occlusive matter, or installation of an apparatus (e.g., a signal-emitting target) into the lumen of the blood vessel, downstream of the obstruction.
  • an apparatus e.g., a signal-emitting target
  • This aspect of the invention may be particularly useful in patients who have previously undergone coronary artery bypass surgery such that a bypass graft is anastomosis to a coronary artery, downstream of a total or near total obstruction. In those patients, it is not unusual for a secondary obstruction to form immediately downstream of the anastomosis of the bypass graft.
  • the temporary arterio-venous fistula of the present invention may be used to permit an interventional apparatus (e.g., balloon angioplasty catheter, thrombolysis catheter, atherectomy catheter, ablation catheter, stent-delivery catheter, etc.) into the lumen of the coronary artery, downstream of the obstruction, to treat the secondary obstruction which has formed adjacent the anastomosis.
  • an interventional apparatus e.g., balloon angioplasty catheter, thrombolysis catheter, atherectomy catheter, ablation catheter, stent-delivery catheter, etc.
  • the temporary arterio-venous fistula may be closed by the above-described procedure, thereby restoring pathency to the segment of the artery downstream of the bypass graft anastomosis.
  • an unstented transmyocardial passageway e.g., a puncture tract, bore, tunnel, or other passageway
  • a chamber of the heart e.g., the left ventricle
  • a coronary vessel e.g., a) an endogenous coronary artery; b) an endogenous coronary vein; c) a man-made passageway which has been formed in the heart, and which leads to an endogenous coronary vein; d) a man-made passageway which has been formed in the heart, and which leads to an endogenous coronary artery; and/or e) a man-made passageway which has been formed in the heart between an endogenous coronary artery and an endogenous coronary vein).
  • a coronary vessel e.g., a) an endogenous coronary artery; b) an endogenous coronary vein; c) a man-made passageway which has been formed in the heart, and which leads to an endogenous coronary vein; d)
  • the unstented transmyocardial passageway(s) created in accordance with this embodiment of the invention may be utilized to improve perfusion of the myocardium by shunting blood from the chamber of the heart (e.g., left ventricle) into the coronary vessel (e.g., vein artery or man-made passageway), or may alternatively be utilized to equalize or normalize flow or pressure within the cardiac vasculature by draining blood from one or more cardiac vessels (e.g., vein, artery or man-made passageway), into the chamber of the heart.
  • the coronary vessel e.g., vein artery or man-made passageway
  • intraluminal valving apparatus which may be positioned within the lumen(s) of the coronary blood vessel(s) (i.e., artery, vein or man-made passageway) which intersect with the transmyocardial passageway, to intermittently block bloodflow, in at least one direction, through the transmyocardial passageway.
  • coronary blood vessel(s) i.e., artery, vein or man-made passageway
  • These intraluminal valving devices generally comprise tubular bodies having at least one occluder member positioned therein, said occluder member(s) being alternately moveable between i) open position(s) whereby bloodflow is permitted to pass through the transmyocardial bloodflow passageway in a desired direction, and ii) closed position(s) whereby blood is prevented from flowing through the transmyocardial bloodflow passageway, in an undesired direction.
  • the present invention also includes endogenous tissue valve(s) which are formed in the transmyocardial passageway to perform a desired one-way valving function whereby blood is permitted to flow through the transmyocardial bloodflow passageway in a first direction, but is prevented from backflowing or regurgitating in a second direction.
  • intracardiac valving devices which are mountable within a chamber of the heart (e.g., left ventricle) immediately adjacent to an opening into a transmyocardial passageway which extends from the cardiac chamber to a coronary vessel (e.g., artery, vein or man-made passageway).
  • a coronary vessel e.g., artery, vein or man-made passageway.
  • Such intracardiac valving device may be constructed such that it will open in response to hemodynamic pressure generated during systole and/or in response to mechanical contraction (i.e., shortening and thickening) of the myocardium during systole. When open, the intracardiac valving device permits blood to flow through the transmyocardial bloodflow passageway.
  • the valving device may be constructed to close when diastolic pressures are present in the cardiac chamber or when the myocardium undergoes mechanical relaxation (i.e., lengthening and thinning during diastole. When closed, the valving device will prevent blood from backflowing or regurgitating from the transmyocardial bloodflow passageway, into the cardiac chamber.
  • stents and stented grafts which are positionable within the transmyocardial passageway, and which protrude into the adjacent coronary vessel (e.g., vein, artery or man-made passageway).
  • These protrusive stents and/or protrusive stented grafts may be self-expanding or pressure-expandable.
  • one or more valves or occluder members may be positioned within such protrusive stents and/or stented grafts to facilitate valving or directed movement of bloodflow in accordance with the diastolic/systolic cardiac cycle.
  • intravascular valving devices which are positionable within the coronary sinus, great cardiac vein or other areas of the coronary venous vasculature to control the back pressure within one or more coronary veins in a manner which will result in increased dwell time of the arterial blood within the capillary bed of the ischemic myocardium, and/or dilation of the capillary bed, thereby improving perfusion of the ischemic region(s) of the myocardium.
  • These intravascular valving devices may generally comprise a radially expandable cylindrical frame having one or more leaflets or other occluding members (e.g., ball-in-cage type check valve, etc.) which are specifically configured and constructed to prevent venous outflow until the pressure within the coronary sinus, great cardiac vein or other coronary vein exceeds a predetermined amount.
  • leaflets or other occluding members e.g., ball-in-cage type check valve, etc.
  • transmyocardial passageways may be formed between the coronary vein(s) and/or coronary artery(s) to provide additional blood flow into the coronary vasculature in conjunction with the increased back pressure created by this intravascular valving apparatus.
  • these intravascular valving apparatus of the present invention may be implanted within the coronary sinus, great cardiac vein, or other coronary vein to regulate coronary venus pressure in conjunction with an interstitial arterio-venous passageway or passageway formed between a chamber of the heart and a coronary vein, in accordance with the procedures previously described in applicant's U.S. patent applications Ser. Nos. 08/730,327 and 08/730,496, filed on Oct. 11, 1996.
  • the tissue penetrating member will reside when varying lengths of said tissue penetrating member have been advanced out of the catheter, said imaging means being thereby useable to focus on a selected one of said distance indicia to optimally position the catheter to form the desired passageway.
  • these intravascular valving apparatus may incorporate one or more of the following additional features:
  • the valving apparatus may be pucturable or traversable so as to permit a catheter to be passed through the valving apparatus in the event that such catheter passage becomes necessary at a later time;
  • the valving apparatus may be removable such that it may be rescued and removed from the body in the event it is no longer necessary, or if removal becomes desirable for some other reason;
  • the valving apparatus may be provided with projections, hooks, material for tissue in growth, or other suitable anchoring apparatus to assist in holding the valving apparatus in its desired position within the venus lumen; and
  • the valving apparatus may be formed of radiologically imagable material, or may be provided with one or more radio dense or radio opaque markers to facilitate visualization of the valving apparatus by x-ray or fluoroscopy.
  • intravascular valving apparatus of the present invention are implantable within the coronary sinus, great cardiac vein or other coronary vein, and will remain indwelling so as to regulate back pressure within the system and/or to improve myocardial perfusion, on an ongoing basis, without the need for continued placement of a catheter-mounted counterpulsation balloon within the coronary sinus and/or deployment of any extracorporeal instrumentation, such as the extracorporeal pumping apparatus which has been traditionally required for intermittent inflation and deflation of the coronary sinus counterpulsation balloon.
  • FIG. 1 is a perspective view of a human heart showing the typical anatomical positioning of the coronary arteries and coronary veins of the left heart.
  • FIG. 1 a is a partial cut-away sectional view of a human heart wherein a transmyocardial passageway has been created between the left ventricle and a coronary vein, in accordance with the present invention.
  • FIG. 1 b is a partial longitudinal sectional view through an obstructed coronary artery and adjacent coronary vein, showing a transmyocardial passageway of the present invention, extending between the chamber of the left ventricle and the coronary vein.
  • FIG. 1 c is a partial longitudinal sectional view through an obstructed coronary artery and adjacent coronary vein, showing a transmyocardial passageway of the present invention extending between the chamber of the left ventricle to the coronary vein, and a secondary bloodflow passageway extending from the coronary vein to the adjacent coronary artery, downstream of the obstruction.
  • FIG. 1 d is a partial longitudinal sectional view through a portion of the myocardium of a human heart, adjacent the left ventricle, showing an alternative embodiment of the present invention wherein a transmyocardial bloodflow passageway extends from the chamber of the left ventricle to a secondary passageway which has been created between the obstructed coronary artery and the adjacent coronary vein.
  • FIG. 2 is a longitudinal sectional view showing a first embodiment of an intravascular valving apparatus of the present invention operatively positioned within a coronary blood vessel (artery, vein or man-made passageway).
  • a coronary blood vessel artery, vein or man-made passageway.
  • FIG. 2 a is a perspective view of the intravascular valving apparatus of FIG. 2.
  • FIG. 2 b is an elevational view of a variant of the intravascular valving apparatus shown in FIGS. 2 and 2 a , wherein a bloodflow blocking bulkhead is formed on the upstream end of the apparatus.
  • FIG. 3 is a longitudinal sectional view of a second embodiment of an intravascular valving apparatus of the present invention operatively positioned in a coronary blood vessel (artery, vein or man-made passageway).
  • a coronary blood vessel artery, vein or man-made passageway.
  • FIG. 3 a is longitudinal sectional view showing variant of the second intravascular valving apparatus embodiment shown in FIG. 3, wherein two (2) separate valving apparatus are respectively positioned upstream and downstream of the junction between the transmyocardial bloodflow passageway and the coronary blood vessel (artery, vein or man-made passageway).
  • FIG. 3 b is a longitudinal sectional view of another variant of the second intravascular valving apparatus embodiment shown in FIG. 3, wherein three (3) valves are incorporated within a single tubular body to accomplish valving of bloodflow through a transmyocardial bloodflow passageway and coronary blood vessel (artery, vein or man-made passageway).
  • FIG. 4 is a longitudinal sectional view showing a third embodiment of an intravascular valving apparatus of the present invention operatively positioned within a coronary blood vessel (artery, vein or man-made passageway).
  • a coronary blood vessel artery, vein or man-made passageway.
  • FIG. 5 is a longitudinal sectional view showing an intracardiac valving apparatus of the present invention along with an optional retainer assembly (dotted lines) useable to mount such intracardiac valving apparatus on the inner wall of the heart.
  • FIG. 5 a is a perspective view of the intracardiac valving apparatus of FIG. 4 having the optional retainer assembly affixed thereto.
  • FIGS. 6 a and 6 b are longitudinal sectional views of a human heart wherein a bloodflow passageway has been created between the left ventricle and a coronary blood vessel (artery, vein or man-made passageway), and a valving tissue valve has been created in the wall of the blood vessel, in accordance with the present invention.
  • a bloodflow passageway has been created between the left ventricle and a coronary blood vessel (artery, vein or man-made passageway)
  • a valving tissue valve has been created in the wall of the blood vessel, in accordance with the present invention.
  • FIGS. 7 a - 7 b are longitudinal sectional views of a human heart wherein a blood vessel passageway has been created between the left ventricle and a coronary blood vessel (artery, vein or man-made passageway), and wherein an elastic suture has been positioned, in accordance with the present invention.
  • FIG. 8 a is a longitudinal sectional view showing a protrusive stent apparatus of the present invention implanted within a transmyocardial passageway and extending into a coronary blood vessel (e.g., artery, vein or man-made passageway).
  • a coronary blood vessel e.g., artery, vein or man-made passageway.
  • FIG. 8 b is a longitudinal sectional view showing an alternative embodiment of the protrusive stent apparatus shown in FIG. 5 a.
  • FIG. 8 c is a longitudinal sectional view showing another alternative embodiment of the protrusive stent apparatus shown in FIG. 5 a , having an optional tubular covering and/or optional valve(s) incorporated therein.
  • FIG. 9 is a partial sectional view of a portion of a mammalian heart wherein an intravascular valving apparatus has been positioned within a coronary vein to provide pressure-controlled intermittent coronary venous occlusion for enhanced coronary retroperfusion.
  • FIG. 9 a is a perspective view of the intravascular valving apparatus shown in FIG. 9.
  • FIG. 9 b is a graph of coronary venous pressure vs. time in a coronary vein having an intravascular valving apparatus of the present invention implanted therein.
  • FIG. 9 c is a draft of coronary venous pressure vs. flow in a coronary vein having an intravascular valving apparatus of the present invention implanted therein.
  • FIG. 10 is a partial longitudinal section view through a portion of a mammalian heart showing a passageway-forming catheter device of the present invention being used to form a transmyocardial passageway from a chamber of the heart, into a coronary blood vessel.
  • FIG. 11 a is a partial section view through a portion of a mammalian heart showing the first stage of a transluminal coronary revascularization procedure wherein a temporary arterio-venous fistula is used to pass a passageway forming catheter into an obstructed coronary artery, downstream of the obstruction.
  • FIG. 11 b is a longitudinal sectional view of a portion of a mammalian heart following completion of the procedure shown in FIG. 11 a.
  • FIG. 12 a is a shematic diagram of the flow of blood through the coronary vasculature without full or partial blocking of venous return in accordance with the present invention.
  • FIG. 12 b is a shematic diagram of the flow of blood through the coronary vasculature with full or partial blocking of venous return in accordance with the present invention.
  • FIG. 13 a is an elevational view of one embodiment of a coronay vein blocking device of the present invention having an optional end cap (dotted lines) disposed on the closed end thereof.
  • FIG. 13 b is a cross sectional view through line 13 b - 13 b of FIG. 13 a.
  • FIG. 13 c is an elevational view of the membrane covering and optional end cap (dotted lines) of the blocker device of FIG. 13 a.
  • FIG. 13 d is an elevational view of the radially expandable wire frame of the blocker device of FIG. 13 a.
  • FIGS. 14 a - 14 c are shematic, staged showings of the operation of a full-occlusion pressure'delay valve of the present invention which utilizes an annular balloon filled w/ viscous fluid as the occluder member.
  • FIGS. 14 a ′- 14 b ′ are shematic, staged showings of the operation of a partial-occlusion pressure delay valve of the present invention which utilizes an annular balloon filled w/ viscous fluid as the occluder member.
  • FIG. 15 is a shematic diagram of an implantable magnetic delay valve of the present invention in its closed position.
  • FIG. 16 is a shematic diagram of an implantable oxygen sensor delay valve of the present invention.
  • FIG. 16 a is a cross sectional view through line 16 a - 16 a of FIG. 16.
  • FIG. 17 is a graph of valve position vs. capillary pressure for any of the time delayed venous occlusion valves of the present invention.
  • FIG. 18 a is a schematic showing of a full-occlusion pressure delay valve of the present invention in its closed position.
  • FIG. 18 b is a schematic showing of a full-occlusion pressure delay valve of the present invention in its open position.
  • FIG. 19 a is a schematic showing of a partial-occlusion pressure delay valve of the present invention in its closed position.
  • FIG. 19 b is a schematic showing of a partial-occlusion pressure delay valve of the present invention in its open position.
  • the present invention includes methods for improving perfusion of regions of the myocardium M which are ischemic or otherwise affected by the existence of an obstruction OB within a coronary artery CA, by forming a transmyocardial passageway 10 which extends from a chamber of the heart, (e.g., left ventricle LV), to a coronary vein CV.
  • a transmyocardial passageway 10 which extends from a chamber of the heart, (e.g., left ventricle LV), to a coronary vein CV.
  • the transmyocardial passageway 10 will simply provide a flow of blood from the chamber of the heart and into the coronary vein CV, such that the blood will pass in retrograde fashion through the coronary vein CV to perfuse the ischemic portion of the myocardium through the coronary vein, as sheen in FIG. 1 b.
  • a secondary bloodflow passageway 12 may be created between the coronary vein CV into which the transmyocardial passageway 10 extends and the obstructed coronary artery CA, at a location which is downstream of the obstruction OB, as shown in FIG. 1 c .
  • the formation of this secondary bloodflow passageway 12 allows blood from the chamber of the heart (e.g., the left ventricle LV) to initially flow through the transmyocardial passageway 10 , through a segment of the coronary vein lumen CVL, through the secondary bloodflow passageway 12 , and into the coronary artery lumen CAL, at a location downstream of the coronary artery obstruction OB, as shown in FIG. 2 b .
  • the secondary bloodflow passageway 12 which extends between the coronary vein CV and the coronary artery CA may optionally be stented or internally supported by a stent, sleeve or coating (e.g., a polymer coating) to maintain patency of the secondary passageway 12 .
  • a stent, sleeve or coating e.g., a polymer coating
  • the coronary vein lumen CVL may be purposely blocked (e.g., ligated, embolized, fused, welded, clamped, etc.) at site(s) upstream and/or downstream of the transmyocardial passageway 10 .
  • a proximal embolization member 14 a may be positioned within the coronary vein lumen CVL, immediately upstream of transmyocardial passageway 10 , to ensure that the shunted blood will flow, in the desired retrograde direction through the coronary vein CV.
  • FIG. 1 b when the transmyocardial passageway 10 formed for the purpose of shunting oxygenated blood into the coronary vein lumen CVL, a proximal embolization member 14 a may be positioned within the coronary vein lumen CVL, immediately upstream of transmyocardial passageway 10 , to ensure that the shunted blood will flow, in the desired retrograde direction through the coronary vein CV.
  • FIG. 1 b when the transmyocardial passageway 10
  • a distal embolization member 14 b may be positioned within the coronary vein lumen CVL immediately downstream of the secondary bloodflow passageway 12 , to divert the flow of blood through the secondary bloodflow passageway 12 .
  • the proximal embolization member 14 a and/or distal 14 b embolization member may comprise any suitable type of lumen blocking matter or apparatus, examples of which are the embolization coils described in U.S. Pat. No. 5,382,260 (Dormandy, Jr. et al.), U.S. Pat. No. 5,108,407 (Geremia et al.), and U.S. Pat. No. 5,256,146 (Ensminger, et al.).
  • the coronary vein lumen CVL may be closed off at the sites of the proximal 14a and/or distal 14b embolization members by any suitable alternative means, such as clamping, clipping, ligating, fusing, welding or adhesively conjoining the inner walls of the coronary vein lumen CVL so as to provide the desired blocking of bloodflow therethrough.
  • FIG. 1 d shows an alternative embodiment of the method of the present invention wherein a secondary bloodflow passageway 12 of the above-described type has been created between the coronary vein CV and coronary artery CA, and wherein the transmyocardial bloodflow passageway 10 a extends from the chamber of the heart (e.g., left ventricle) such secondary bloodflow passageway 12 .
  • FIGS. 11 a - 11 b show an alternative TMDCR procedure of the present invention wherein a passageway-forming catheter 100 is initially advanced into a coronary vein CV which is situated adjacent a coronary artery CA in which an obstruction OB is present.
  • the passageway forming catheter 100 When the distal end of the passageway-forming catheter 100 has been advanced to a location which is adjacent the segment of the coronary artery CA downstream of the obstruction OB, the passageway forming catheter 100 is oriented appropriately and a tissue-penetrating element 102 is passed out of the catheter 100 , through the wall of the coronary vein, through any tissue located between the coronary vein CV and coronary artery CA, through the wall of the coronary artery CA and into the lumen of the coronary artery CA at a site downstream of the obstruction OB. In this manner, an arterio-venous passageway 104 is formed between the coronary vein CV and coronary artery CA.
  • tissue-penetrating member 102 After the distal end of the tissue-penetrating member 102 is advanced into the lumen of the coronary artery, a guidewire 104 is advanced through a lumen formed in the tissue-penetrating element 102 such that the guidewire enters the lumen of the coronary artery CA. Thereafter, the tissue-penetrating element 102 may be retracted into the catheter 100 , and the catheter 100 may be further advanced over the guidewire 104 such that the distal portion of the catheter will pass through the arterio-venous passageway 104 and into the lumen of the coronary artery.
  • the guidewire 104 is once again retracted into the tissue-penetrating element 102 and the catheter 100 is rotationally reoriented, as necessary, to direct the tissue-penetrating element 102 toward the left ventricle LF.
  • the tissue- penetrating element 102 is advanced from the catheter 100 , through the wall of the coronary artery CA, through the myocardium M and into the left ventricle LV. This results in the formation of a transmyocardial passageway 10 in accordance with the present invention.
  • the guidewire 104 may then be once again passed through the lumen of the tissue-penetrating element 102 and into the left ventricle LV such that the tissue-penetrating element 102 may be retracted into the catheter 102 while the guidewire 104 remains extended through the transmyocardial passageway 10 and into the left ventricle LV.
  • the guidewire 104 may be used to guide the advancement of one or more passageway-modifying devices, and/or the placement of an internal sleeve, stent, valve or other apparatus within the transmyocardial passageway 10 as known in the prior art, described herein, or described in applicant's earlier filed U.S. patent application Ser. Nos. 08/730,327 and 08/730,496 and the corresponding counterparts thereof filed internationally under the PCT.
  • the catheter 100 is extracted and removed from the body.
  • the arterio-venous passageway 104 is then closed off (i.e., sealed, fused, cauterized, blocked, occluded, plugged, or otherwise closed) thereby preventing subsequent passage of blood between the coronary vein CV and coronary artery CA. In this manner, as shown in FIG.
  • this procedure of the present invention results in the formation of a transmyocardial passageway 10 between the left ventricle LV and a coronary artery CA, such that blood may pass from the left ventricle LV, through the transmyocardial passageway 10 and into the lumen of the coronary artery CA, downstream of the obstruction OB.
  • the passage of the tissue-penetrating catheter 100 in the manner described hereabove and shown in FIG. 11 a eliminates any necessity for advancing the catheter through the obstruction, and avoids the potential dislodgement of portions or particles of the obstruction OB into the coronary circulation.
  • any type of cauterizing, fusing, suturing or blocking apparatus may be used to close off the arterio-venous passageway 104 , including at least some of the blocking devices described in applicant's above cited previously filed applications.
  • the temporary arterio-venous passageway 104 described hereabove in Section ii. May also be used for various other therapeutic or interventional procedures wherein it is desirable to gain access to the lumen of a blood vessel, downstream of an occlusion.
  • This temporary arterio-venous passageway 104 is particularly suitable for use in procedures wherein a total or near total occlusion is present in the blood vessel so as to render it difficult or impossible to pass a catheter through the occlusion.
  • the types of therapeutic or interventional procedures which may be performed through the temporary arterio-venous passageway 104 include, but are not necessarily limited to, balloon angioplasty, atherectomy, thrombolysis, placement of apparatus (e.g., a signal emitting target) within the lumen of the blood vessel downstream of the obstruction, or revascularization procedures such as the TMDCR procedure described hereabove.
  • apparatus e.g., a signal emitting target
  • This aspect of the invention may be particularly usable in patients who have previously undergone coronary artery bypass surgery, for bypassing of a total or near total occlusion.
  • new occlusions may occur at sites downstream of the anastomosis which connects the bypass graft to the occluded artery.
  • the present invention also includes alternative TMDCR methods wherein a transmyocardial passageway 10 is formed between a chamber of the heart and a coronary vessel (i.e., a) an endogenous coronary vein, b) an endogenous coronary artery, c) a man-made passageway in the heart which connects to an endogenous coronary vein; d) a man-made passageway in the heart which connects to an endogenous coronary or e) a man-made passageway which extends between an endogenous coronary artery and an endogenous coronary vein), and such transmyocardial passageway 10 is allowed to remain non-stented (e.g., devoid of any stent or internal support member positioned therewith).
  • a coronary vessel i.e., a) an endogenous coronary vein, b) an endogenous coronary artery, c) a man-made passageway in the heart which connects to an endogenous coronary vein; d) a man-
  • the non-stented transmyocardial passageway 10 of the present invention When the non-stented transmyocardial passageway 10 of the present invention is intended to provide bloodflow from the chamber of the heart (e.g., left ventricle) into the coronary vessel (e.g., vein, artery or man-made passageway), the non-stented transmyocardial passageway 10 must remain open during systolic contraction of the myocardium. If the non-stented passageway 10 is permitted to substantially occlude or close-off during systolic contraction of the myocardium, such could prevent or deter the desired blood flow from passing through the transmyocardial passageway 10 .
  • the coronary vessel e.g., vein, artery or man-made passageway
  • the passageway 10 it may be desirable to debulk, core or otherwise enlarge the diameter of the passageway 10 during it's formation so as ensure that the passageway 10 will remain patent and open, even during systolic contraction of the myocardium.
  • Such coring, debulking or other enlargement of the passageway 10 may be accomplished by any suitable means, including the use of a hollow coring needle, laser, electrosurgical probe, or other tissue removing/ablating device capable of debulking and removing tissue so as to create a transmyocardial passageway 10 of the desired diameter.
  • the non-stented transmyocardial passageway preferably should not fill-in with granulation tissue or otherwise close-off as a result of any scarring or healing process of the myocardium.
  • the coring, de-bulking or other enlargement of the non-stented passageway 10 and/or the continuing passage of blood, therethrough may be sufficient to prevent or deter such scarring or natural closing of the non-stented passageway 10 .
  • the transmyocardial passageway 10 , 10 a may function in it's intended manner without the inclusion of any valving apparatus, for intermittently blocking the flow of blood therethrough.
  • it may be desired to prevent the backflow of blood through the transmyocardial passageway 10 , 10 a during certain phase(s) of the cardiac cycle when the relative hemodynamic pressures would tend to cause such backflow.
  • the present invention includes intravascular valving apparatus 20 , 30 , 31 , 33 , 40 , examples of which are shown in FIGS. 2 - 4 .
  • These intravascular valving apparatus 20 , 20 , 31 , 33 , 40 are positionable within the lumen of the coronary blood vessel CBV (e.g., vein, artery or man-made passageway), and operate to prevent backflow of blood into the transmyocardial bloodflow passageway 10 , 10 a.
  • CBV coronary blood vessel
  • each of the intravascular valving apparatus 20 , 30 , 31 , 33 , 40 of the present invention comprise a radially expandable cylindrical or tubular body which is transluminally advanceable into the lumen of the coronary blood vessel CBV (e.g., artery, vein or man-made passageway), and which is then radially expandable so as to become implanted at a location which is adjacent or near to the intersection of that coronary vessel CBV with a transmyocardial bloodflow passageway 10 , 10 a .
  • CBV e.g., artery, vein or man-made passageway
  • the valving apparatus 20 , 30 , 31 , 33 , 40 has an axial bore 24 , 34 , 42 through which blood may pass as it flows through the lumen of the coronary blood vessel CBV or secondary passageway 12 in which the apparatus 20 , 30 , 31 , 33 , 40 is positioned.
  • One or more occluder members 26 , 36 , 46 are formed within the apparatus 20 , 30 , 31 , 33 , 40 .
  • Such occluder member(s) 26 , 36 , 46 are alternately moveable between a first (e.g., open) position whereby blood is permitted to flow from the transmyocardial bloodflow passageway into the coronary blood vessel CBV or secondary passageway 12 , and a second (e.g., closed) position whereby blood is prevented or deterred from backflowing or regurgitating from the coronary blood vessel CBV or secondary passageway 12 , into the transmyocardial bloodflow passageway.
  • each of the intravascular valving apparatus 20 , 30 , 31 , 33 , 40 of the present invention offer advantages over the intramyocardial stenting/valving apparatus described in U.S. Pat. No. 5,248,861 (Wilk), U.S. Pat. No. 5,409,019 (Wilk) and U.S. Pat. No.
  • 5,429,144 in that they are operatively situated entirely within the lumen of the coronary blood vessel CBV of secondary passageway 12 and do not extend into the transmyocardial passage way (e.g., the first passageway 10 , 10 a ) which emanates from the chamber (e.g., left ventricle) of the heart.
  • the valving apparatus 20 , 30 , 31 , 33 , 40 of the present invention do not require precise measurement or precise cutting-to-length, as is purportedly required of the intramyocardial stenting/valving apparatus described in U.S. Pat. No. 5,248,861 (Wilk), U.S. Pat. No. 5,409,019 (Wilk) and U.S. Pat. No. 5,429,144 (Wilk).
  • the valving apparatus 20 , 30 , 31 , 33 , 40 of the present invention be initially disposable in a first radially compact diameter which is small enough to be mounted upon or inserted into an intravascular delivery catheter.
  • intravascular delivery catheter having the valving apparatus 20 , 30 , 31 , 33 , 40 mounted thereon or therewithin, is transluminally passable through the vasculature and into the lumen of the coronary blood vessel CBV wherein the apparatus 20 , 30 , 31 , 33 , 40 is to be implanted.
  • the apparatus 20 , 30 , 31 , 33 , 40 is radially expanded (by self-expansion or pressure-expansion) to a second radially expanded diameter, wherein the outer surface of the apparatus 20 , 30 , 31 , 33 , 40 frictionally engages the surrounding wall of the coronary blood vessel CBV such that the apparatus 20 , 30 , 31 , 33 , 40 is thereby implanted and retained in a stationary position.
  • blood may flow through the axial bore 24 , 34 , 42 of the apparatus 20 , 30 , 31 , 33 , 40 , as described in more detail herebelow.
  • the valving apparatus 20 , 30 , 31 , 33 , 40 may be either self-expanding or pressure- expandable.
  • the cylindrical body of the apparatus 20 , 30 , 31 , 33 , 40 may be formed of a shape memory alloy or resilient material (e.g., spring metal) which is inherently biased to it's second radially expanded diameter.
  • the cylindrical body of the apparatus 20 , 30 , 31 , 33 , 40 may be formed of plastically deformable material which is initially formed it's first radially compact diameter, and which may be pressure deformed to it's second radially expanded diameter by the exertion of outward force from an internally positioned balloon or other radial expansion device.
  • the potential useability and applicability of the intravascular valving apparatus 20 , 30 , 31 , 33 , 40 , 50 described herebelow is not limited only to uses in connection with the improved TMDCR methods of the present invention, but may also be useable as a modification of the previously described TMDCR methods, such as those of U.S. Pat. No. 5,287,816(Wilk), U.S. Pat. No. 5,409,019(Wilk), and U.S. Pat. No. 5,429,144 (Wilk).
  • FIGS. 2, 2 a and 2 b show a first embodiment of an intravascular valving apparatus 20 which is positioned within the lumen of a coronary-blood vessel CBV (artery, vein or man-made passageway), at a location which is adjacent it's intersection with the transmyocardial passageway 10 .
  • This embodiment of the valving apparatus 20 has a cylindrical body having an axial bore 24 which extends longitudinally therethrough, and a side aperture 22 formed in the sidewall thereof.
  • the side aperture 22 is preferably the same size or larger than the diameter of the adjacent end of the transmyocardial passageway 10 , such that blood flowing from the cardiac chamber (e.g., left ventricle LV) through the transmyocardial passageway 10 will pass directly through the side aperture 22 and into the bore 24 of the valving apparatus 20 .
  • An occluder member 26 such as a hinged obturator or pliable elastomeric leaflet is affixed to the cylindrical body of the valving apparatus 20 , and extends over and substantially blocks the side aperture 22 so as to prevent the flow of blood out of the side aperture 22 .
  • the occluder member 26 is alternately moveable between a first position wherein it blocks blood from flowing out of the side aperture 22 , and a second position wherein it permits blood to flow into the bore 24 through the side aperture 22 .
  • This first embodiment of the valving apparatus 20 may be implanted in the lumen of the coronary blood vessel CBV such that the side aperture 22 is in alignment with the adjacent end of the bloodflow passageway 10 .
  • the relatively high pressure within the left ventricle will force the occluder member 26 to its second (open) position, allowing blood to flow from the left ventricle, through the transmyocardial passageway 10 , through the side aperture 22 , through the bore 24 and into the lumen of the coronary blood vessel CBV in the perfusive direction PD, as shown.
  • the relatively low filling pressure within the left ventricle LV will draw the occluder member 26 to its first (closed) position whereby the occluder member 26 will prevent blood from regurgitating or moving in the backflow direction BD from the lumen of the coronary blood vessel CBV, out of the side aperture 22 , and into the bloodflow passageway 10 .
  • the first embodiment of the valving apparatus 20 serves to facilitate efficient pumping of oxygenated blood from the left ventricle and into the lumen of the coronary blood vessel CBV, to improve the flow of oxygenated blood to an ischemic or blood-flow-deprived region of the myocardium M.
  • a closure member 21 in the nature of an end cap, may be formed on the upstream end of the apparatus 20 so as to completely or substantially block the flow of blood through the coronary blood vessel CBV and into the upstream end of the bore 24 of the apparatus 20 .
  • the optional inclusion of the end closure member 21 in the apparatus 20 may serve to obviate any need for the placement of a proximal embolization member 14 a within the lumen of the coronary blood vessel CBV, upstream of the valving apparatus 20 .
  • FIG. 3 shows a second embodiment of the intravascular valving apparatus 30 which comprises a generally cylindrical body having an axial bore 34 extending longitudinally therethrough and a pair of occluder members 46 positioned therewithin, and a side aperture 32 formed in the cylindrical sidewall of the apparatus 30 , behind the occluder members 36 .
  • Each occluder member 36 is affixed at least one point to the cylindrical body of the apparatus 30 , and may comprise any suitable structure or openable and closeable passage, such as a self-sealing slit or hole, or a hinged leaflet or pliable elastomeric member.
  • the occluder members 46 are alternately moveable between first positions wherein the occluder members 36 directly contact one another so as to prevent blood from backflowing in the backflow direction BD through the axial bore 34 of the apparatus 30 , and second positions wherein the occluder members 36 move out of contact with one another such that blood may flow through the axial bore 34 of the apparatus 30 in the perfusion direction PD.
  • the side aperture 32 is preferably as large as or larger than the diameter of the bloodflow passageway 10 which extends through the myocardium M from the left ventricle LV to the lumen of the coronary blood vessel CBV.
  • This embodiment of the apparatus 30 is implanted in the lumen of the coronary blood vessel CBV such that its side aperture 32 is directly aligned with the bloodflow passageway 10 so that blood may flow through the bloodflow passageway 10 , into the axial bore 34 of the apparatus 30 .
  • this second embodiment of the intravascular valving apparatus 30 serves to facilitate efficient pumping of oxygenated blood from the left ventricle LV and through the lumen of the coronary blood vessel CBV, in order to provide improved bloodflow to an ischemic or blood-flow-deprived region of the myocardium M.
  • secondary occluder members 38 may be formed or mounted within the bore 34 of the apparatus 30 , upstream of the side opening 32 .
  • These optional secondary occluder members 38 may be of the same type and construction as the above-described downstream occluder members 36 . If present, such additional occluder members 38 will assume their first (e.g., closed) position when the pressure of blood within the bore 34 of the apparatus 30 downstream of such secondary occluder members 38 is greater than the pressure of blood within the coronary blood vessel CBV upstream of the such secondary occluder member 38 .
  • the provision of such secondary occluder members 38 within the apparatus 30 will obviate the need for placement of a proximal occlusion apparatus 14 a within the lumen of the coronary blood vessel CBV upstream of the transmyocardial bloodflow passageway 10 .
  • the inclusion of such secondary occluder members 38 , or the alternative use of a proximal occlusion member 14 a will be of particular importance when the coronary blood vessel CBV is a coronary vein CV, due to the substantial difference between endogenous coronary venous blood pressures and those pressures which will be created by systolic arterial bloodflow through the coronary vein, downstream of the transmyocardial bloodflow passageway 10 .
  • FIG. 3 a shows one variant of the second embodiment wherein two (2) separate intravascular valving apparatus 31 a , 31 b are respectively positioned upstream and downstream of the transmyocardial bloodflow passageway.
  • the above-described occluder members 36 are formed in the apparatus 31 b which is positioned downstream of the transmyocardial bloodflow passageway 10 and the above-described secondary occluder members 38 are formed within the apparatus 31 a which is positioned upstream of the transmyocardial bloodflow passageway 10 .
  • these separate intravascular valving apparatus 31 a , 31 b will function in the same manner as the apparatus 30 shown in FIG. 3, when it is equipped with the optional secondary occluder members 38 .
  • these separate intravascular valving apparatus 31 a , 31 b do not have any side aperture 32 , as does the device shown in FIG. 3, and accordingly, will obviate any need for correctly sizing an aligning such side aperture 32 with the transmyocardial bloodflow passageway 10 .
  • FIG. 3 b shows another variant of the second embodiment wherein a single intravascular valving apparatus 33 , in the nature of a tubular stent or tubular body, is provided with three (3) separate valves 26 , 36 , 38 at locations which are a) at the junction of the transmyocardial passageway 10 and the coronary blood vessel CBV, b) upstream of the transmyocardial passageway 10 and c) downstream of the transmyocardial passageway 10 , respectively.
  • valves 26 , 36 , 38 may comprise self-sealing pliable slit openings, elastomeric leaflets, hinged occluder members or any other suitable type of structure or apparatus which will intermittently open and close, to permit bloodflow in the desired direction therethrough.
  • the first valve 26 will operate to open during systole to permit blood to flow from the transmyocardial passageway 10 into the coronary blood vessel CBV, but will close during diastole to prevent backflow or regurgitation into the cardiac chamber.
  • the second (upstream valve 38 will close during systole to prevent backflow of blood through the proximal end opening of the valving apparatus 33 .
  • the third (downstream) valve 36 will open during systole to permit the desired flow of blood entering through the transmyocardial passageway 10 , to continue on downstream through the coronary blood vessel CBV in the desired perfusion direction.
  • FIG. 4 shows a third embodiment of the intravascular valving apparatus 40 which comprises a generally cylindrical body having an axial bore 42 extending longitudinally therethrough and a plurality of occluder members 46 formed therewithin.
  • the cylindrical body and occluder members 46 of this third embodiment of the apparatus 40 are the same as those of the above described second embodiment, except that the cylindrical body of this third embodiment is devoid of any side aperture(s) or openings in the cylindrical sidewall.
  • this third embodiment of the apparatus 40 is implanted in the lumen of the coronary blood vessel CBV at a location which is downstream of the junction between the coronary blood vessel CBV and the first bloodflow passageway 10 .
  • valving apparatus 20 , 30 , 31 , 33 , 40 may be incorporated into any or all of the other above-described valving apparatus 20 , 30 , 31 , 33 , 40 as feasible, to accomplish the desired hemodynamic bloodflow within the coronary vasculature.
  • FIGS. 5 and 5 a show examples of intracardiac valving apparatus 80 which may be utilized to prevent backflow of blood through the transmyocardial passageway 10 , or to otherwise control the flow of blood through the transmyocardial passageway 10 in accordance with the systolic/diastolic cardiac cycle.
  • the intracardiac valving apparatus 80 is positionable within the cardiac chamber (e.g., left ventricle) immediately adjacent the opening of the transmyocardial passageway 10 thereinto.
  • the intracardiac valving apparatus 80 may comprise any suitable type of hinged, pliable or moveable occlusion member or self-sealing slit which will operate to intermittently block or unblock the flow of blood in at least one direction through the transmyocardial passageway 10 . In the embodiment shown in FIGS.
  • the intracardiac valving apparatus 80 comprises a generally annular body having a central aperture formed therein and an occluder member 81 , such as a pliable elastomeric flap, mounted within the aperture.
  • the occluder member 81 will move, in relation to hemodynamic bloodflow and/or contraction of the myocardium M, between an open position whereby blood is permitted to pass in at least one direction through the transmyocardial passageway 10 , and a closed position whereby blood is prevented from flowing in at least one direction through the transmyocardial passageway 10 .
  • the intracardiac valving apparatus 80 may be implanted within the cardiac chamber by any suitable surgical or non-surgical technique.
  • the intracardiac valving apparatus 80 is initially positioned within or upon a delivery catheter, and the delivery catheter is advanced through the coronary blood vessel CBV, and through the transmyocardial passageway 10 . Thereafter, the intracardiac valving apparatus 80 is released or ejected from the delivery catheter, and is caused to radially expand to it's operative configuration. the expanded valving apparatus 80 is then retracted into abutting contact with the myocardial wall, as shown.
  • the intracardiac valving apparatus 80 may be attached to the myocardial wall by any suitable attachment such as hooks, sutures, adhesives or a retaining assembly which is operative to hold the intracardiac valving apparatus 80 in its desired fixed position upon the myocardial wall.
  • a retaining apparatus shown in FIGS. 5 and 5 a , comprises an annular retaining ring 82 which is positionable within the coronary blood vessel CBV and a plurality of elastomeric tether members 84 which extend between the retainer ring 82 and the intracardiac valving apparatus 80 .
  • the elastomeric tethers 84 will resiliently draw the retaining ring 82 and intracardiac valving apparatus 80 toward one another, so as to hold the intracardiac valving apparatus 80 in fixed abutment with the myocardium M as shown.
  • the occluder member 81 will be designed to move in response to changes in hemodynamic pressure, such that when the hemodynamic pressure within the cardiac chamber (e.g., left ventricle) exceeds that within the transmyocardial passageway 10 , the occluder member 81 will move to it's open position, and when the pressure within the transmyocardial passageway 10 exceeds that within the cardiac chamber (e.g., left ventricle) the occluder member 81 will move to it's closed position.
  • the cardiac chamber e.g., left ventricle
  • the occluder member 81 may be designed to move in relation to contractile changes in the myocardial muscle.
  • the occluder member 81 will be mechanically linked or coupled to the body of the intracardiac valving apparatus 80 such that, when the myocardium undergoes contraction (e.g., shortening and thickening), the occluder member 81 will be propelled to it's open position, and when the myocardium undergoes relaxation (e.g., lengthening and narrowing) the occluder member 81 will move to it's closed position.
  • contraction e.g., shortening and thickening
  • relaxation e.g., lengthening and narrowing
  • the intracardiac valving apparatus 80 of the present invention serves to control the desired bloodflow through the transmyocardial passageway 10 , without the need for customizing or precise cutting-to- size of any intramyocardial stent, as has been described in the prior art.
  • FIGS. 6 a - 6 b show an endogenous tissue valve 50 which is formed at the junction of the transmyocardial bloodflow passageway 10 and a coronary blood vessel CBV (e.g., artery vein or man-made passageway).
  • CBV coronary blood vessel
  • the endogenous tissue valve 50 may comprise one or more segment(s) 54 of the wall of the coronary blood vessel CBV, along with one or more tapered segment(s) of underlying myocardial tissue 52 .
  • This endogenous tissue valve 50 is formed such that the segment(s) of blood vessel wall 54 and underlying portion(s) of myocardial tissue 52 will receive sufficient blood supply so as not to become necrotic or infarcted.
  • the thickness and mass of 'the tissue valve 50 is preferably defined so that, when the heart undergoes systolic contraction the elevated pressure created within the left ventricle LV and transmyocardial bloodflow passageway 10 will force the tissue valve 50 to an open position, as illustrated in FIG. 5 a , thereby creating an opening 56 through which blood may flow into the lumen of the coronary blood vessel CBV, in the profusion direction PD.
  • the tissue valve 50 will return to a second or closed position, as illustrated in FIG. 5 b .
  • the tissue valve 50 will substantially or completely close off the transmyocardial bloodflow passageway 10 , so as to prevent blood from backflowing or regurgitating in the backflow direction BD, from the lumen of the coronary blood vessel CBV into the transmyocardial bloodflow passageway 10 .
  • the tissue valve 50 may be created by any suitable means, including a procedure whereby the tissue penetrating, cutting or boring device used to create the transmyocardial bloodflow passageway is provided with a tapered distal end having a configuration analogous to that of the inner edge(s) 55 of the wall segment(s) 54 so as to form the desired tissue valve(s) or segment(s) when form the endogenous tissue valve 50 , or by another catheter-based device which is equipped to form such tissue valve(s) or segment(s).
  • tissue valve 50 may be formed in various configuration.
  • tissue valve 50 shown in FIGS. 6 a and 6 b hereof consists of a single flap
  • various alternative configurations may be utilized wherein multiple tissue protrusions, multiple tissue flaps, or angularly tapered or funnel shaped tissue flaps are formed to perform the desired valving function. Any and all such configurations of endogenous tissue are intended to be included within the scope of the term “tissue valve” 50 as used herein.
  • An alternative to the mechanical valving apparatus 20 , 30 , 31 , 33 , 40 or endogenous tissue valve 50 is the elastic closure member 60 , shown in FIG. 7 a and 7 b.
  • the elastic closure member 6 d may comprise one or more sutures formed of stretchable or elastic material such as latex or other elastomeric polymer materials. Such elastic closure member(s) 60 are preferably passed through adjacent portions of myocardial tissue next to the opening 66 between the transmyocardial bloodflow passageway 10 and the lumen of the coronary blood vessel CBV (or secondary bloodflow passageway 12 ).
  • the elastic closure member(s) 60 is the elastically biased to a retracted state whereby the closure member(s) 60 will draw the adjacent portions of myocardium M together so as to close off the opening 66 between the transmyocardial bloodflow passageway 10 and the lumen of the coronary bloodflow CBV, as shown in FIG. 7 b .
  • the relatively high pressures created within the left ventricle LV and transmyocardial bloodflow passageway 10 will cause the elastic closure member(s) 60 to stretch or expand, thereby forming opening 66 through which blood may flow from the transmyocardial bloodflow passageway 10 into the lumen of the coronary blood vessel CBV (or secondary bloodflow passageway 12 ) in the perfusion direction PD, as shown in FIG. 7 a.
  • the elastic closure member 60 may be installed in any suitable method, such as by way of an appropriate suturing or stapling device which operates to attach the elastic closure member 60 at its desired location.
  • Such installation of the elastic closure member 60 may be accomplished by open surgical technique or by way of catheter-based, transluminal methodology.
  • a catheter having a suturing or stapling device positioned therewithin may be advanced to a position adjacent the opening 66 .
  • negative pressure or other suitable drawings means may be utilized to draw adjacent segments of the myocardial tissue, from either side of the transmyocardial passageway 10 , into the catheter.
  • the desired elastic closure member 60 may be penetrated and threaded through the adjacent sides of the myocardial tissue so as to form the desired elastic closure member 60 , as shown.
  • protrusive stents or stented grafts may be positioned within the transmyocardial passageway 10 , and may extend into one or more adjacent coronary vessels including a) an endogenous coronary vein, b) an endogenous coronary artery, c) a man-made passageway in the heart which connects to an endogenous coronary vein, d) a man-made passageway in the heart which connects to an endogenous coronary artery and/or e) a man-made passageway which extends between an endogenous coronary vein and an endogenous coronary artery.
  • the protrusive stent apparatus 90 , 90 a , 90 b of the present invention may incorporate one or more valving apparatus to intermittently block or direct bloodflow in accordance with various stages of the systolic/diastolic cardiac cycle. Furthermore, such protrusive stent apparatus may optionally be covered or juxtapositioned to a tubular graft or sheath so as to form a discrete tubular passageway.
  • FIG. 8 a shows a non-valved, non-covered protrusive stent apparatus 90 of the present invention positioned partially within a transmyocardial passageway 10 , and extending into the coronary vessel Cv (e.g., artery, vein or man-made passageway) to which such transmyocardial passageway 10 extends.
  • the protrusive stent apparatus 90 is curved or bent at the junction of the transmyocardial passageway 10 and the coronary vessel CV, and preferably extends into the coronary vessel CV in the desired bloodflow direction.
  • the protrusive stent apparatus 90 may be formed of any suitable material, such as wire mesh or other metal or polymeric material, and may be self-expanding or pressure-expandable.
  • FIG. 8 b shows a variant of the protrusive stent apparatus 90 a positioned partially within a transmyocardial passageway 10 , extending through a coronary vein CV, through a secondary passageway 12 , and into a coronary artery CA.
  • the protrusive stent apparatus 90 a is curved or bent at the junction of the secondary passageway 12 and the coronary artery CA and preferably extends into the coronary artery CA in the desired bloodflow direction.
  • FIG. 8 c shows alternative variations of the protrusive stent apparatus 90 b wherein an optional tubular covering 92 is formed on the protrusive stent 90 b .
  • Such optional covering 92 may be any suitable tubular covering such as woven polyester or expanded, sintered polytetrafluoroethylene (PTFt).
  • one or more valves such as hinged occluder members or pliable elastomeric leaflets may be located within the protrusive stent apparatus 90 b with or without covering 92 , at locations L 1 and/or L 2 and/or L 3 to facilitate control and valving of bloodflow through the transmyocardial passageway 10 , coronary vein CV, secondary passageway 12 and/or coronary artery CA.
  • embodiments of the protrusive valving apparatus 90 b which incorporates such valves at locations L 1 and/or L 2 and/or L 3 may be provided with appropriate openings or apertures in any covering 92 formed thereon to facilitate the desired inflow or outflow of blood at specific locations thereon.
  • protrusive stent apparatus 90 , 90 a , 90 b with or without the optional covering 92 and/or without the optional valves at locations L 1 and/or L 2 and/or L 3 offer advantages over previously known intramyocardial stents in that they do not require precise cutting to length or precise positioning within the myocardial passageway 10 .
  • the protrusive stent apparatus 90 , 90 a , 90 b of the present invention are intended to protrude into a coronary blood vessel CBV (e.g., artery, vein and/or man-made passageway) and the length of the portion of the stent apparatus 90 , 90 a , 90 b which extends into such coronary blood vessel CBV is typically not critical. In this regard, there will exist no need for custom-fitting or precise pre-cutting of the stent apparatus 90 , 90 a , 90 b prior to implantation within the patient.
  • CBV coronary blood vessel
  • such covering may be formed of any suitable material including but not necessarily limited to polyester, woven polyester, polytetrafluroethylene, expanded polytetraflouroethylene, polyurethane; silicone, polycarbonate, autologous tissue and, xenograft tissue.
  • FIGS. 9 - 9 b are illustrative of a method of the present invention wherein a valving device 110 is positioned within the coronary sinus, great cardiac vein or other coronary vein to control coronary venous pressure in a manner which results in increased dwell time of arterial blood within a myocardial capillary bed and/or dilation of the capillary bed and/or other improvement of perfusion of an ischemic region of the myocardium M.
  • FIGS. 12 a - 12 b provide a shematic diagram of the path of blood flow during normal, unrestricted flow ( 12 a ), and valved or blocked flow ( 12 b ).
  • the outflow from the capillary bed is restricted thereby increasing the dwell time of the blood in the capillary bed, and allowing for the ischemic area to be in contact with oxygenated blood for an increased interval, providing the proposed therapeutic effect.
  • Several devices can be employed to achieve partial, total or intermittent venous occlusion.
  • the range of therapeutic benefits will depend on the 1) placement of the devices in relation to the ischemic tissue, 2) the rate at which the heart's second venous system, the Thebesian system, compensates for the blockage and takes over the function of the venous flow through its capillary network, 3) the device used to create the occlusion, namely, the rate of blockage, and whether or not the blockage is valved, and 4) the extent of the collateralization that may already exist in the circulation.
  • the Thebesian system diverts venous flow and compensates for any flow taken off-line by the placement of a venous block, it may be necessary to valve the blocking device to provide a two-phase effect.
  • the valve In the first phase, Phase I, the valve is in a closed position, restricting the outflow from the capillary bed and providing the desired benefit.
  • Phase II the valve opens, releasing the flow into the venous system at an interval such that the Thebesian system does not begin compensating for the venous blockage and diminishing the therapeutic effect.
  • the degree to which the flow is restricted is a function of both the magnitude of the restriction and its duration.
  • therapeutic value may be achieved by totally blocking the venous system, e.g. continuously blocking blood flow through the vein.
  • total or partial occlusion can be achieved by implantation of a particular embodiment of the valaving device 110 , such embodiment comprising a non-valved, cylindrical blocker 115 .
  • this blocker 115 comprises a cylindrical frame structure 118 which is fully or partially encased or covered by a tubular polymer 116 or fabric 117 covering or combination thereof.
  • a sinusoidal wire frame structure 115 is covered with a silicone film 116 .
  • this covering 116 aids in shielding the thin walled vein from any trauma caused by the metal struts of the wire frame structure.
  • the frame structure of the blocker device 115 may be formed of various materials, including stainless steel, NiTi, platinum, titanium and the like.
  • the structure of said frame can be wound wire, a slotted tube, expanded to a larger configuration, or coiled structure.
  • the frame structure will be formed of a material such as NiTi that will exert a constant force on the vessel wall, compensating for any enlargement of the vein due to the changes in pressure.
  • the blocker device may be fashioned in the form of a wedge-like geometry (not shown) to further ensure secure placement within the vessel.
  • a cap of material is secured to the distal end of the blocking device, to aid in embolization, securement of the device upon placement in a vessel, and ultimately endothelialization (tissue ingrowth).
  • Said cap, 117 can be formed of various materials including polyester fabric (e.g. DacronTM), PTFE, a high-porosity silicone or polyurethane. (see, PCT International Patent Application No. PCT/US97/01463 for further details, the contents of such application being expressly incorporated herein by reference.
  • the valving apparatus 110 of this invention may be positioned within a coronary vein, CV (or within the coronary sinus).
  • the valving apparatus 110 may comprise a cylindrical framework or stent 112 having one or more occluder flaps 114 mounted axially therewithin.
  • the occluder flaps 114 have proximal ends PE and distal ends, DE.
  • the proximal ends PE of the occluder flaps 114 define an inflow opening, and the flaps 114 are alternately moveable between a closed configuration wherein the flaps 114 are in abutment with one another so as to block or prevent blood from flowing in the outflow direction OD, and an open configuration wherein the flaps 114 are sufficiently separated from one another to permit blood to flow through the valving apparatus in the outflow direction OD.
  • valved structures can be employed that open and allow flow at a certain pressure (P), and close when the pressure goes below P.
  • Certain valves known in the art such as a duckbill valve, slit valve, poppet valve, umbrella valve or like structures can be employed in this manner within an implantable structure for placement into the vein.
  • Delayed Action Valve In contrast to the single pressure valve, embodiments that provide for delayed valving may also be employed, enabling the blockage to be maintained for an extended period of time based on a fixed time delay or a lower closure pressure than that pressure required to open the valve.
  • the length of delay or trigger for release of flow may be timed to the cardiac cycle to maximize the oxygenation phase, or Phase I, and minimize the effect of alternative venous return (such as the Thebesian veins). Examples of such delayed action valves 119 , 122 , 125 , 123 are shown in FIGS. 14 a - 18 b.
  • FIGS. 14 a - 14 c and 14 a ′- 14 b ′ there are shown alternative embodiment of valves 119 , 119 ′ providing for a pressure activated, time-delayed full ( 119 ) or partial ( 119 ′) venous occlusion.
  • a tubular structure is provided with an outer lumen and an inner lumen, said inner lumen forming a flowable valve flap, 119 , 119 ′ containing a viscous substance, such as silicone gel filled balloon (shown), biased to a closed position CP as shown in FIG. 12 a .
  • a viscous substance such as silicone gel filled balloon (shown)
  • valve 119 is initially fullu closed and, upon being contacted by increasing inflow pressure, move to an open configuration and remain open for a period of time sufficient for the viscous substance to settle back to its original biased position.
  • the time delay is a function of the viscosity of the flowable substance, which can be varied depending on the desired length of delay.
  • a similar embodiment of the valve 119 ′ shown in FIGS. 14 a ′ and 14 b ′ operates in the sa,e manner as the above-described valve 119 , but does not completely occlude venous return even when in its fully closed state (FIG. 14 a ′).
  • the valving apparatus comprises a tubular structure or valve body 122 , having an inflow direction (IF) and an outflow direction (OF), and further having a valving member comprised of a substantially cylindrical ferrous element 123 , detatchably coupled with a fixed magnetic surface 124 , located at the inflow IF end of the valve body.
  • a valving member comprised of a substantially cylindrical ferrous element 123 , detatchably coupled with a fixed magnetic surface 124 , located at the inflow IF end of the valve body.
  • a first or closed position the valving member 123 and the magnetic surface 124 are coupled thereby blocking flow through the valve body.
  • the magnetic force of the coupling between the valving member 123 and the magnetic surface 124 dictates the opening pressure of the valve.
  • the valving member 123 When the pressure exerted by blood flow in the inflow direction is sufficient to overcome the magnetic force of the coupling between the valving member 123 and the magnetic surface 124 (P1 or opening pressure), the valving member 123 is dislodged, allowing flow to travel through the valve body.
  • the time delay function of this embodiment occurs during the interval when the pressure in the inflow direction falls below P 1 and the valving member 123 is drawn back into contact with the magnetic surface 124 of the valve body by the magnetic force existing between them.
  • the time delay mechanism may also be a function of the level of oxygenation sensed by the valving apparatus.
  • This embodiment of the valving apparatus is triggered to an open or closed position based upon the percent oxygenation it senses at its inlet port.
  • this valving apparatus has an inlet port IP and and outlet port OP and a flowthrough lumen provided therebetween.
  • a septum 125 disposed within the flowthrough lumen, thereby separating the valving apparatus into two chambers, and inflow chamber IFC and an outflow chamber OFC.
  • Said septum 125 being comprised of a valved structure 126 having an oxygen sensor 127 mounted thereon.
  • Said oxygen sensor 127 triggers the valve to be in an open or closed position, depending on the percent oxygenation in the inflowing blood.
  • Said sensor maintains the valved structure in a closed position until a preset desired oxygen content is reached within the blood in the inflow chamber IFC.
  • the valved structure opens and releases flow into the outflow chamber OFC and the venous system.
  • d) Pressure Delay Mechanism It may be desirable to have valve structures that open and close along a certain hysteresis curve as shown graphically in FIG. 17.
  • a device having a tubular structure with an inflow direction (IF) and outflow direction (OF), having a piston mechanism 128 that is set to open at a pressure (P1), and remain open until the pressure falls below P2, where P2 is less than P1.
  • the piston 128 is biased towards a closed position with a spring-like member 129 , which is secured to strut member on the outflow end of the device. In the closed position, the piston member abuts a ledge 130 , provided by the inner contour of the tubular structure.
  • an inlet port (IP) and an outlet port (OP) defining a flow path therethrough.
  • IP inlet port
  • OP outlet port
  • a fluid seal is created between the piston and the ledge, thereby blocking flow between the inlet port IP and the outlet port OP, and defining certain chambers within the tubular structure; an inflow chamber (IFC), and outflow chamber (OFC), a pressure chamber (PC).
  • IFC inflow chamber
  • OFC outflow chamber
  • PC pressure chamber
  • the force on the piston in the closed position is equal to the pressure of the fluid at the inlet port IP multiplied by the surface area 1 (SA1).
  • the correlating pressure P1 When the force exceeds a certain threshold Ft, the correlating pressure P1 will cause the piston to travel toward the OP, thereby compressing the spring mechanism 129 , and allowing flow to travel from IFC to OFC.
  • the open position fluid communication is established between the inflow chamber IFC and the pressure chamber PC, thus increasing the force on the piston by an amount equal to the pressure at the inlet port IP multiplied by surface area 2(SA2).
  • SA2 surface area 2
  • the valve will not re-open until a pressure P1 is achieved.) In clinical application, this results in an intermittent occlusion of venous flow which may prevent the activation of alternative venous conduits such as the Thebesian veins.
  • the desired crack open pressure and hold open pressure is a function of the spring force of spring member 129 , and the values of SA1 and SA2 and can be varied depending on the activity intervals desired.
  • a partial blocker may also be placed in an alternative embodiment, wherein flow through the valve body is never fully blocked, but is restricted to the degree necessary to achieve a therapeutic benefit.
  • an opening, 120 can be formed in the distal tip of the blocking device, sufficient to provide for a certain amount of flow therethrough, while still providing a restriction sufficient to achieve a therapeutic effect.
  • Delayed Action Valve may be desirable to provide the combined effect of a partial blockage (i.e. reduced by continuous flow) and a hysteresis, or delayed action valve.
  • the delayed action valve embodiments described above may additionally provide a flow through lumen-positioned within the tubular valving apparatus.
  • the pressure delay valving apparatus 123 ′ includes a flow through lumen 120 which allows continuous flow through the valve body even when the occluder 128 is in its closed position (FIG. 19 a ), while in the full-occlusion embodiment shown in FIGS. 18 a - 18 b , no flow-through passageway is provided and, when the occluder 128 is in its closed position (FIG. 18 a ) the flow of blood through the vein will be totally blocked.
  • Femoral or jugular vascular access is gained to the venous system via standard sheath and dilator placement in the femoral or jugular vein.
  • a coronary sinus access catheter is placed to cannulate the coronary sinus to assist in the placement of guidewires into the GCV and AIV over which subsequent interventional devices will be placed, including the blocking devices described hereabove.
  • a coronary sinus guide catheter (not shown), with introducer dilator is advanced over the GCV/AIV wire until the tip of the guide is deep seated past the “mouth” of or entrance to the coronary sinus. The introducer dilator is then removed.
  • a blocker delivery catheter Not shown is advanced over the GCV/AIV guidewire under flouroscopy to a position in the vein approximate the ischemic segment.
  • the GCV/AIV guidewire is then removed, and a blocker is inserted into the proximal end of the delivery catheter.
  • a push rod (not shown) is then inserted into the blocker delivery catheter, and the blocker device is pushed until it exits the delivery catheter and expands into position in the vein.
  • the positioning of the blocker varies depending on the location of the ischemic region.
  • a blocker is placed in the vein to occlude the specific venous return flow from the region. It is appreciated that it may be necessary to block multiple small veins, or the larger main venous conduits fed by the smaller veins.
  • a transmyocardial passageway 10 of the present invention may optionally, but not necessarily, be formed between a chamber of the heart such as the left ventricle LV and the coronary vein CV such that oxygenated blood may enter the lumen of the coronary vein CV to enhance the retroperfusion of the myocardium M.
  • the flaps 114 of the valving apparatus 110 are constructed so as to be biased to their closed configuration, but so as to separate and move to their open configuration when the pressure of blood exerted against the flaps 114 in the outflow direction OD exceeds a predetermined maximum amount. This causes the pressure of blood within the coronary vein to exceed its normal pressure during a portion of the cardiac cycle. This is illustrated in FIG. 9 b wherein the normal pressure of blood within the coronary vein CV is illustrated by the dotted line, and wherein the modified pressure of blood within the coronary vein having the valving apparatus 110 of the present invention positioned therein is illustrated by the solid line.
  • the valving apparatus 110 of the present invention serves to cause the pressure of blood within the coronary vein CV to raise to a substantially higher level (e.g., 40 /hg) before the occluder flaps 114 of the valving apparatus 110 move to their open configuration, thereby allowing the pressure of blood within the coronary vein CV to once again fall.
  • a substantially higher level e.g. 40 /hg
  • valving apparatus 110 of the present invention may optionally incorporate one or more of the following additional features:
  • the valving apparatus may be pucturable or traversable so as to permit a catheter to be passed through the valving apparatus in the event that such catheter passage becomes necessary at a later time;
  • the valving apparatus may be removable such that it may be rescued and removed from the body in the event it is no longer necessary, or if removal becomes desirable for some other reason;
  • the valving apparatus may be provided with projections, hooks, material for tissue in growth, or other suitable anchoring apparatus to assist in holding the valving apparatus in its desired position within the venus lumen; and
  • the valving apparatus may be formed of radiologically imagable material, or may be provided with one or more radio dense or radio opaque markers to facilitate visualization of the valving apparatus by x-ray or fluoroscopy.
  • any of the transmyocardial passageways between a chamber of the heart and a coronary blood vessel CBV may be formed by any suitable means.
  • a passageway-forming catheter 100 a may be advanced into a chamber of the heart, such as the left ventricle LV, and will be oriented/positioned such
  • tissue-penetrating element 102 a of the catheter 100 a is directed to the desired coronary blood vessel CBV. Thereafter, the tissue-penetrating element 102 a is passed from the passageway-forming catheter 100 a , through the wall of the myocardium M and into the desired coronary blood vessel CBV.
  • a guidewire 104 a may optionally be advanced through an optional lumen in the tissue-penetrating element 102 a and into the coronary blood vessel CBV such that the tissue-penetrating element 102 a may subsequently be retracted into the catheter 100 a leaving the guidewire 104 a extended through the transmyocardial passageway 10 and into the coronary blood vessel CBV. Thereafter, one or more passageway-modifying apparatus may be advanced over the guidewire 104 a to modify or complete the formation of the desired transmyocardial passageway 10 .

Abstract

Methods and apparatus for direct coronary revascularization wherein a transmyocardial passageway is formed between a chamber of the heart and a coronary blood vessel to permit blood to flow therebetween. In some embodiments, the transmyocardial passageway is formed between a chamber of the heart and a coronary vein. The invention includes unstented transmyocardial passageways, as well as transmyocardial passageways wherein protrusive stent devices extend from the transmyocardial passageway into an adjacent coronary vessel or chamber of the heart. The apparatus of the present invention include protrusive stent devices for stenting of transmyocardial passageways, intraluminal valving devices for valving of transmyocardial passageways, intracardiac valving devices for valving of transmyocardial passageways, endogenous tissue valves for valving of transmyocardial passageways, and ancillary apparatus for use in conjunction therewith.

Description

    RELATED APPLICATIONS
  • This patent application is a continuation-in-part of co-pending U.S. patent application Ser. No. 08/730,327, filed Oct. 11, 1996, Ser. No. 08/730,496 filed Oct. 11, 1996, and Ser. No. 08/837,295 filed Apr. 11, 1997 the entire disclosure of each such related application being expressly incorporated herein by reference.[0001]
  • FIELD OF THE INVENTION
  • The present invention pertains generally to medical treatment methods and devices, and more particularly to methods and devices for transluminal direct coronary revascularization. [0002]
  • BACKGROUND OF THE INVENTION
  • 1. Coronary Artery Disease [0003]
  • Coronary artery disease continues to be one of the leading causes of morbidity and mortality, throughout the world. The typical etiology of coronary artery disease is characterized by the build-up of atherosclerotic plaque within the coronary arteries. Such deposits of atherosclerotic plaque tend to fully or partially block the flow of blood through the affected coronary arteries, and if untreated can result in myocardial ischemia, infarction and death. [0004]
  • For many years, the traditional surgical treatment of coronary artery disease has been coronary artery bypass surgery. In traditional coronary artery bypass surgery, the patient is generally anesthetized and placed on cardiopulmonary bypass. A thoracotomy is performed and the obstructed coronary blood vessels are exposed by surgical dissection. One or more segments of the patient's saphenous vein or internal mammary artery is/are harvested for use as bypass graft(s). The harvested segment(s) of vein or artery is/are then anastomosed to the obstructed coronary artery(ies) to form bypass conduit(s) around the arterial obstruction(s). Such traditional coronary artery bypass surgery is expensive, extremely invasive, and is associated with significant operative and perioperative complications. [0005]
  • One alternative to traditional coronary artery bypass surgery is balloon angioplasty. In balloon angioplasty, a flexible guide catheter is percutaneously inserted into a peripheral artery (e.g., the femoral artery) and is transluminally advanced through the vasculature until the distal tip of the catheter is within an obstructed coronary artery. Thereafter, a balloon catheter is passed through the guide catheter and into the obstructive lesion. The balloon of the balloon catheter is inflated one or more times to dilate coronary artery in the region of the obstructive lesion. These balloon angioplasty procedures tend to be less expensive and less traumatic than traditional coronary artery bypass surgery. However, balloon angioplasty procedures of this type have been associated with a significant incidence of restenosis at the angioplasty site. The cause and mechanism of such restenosis continues to be the subject of ongoing study. However, such restenosis has generally been attributed to either a) an increase in the mass of the artery wall (e.g., neointima formation), b) a thickening of the artery wall without substantial change in it's mass (e.g., vascular remodeling) and/or c) radial contraction of the balloon-dilated artery wall upon healing of cracks and fissures that have been created by the balloon dilation process. [0006]
  • Another alternative to traditional coronary artery bypass surgery is transluminal atherectomy or ablation of the obstructive matter within the coronary artery. These transluminal atherectomy or ablation procedures are performed by passing a catheter-mounted ablation apparatus through the vasculature to the site of the coronary obstruction. the catheter-mounted ablative apparatus is then utilized to cut, shave, sonicate, pulverize or otherwise ablate the obstructive matter from the lumen of the coronary artery. These atherectomy or ablative procedures must be performed with caution to avoid abrasion or damage to the artery wall, as such abrasion or damage can result in excessive scaring and subsequent reclusion of the artery lumen. Furthermore, these atherectomy or ablative procedures may, in some cases at least, be confounded by the need to meticulously contain and remove the severed fragments of obstructive matter in order to prevent such fragments of obstructive matter from escaping into the patient's circulatory system. Examples of such atherectomy catheters and other catheter-mounted ablative apparatus are described in U.S. Pat. No. 3,433,226 (Boyd), U.S. Pat. No. 3,823,717 (Pohlman, et al.), U.S. Pat. No. 4,808,153 (Parisi), U.S. Pat. No. 4,936,281 (Stasz), U.S. Pat. No. 3,565,062 (Kuris), U.S. Pat. No. 4,924,863 (Sterzer), 4B70,953 (Don Michael, et al.), U.S. Pat. No. 5,069,664 (Suess, et al.), U.S. Pat. No. 4,920,954 (Alliger, et al.) and U.S. Pat. No. 5,100,423 (Fearnot), as well as foreign patents/patent publications EP0347098A2 (Shiber), WO87-05739 (Cooper), WO89-06515 (Bernstein, et al.), WO90-0130 (Sonic Needle Corp.), EP316789 (Don Michael, et al.), DE 3,821,836 (Schubert), DE2438648 (Pohlman), and EP 0443256A1 (Baruch). [0007]
  • Other alternatives to traditional coronary artery bypass surgery have included minimally invasive endoscopic procedures which, ostensibly at least, can be performed through small (e.g., 1-3 cm) incisions formed in the patient's chest wall, by insertion of a thoracoscope and associated operative instruments through such incisions. One such thoracoscopic coronary bypass procedure is described in U.S. Pat. No. 5,452,733 (Sterman et al.). If perfected, these minimally invasive coronary artery bypass procedures may lessen the discomfort and length of recovery time experienced by patients who undergo such minimally invasive procedures vis a vis those who undergo traditional coronary artery bypass surgery. However, the performance of endoscopic surgical procedures of this type typically requires a great deal of operator skill and training. Furthermore, as with traditional coronary artery bypass surgery, the patients on whom these thoracoscopic procedures are performed are likely to undergo general anesthesia (with or without cardiopulmonary bypass) and the creation of a pneumothorax due to the formation of full-thickness incision(s) in the chest wall. Thus, many of the drawbacks associated with traditional coronary artery bypass surgery, are also associated with these minimally invasive thoracoscopic procedures. [0008]
  • ii. Transmyocardial Revascularization [0009]
  • Another type of procedure which has been devised for improving blood flow to ischemic regions of the myocardium is known as transmyocardial revascularization (TMR). These TMR procedures generally involve the formation of tunnels or passageways through the myocardial muscle for the purpose of providing improved blood flow. In one such TMR procedure, a tissue-boring device, such as a laser, is utilized to form a'series of small-diameter passageways from the epicardial surface of the heart, through the myocardium, and into the left ventricle. Jeevanandam, et al., [0010] Myocardial Revascularization By Laser-Induced Channels, Surgical Forum XLI, 225-227 (Oct. 1990); also see, U.S. Pat. No. 4,658,817 (Hardy).
  • A variant of the above-described TMR procedure is described in U.S. Pat. No. 5,389,096, (Aita, et al.), wherein a catheter-mounted tissue-boring apparatus (e.g., a laser) is advanced into a chamber (i.e., left ventricle) of the heart and is used to form a plurality of blind, partial-thickness passageways from the chamber of the heart into the myocardium. [0011]
  • Modified TMR procedures have also been described wherein an internally valved transmyocardial passageway is formed between a coronary artery and the left ventricle of the heart, such that blood from left ventricle may flow into the coronary artery. These modified TMR procedures, hereinafter generally referred to as “Transmyocardial Direct Coronary Revascularization” (TMDCR), are described in U.S. Pat. Nos. 5,287,861 (Wilk), 5,409,019 (Wilk), and 5,429,114 (Wilk). At least some of these TMDCR methods require that a catheter be introduced into the obstructed coronary artery and advanced through the obstructive lesion. After the catheter has been advanced through the obstructive lesion, the distal tip of the catheter is stirred or bent toward the artery wall and a tissue- penetrating element is passed through the artery wall, through the adjacent myocardium, and into the chamber of the left ventricle. Also, in this previously described TMDCR method, a stent or valving apparatus is required to be positioned within the transmyocardial passageway to perform a one-way valving function (i.e., to open and close the transmyocardial passageway in accordance with changes in the systolic-diastolic cardiac cycle). [0012]
  • These TMDCR methods, previously described in U.S. Pat. No. [0013] 5,287,861 (Wilk), U.S. Pat. No. 5,409,019 (Wilk) and U.S. Pat. No. 5,429,114 (Wilk), may be difficult or impossible to perform in patients who suffer from total or near total obstructions of a coronary artery, because of the necessary for advancing the catheter through the coronary artery obstruction to accomplish creation of the transmyocardial passageway at a location which is downstream of the coronary obstruction. Furthermore, because these previously described TMDCR methods require placement of a stent within the transmyocardial passageway, such procedures are necessarily associated with procedural complexities associated with measuring and pre-cutting the stent to a precise length so that it fits within the transmyocardial passageway without protruding into the chamber of the left ventricle and/or the lumen of the coronary artery. Also, any stent which is positioned solely within the transmyocardial passageway may be subject to repetitive flexing and/or stressing as the myocardium undergoes its normal contraction and relaxation. Such repeated flexing and/or stressing of the intramyocardial stent may lead to unwanted migration, dislodgement or damage of the stent.
  • iii. Intermittent Coronary Sinus Occlusion For Coronary Retroperfusion [0014]
  • Yet another procedure which has been proposed as a means for treating acute myocardial ischemia is known as intermittent coronary sinus occlusion (ICSO). In many if not all ICSO procedures, the inflatable balloon is placed in the coronary sinus and is attached to a mechanical pump. The mechanical pump operates to intermittently inflate and deflate the balloon so as to intermittently occlude the coronary sinus. Such intermittent inflation and deflation of the balloon may be linked to the coronary sinus pressure so as to optimize the retroperfusion of the ischemic myocardium. Specific ICSO procedures have been described in Belamy, R. F: (et al.) [0015] Effect of Coronary Sinus Occlusion on Coronary Pressure-Flow Relations, Am. J. Physiol. 239 (Heart Circ. Physiol. 8) HS 57-HS64, 1980; Pantely, G. A. (et al.) Effect of Resistance, And Zero Flow Pressure During Maximum Vasodilation in Swine, Cardiovascular Research, 22:79-86, 1988.
  • Because the coronary sinus balloon is typically mounted on a percutaneously inserted catheter and is connected to an extracorporeally located pumping system, the clinical usefulness of these ICSO procedures is presently limited to temporary applications intended to minimize heart muscle damage following infarction or during acute periods of myocardial ischemia. However, the general concept of these ICSO procedures could be applicable for the long-term treatment of chronic myocardial ischemia if a totally indwelling system could be devised which would eliminate the need for continued coronary sinus catheterization and/or the deployment of an extracorporeal pumping apparatus connected to such catheter. [0016]
  • When considering the manner in which the ICSO procedures operate, it is helpful to bear in mind that the human circulatory system functions to send oxygenated blood from the aorta to the heart muscle (myocardium) via the left and right coronary arteries (small and large arteries). Following the oxygen/metabolite exchange in the myocardium, the venous system returns the de-oxygenated blood via the epicardial veins (large and small veins). A small fraction of the de-oxygenated blood returns through a set of small vessels which empty directly into the chambers of the heart called the Thebesian veins. Support exists in clinical literature that these Thebesian vessels can carry as much as 90 percent of the total coronary inflow back into the chambers of the heart. The Thebesian vessels connect to both the venous and arterial beds in an interface at the capillary level. Based upon this knowledge of heart function, researchers have suggested that occluding the venous system (e.g. blocking the coronary sinus or other large vein), does not compromise heart function and may in fact create a beneficial effect in cases of diseased or ischemic myocardium. [0017]
  • One particular type of ICSO procedure, known as pressure- controlled intermittent coronary sinus occlusion (PICSO), and apparatus for performing such procedure are described in European Patent Application No. EP0230996 to Mohl. In this PICSO procedure, an external balloon catheter is inflated in the coronary sinus for a period of time (several cardiac cycles). This PICSO procedure is typically performed in a hospital setting, during a coronary catheterization procedure. This PICSO procedure has been shown to elevate the pressure in the venous bed, providing a therapeutic benefit. (see, Mohl, [0018] The Development and Rationale of Pressure Controlled Intermittent Coronary Sinus Occlusion—A New Approach to Protect Ischemic Myocardium, Wiener klinische Wochenschrift, pp 20-25, Jan. 6, 1984; also see, Moser, Optimization of Pressure Controlled Intermittent Coronary Sinus Occlusion Intervals by Density Measurements, in The Coronary Sinus, Eds. Mohl, Wolner, Glogar, Darmstadt: Steinkopff Verlag, 1984 pp. 529-536; Schreiner, The Role of Intramyocardial Pressure During Coronary Sinus Interventions: A Computer Model Study, IEEE Transactions on Biomedical Engineering, Vol. 37, No. 10, October (1990). In addition, research has shown that, in patients who suffer from occlusive coronary artery disease, venous occlusion may actually prevent or reduce the size of a subsequent infarct (heart attack). (Kralios, Protective Effect of Coronary Sinus Obstruction from Primary Ischemia-Induced Ventricular Fibrillation in the Dog, Am. Heart J (1993) 125:987; Lazar, Reduction of Infarct Size With Coronary Venous Retroperfusion, Circulation (1992) 86:II 352).
  • There currently exists a need to provide minimally invasive methods and devices which have the capability of achieving therapeutic effects similar to those of the above- described PICSO procedure of the prior art, but which do not require continuing cardiac catheterization of the patient in order for the beneficial effects of the procedure to remain. Accordingly, it is the object of the present invention to describe various devices that can be implanted percutaneously in the patient's coronary sinus or great cardiac vein where they remain implanted to achieve partial or total occlusion of the coronary venous system. One mechanism of the therapeutic benefits seen clinically are understood to be based upon the slowing of the arterial flow and subsequently the increased the dwell time of the blood in the capillary bed allowing for an increased oxygen-metabolite exchange. The benefits of this phenomenon are better oxygen uptake and potentially a decrease in the infarct size in the event of a future cardiac arrest, and/or potentially global ischemic protection. Another mechanism providing potential benefit is the resultant redistribution of flow through collateral capillary beds, allowing perfusion of regions of the heart that may be otherwise ischemic (lack of perfusion of blood flow due to disease in vessels feeding those regions). In addition, angiogenesis, a stimulation of the endothelial cells lining the internal walls of vessels to form new blood vessels, may be stimulated as a compensatory mechanism in response to the disruption of normal venous blood flow, thereby providing additional myocardial perfusion through newly created blood flow conduits. [0019]
  • In view of the above-summarized shortcomings and complexities of the previously described TMDCR methods, there exists a need in the art for the development of improved TMDCR methods and associated apparatus which may be utilized without the need for cumbersome stenting of the transmyocardial passageway and/or implantation of one-way valving apparatus within the transmyocardial passageway. Also, there exists a need for the development of a new TMDCR methods which can be performed in patients who suffer from total or near total coronary artery occlusion(s), without the need for advancing a catheter through such coronary artery occlusion(s). [0020]
  • SUMMARY OF THE INVENTION
  • The present invention provides new TMDCR methods, as well as certain valving devices which are usable in conjunction with these TMDCR methods. [0021]
  • i. TMDCR Procedures Wherein Transmyocardial Passageway is Formed Between a Chamber of the Heart and a Coronary Vein [0022]
  • In accordance with the present invention, there is provided a specific TMDCR method wherein a transmyocardial passageway is formed between a chamber of the heart (e.g., left ventricle) and a coronary vein. In this embodiment of the invention, blood may pass from the cardiac chamber, through the transmyocardial passageway, and into the coronary vein for the purpose of improving blood flow to the myocardium and/or to equalize or normalize pressures within the coronary venous vasculature by draining blood from the vein into the cardiac chamber. The coronary vein of this embodiment may be situated next to an obstructed coronary artery, and one or more secondary blood flow passageways may be created between the coronary vein and the adjacent artery, at site(s) which is/are downstream of the coronary artery obstruction. Also, the lumen(s) of the coronary vein and/or adjacent coronary artery may be blocked or embolized at appropriate positions to facilitate the flow of blood in the desired direction (s) through the man-made blood flow passageway (s), the coronary vein and/or the coronary artery. Additionally, one or more valving apparatus may be positioned within the coronary vein and/or within the cardiac chamber, to control or intermittently block the flow of blood through the transmyocardial passageway. [0023]
  • ii. TMDCR Procedures Wherein Temporary A-V Fistula is Used to Facilitate Formation of Transmyocardial Passageway Entering Coronary Artery Downstream of Obstruction or Other Intravascular Procedure [0024]
  • Further in accordance with the present invention, there are provided TMDCR procedures wherein a transmyocardial passageway-forming catheter is initially advanced into a coronary vein which lies adjacent to an obstructed coronary artery. The passageway forming catheter is advanced through the coronary vein until the distal end of the catheter is adjacent a location on the coronary artery which is downstream of the coronary artery obstruction. Thereafter, the passageway-forming catheter is utilized to form an arterio-venous passageway which extends from the coronary vein wherein the catheter is located into the coronary artery, at a site downstream of the obstruction. Thereafter, the passageway-forming catheter is advanced through the arterio-venous passageway and into the coronary artery. The passageway- forming catheter is then oriented such that the tissue- penetrating element of the catheter will pass out of the catheter, through the wall of the artery and into a chamber of the heart (e.g., left ventricle). Thereafter, the tissue-penetrating catheter is removed and the arterio-venous passageway, which had been initially formed to allow the passageway-forming catheter to enter the coronary artery downstream of the obstruction, is closed by way of an occlusion apparatus, sutures, cautery, adhesive, or any other suitable tissue closure method or apparatus. Thus, by this procedure, a transmyocardial passageway is formed between a chamber of the heart (e.g., left ventricle) and an obstructed coronary artery, at a site downstream of the coronary artery obstruction, without the need for advancing any guidewire, catheter or other apparatus through the obstruction located within the coronary artery. [0025]
  • The temporary arteriovenous fistula created in this procedure may also be used for other purposes, such as to perform an atherectomy within the lumen of the occluded vessel, or to place a guidance/aiming apparatus (e.g., a target or signal-emitting apparatus) within the lumen of the occluded artery downstream of the obstruction to facilitate formation of a transmyocardial or interstitial passageway into the occluded blood vessel, downstream of the obstruction. This aspect of the invention will be particularly useful in patients in whom the obstruction is sufficiently complete as to prevent a catheter from being passed through the obstruction, but in whom it is desirable to catheterize the distal portion of the occluded blood vessel downstream of the obstruction to accomplish a therapeutic procedure (e.g., atherectomy, ablation of the occlusive matter, placement of a target, etc.) [0026]
  • iii. Other Procedures Using the Temporary A-V Fistula [0027]
  • Further in accordance with the invention, a temporary arterio-venous fistula of the above-described type may be utilized to facilitate the performance of other therapeutic or interventional procedures within the lumen of a blood vessel, downstream of an occlusion. This aspect of the invention will be particularly applicable in patients who have total or near total occlusions of an artery, and in whom it would be difficult or impossible to advance a catheter through the total or near total occlusion. [0028]
  • The types of interventional or therapeutic procedures which may be performed through the temporary arterio-venous fistula include, but ar not necessarily limited to, balloon angioplasty, atherectomy, stenting, thrombolysis, full or partial ablation or removal of occlusive matter, or installation of an apparatus (e.g., a signal-emitting target) into the lumen of the blood vessel, downstream of the obstruction. [0029]
  • This aspect of the invention may be particularly useful in patients who have previously undergone coronary artery bypass surgery such that a bypass graft is anastomosis to a coronary artery, downstream of a total or near total obstruction. In those patients, it is not unusual for a secondary obstruction to form immediately downstream of the anastomosis of the bypass graft. In the event that such secondary obstruction does form, the temporary arterio-venous fistula of the present invention may be used to permit an interventional apparatus (e.g., balloon angioplasty catheter, thrombolysis catheter, atherectomy catheter, ablation catheter, stent-delivery catheter, etc.) into the lumen of the coronary artery, downstream of the obstruction, to treat the secondary obstruction which has formed adjacent the anastomosis. After such therapeutic or interventional procedure has been completed, the temporary arterio-venous fistula may be closed by the above-described procedure, thereby restoring pathency to the segment of the artery downstream of the bypass graft anastomosis. [0030]
  • iv. TMDCR Procedures Using Unstented Transmvocardial Passageway [0031]
  • Further in accordance with the present invention, there is provided a method for coronary re-vascularization wherein an unstented transmyocardial passageway (e.g., a puncture tract, bore, tunnel, or other passageway) is formed between a chamber of the heart (e.g., the left ventricle) and a coronary vessel (e.g., a) an endogenous coronary artery; b) an endogenous coronary vein; c) a man-made passageway which has been formed in the heart, and which leads to an endogenous coronary vein; d) a man-made passageway which has been formed in the heart, and which leads to an endogenous coronary artery; and/or e) a man-made passageway which has been formed in the heart between an endogenous coronary artery and an endogenous coronary vein). The unstented transmyocardial passageway(s) created in accordance with this embodiment of the invention may be utilized to improve perfusion of the myocardium by shunting blood from the chamber of the heart (e.g., left ventricle) into the coronary vessel (e.g., vein artery or man-made passageway), or may alternatively be utilized to equalize or normalize flow or pressure within the cardiac vasculature by draining blood from one or more cardiac vessels (e.g., vein, artery or man-made passageway), into the chamber of the heart. [0032]
  • v. Valving Devices Positionable in Coronary Vessels [0033]
  • Still further in accordance with the present invention, there are provided several types of intraluminal valving apparatus which may be positioned within the lumen(s) of the coronary blood vessel(s) (i.e., artery, vein or man-made passageway) which intersect with the transmyocardial passageway, to intermittently block bloodflow, in at least one direction, through the transmyocardial passageway. These intraluminal valving devices generally comprise tubular bodies having at least one occluder member positioned therein, said occluder member(s) being alternately moveable between i) open position(s) whereby bloodflow is permitted to pass through the transmyocardial bloodflow passageway in a desired direction, and ii) closed position(s) whereby blood is prevented from flowing through the transmyocardial bloodflow passageway, in an undesired direction. [0034]
  • vi. Tissue Valves For TMDCR Passageway [0035]
  • Alternatively, the present invention also includes endogenous tissue valve(s) which are formed in the transmyocardial passageway to perform a desired one-way valving function whereby blood is permitted to flow through the transmyocardial bloodflow passageway in a first direction, but is prevented from backflowing or regurgitating in a second direction. [0036]
  • vii. Intracardiac Valving Devices for TMDCR Passageway [0037]
  • Still further in accordance with the present invention, there are provided intracardiac valving devices which are mountable within a chamber of the heart (e.g., left ventricle) immediately adjacent to an opening into a transmyocardial passageway which extends from the cardiac chamber to a coronary vessel (e.g., artery, vein or man-made passageway). Such intracardiac valving device may be constructed such that it will open in response to hemodynamic pressure generated during systole and/or in response to mechanical contraction (i.e., shortening and thickening) of the myocardium during systole. When open, the intracardiac valving device permits blood to flow through the transmyocardial bloodflow passageway. Thereafter, the valving device may be constructed to close when diastolic pressures are present in the cardiac chamber or when the myocardium undergoes mechanical relaxation (i.e., lengthening and thinning during diastole. When closed, the valving device will prevent blood from backflowing or regurgitating from the transmyocardial bloodflow passageway, into the cardiac chamber. [0038]
  • viii. Protrusive Stents and Stented Grafts for TMDCR Passageways [0039]
  • Still further in accordance with the present invention, there are provided stents and stented grafts which are positionable within the transmyocardial passageway, and which protrude into the adjacent coronary vessel (e.g., vein, artery or man-made passageway). These protrusive stents and/or protrusive stented grafts may be self-expanding or pressure-expandable. Optionally, one or more valves or occluder members may be positioned within such protrusive stents and/or stented grafts to facilitate valving or directed movement of bloodflow in accordance with the diastolic/systolic cardiac cycle. [0040]
  • ix. Intravascular Valving Apparatus and Methods for Intermittent Coronary Venous Occlusion [0041]
  • Still further in accordance with the present invention, there are provided intravascular valving devices which are positionable within the coronary sinus, great cardiac vein or other areas of the coronary venous vasculature to control the back pressure within one or more coronary veins in a manner which will result in increased dwell time of the arterial blood within the capillary bed of the ischemic myocardium, and/or dilation of the capillary bed, thereby improving perfusion of the ischemic region(s) of the myocardium. [0042]
  • These intravascular valving devices may generally comprise a radially expandable cylindrical frame having one or more leaflets or other occluding members (e.g., ball-in-cage type check valve, etc.) which are specifically configured and constructed to prevent venous outflow until the pressure within the coronary sinus, great cardiac vein or other coronary vein exceeds a predetermined amount. Optionally, one or more transmyocardial passageways may be formed between the coronary vein(s) and/or coronary artery(s) to provide additional blood flow into the coronary vasculature in conjunction with the increased back pressure created by this intravascular valving apparatus. Alternatively or additionally, these intravascular valving apparatus of the present invention may be implanted within the coronary sinus, great cardiac vein, or other coronary vein to regulate coronary venus pressure in conjunction with an interstitial arterio-venous passageway or passageway formed between a chamber of the heart and a coronary vein, in accordance with the procedures previously described in applicant's U.S. patent applications Ser. Nos. 08/730,327 and 08/730,496, filed on Oct. 11, 1996. The tissue penetrating member will reside when varying lengths of said tissue penetrating member have been advanced out of the catheter, said imaging means being thereby useable to focus on a selected one of said distance indicia to optimally position the catheter to form the desired passageway. [0043]
  • Optionally, these intravascular valving apparatus may incorporate one or more of the following additional features: [0044]
  • The valving apparatus may be pucturable or traversable so as to permit a catheter to be passed through the valving apparatus in the event that such catheter passage becomes necessary at a later time; [0045]
  • The valving apparatus may be removable such that it may be rescued and removed from the body in the event it is no longer necessary, or if removal becomes desirable for some other reason; [0046]
  • The valving apparatus may be provided with projections, hooks, material for tissue in growth, or other suitable anchoring apparatus to assist in holding the valving apparatus in its desired position within the venus lumen; and [0047]
  • The valving apparatus may be formed of radiologically imagable material, or may be provided with one or more radio dense or radio opaque markers to facilitate visualization of the valving apparatus by x-ray or fluoroscopy. [0048]
  • These intravascular valving apparatus of the present invention are implantable within the coronary sinus, great cardiac vein or other coronary vein, and will remain indwelling so as to regulate back pressure within the system and/or to improve myocardial perfusion, on an ongoing basis, without the need for continued placement of a catheter-mounted counterpulsation balloon within the coronary sinus and/or deployment of any extracorporeal instrumentation, such as the extracorporeal pumping apparatus which has been traditionally required for intermittent inflation and deflation of the coronary sinus counterpulsation balloon. [0049]
  • Further objects and advantages of the present invention will become apparent to those skilled in the art upon reading and understanding of the following detailed descriptions of preferred embodiments.[0050]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a perspective view of a human heart showing the typical anatomical positioning of the coronary arteries and coronary veins of the left heart. [0051]
  • FIG. 1[0052] a is a partial cut-away sectional view of a human heart wherein a transmyocardial passageway has been created between the left ventricle and a coronary vein, in accordance with the present invention.
  • FIG. 1[0053] b is a partial longitudinal sectional view through an obstructed coronary artery and adjacent coronary vein, showing a transmyocardial passageway of the present invention, extending between the chamber of the left ventricle and the coronary vein.
  • FIG. 1[0054] c is a partial longitudinal sectional view through an obstructed coronary artery and adjacent coronary vein, showing a transmyocardial passageway of the present invention extending between the chamber of the left ventricle to the coronary vein, and a secondary bloodflow passageway extending from the coronary vein to the adjacent coronary artery, downstream of the obstruction.
  • FIG. 1[0055] d is a partial longitudinal sectional view through a portion of the myocardium of a human heart, adjacent the left ventricle, showing an alternative embodiment of the present invention wherein a transmyocardial bloodflow passageway extends from the chamber of the left ventricle to a secondary passageway which has been created between the obstructed coronary artery and the adjacent coronary vein.
  • FIG. 2 is a longitudinal sectional view showing a first embodiment of an intravascular valving apparatus of the present invention operatively positioned within a coronary blood vessel (artery, vein or man-made passageway). [0056]
  • FIG. 2[0057] a is a perspective view of the intravascular valving apparatus of FIG. 2.
  • FIG. 2[0058] b is an elevational view of a variant of the intravascular valving apparatus shown in FIGS. 2 and 2a, wherein a bloodflow blocking bulkhead is formed on the upstream end of the apparatus.
  • FIG. 3 is a longitudinal sectional view of a second embodiment of an intravascular valving apparatus of the present invention operatively positioned in a coronary blood vessel (artery, vein or man-made passageway). [0059]
  • FIG. 3[0060] a is longitudinal sectional view showing variant of the second intravascular valving apparatus embodiment shown in FIG. 3, wherein two (2) separate valving apparatus are respectively positioned upstream and downstream of the junction between the transmyocardial bloodflow passageway and the coronary blood vessel (artery, vein or man-made passageway).
  • FIG. 3[0061] b is a longitudinal sectional view of another variant of the second intravascular valving apparatus embodiment shown in FIG. 3, wherein three (3) valves are incorporated within a single tubular body to accomplish valving of bloodflow through a transmyocardial bloodflow passageway and coronary blood vessel (artery, vein or man-made passageway).
  • FIG. 4 is a longitudinal sectional view showing a third embodiment of an intravascular valving apparatus of the present invention operatively positioned within a coronary blood vessel (artery, vein or man-made passageway). [0062]
  • FIG. 5 is a longitudinal sectional view showing an intracardiac valving apparatus of the present invention along with an optional retainer assembly (dotted lines) useable to mount such intracardiac valving apparatus on the inner wall of the heart. [0063]
  • FIG. 5[0064] a is a perspective view of the intracardiac valving apparatus of FIG. 4 having the optional retainer assembly affixed thereto.
  • FIGS. 6[0065] a and 6 b are longitudinal sectional views of a human heart wherein a bloodflow passageway has been created between the left ventricle and a coronary blood vessel (artery, vein or man-made passageway), and a valving tissue valve has been created in the wall of the blood vessel, in accordance with the present invention.
  • FIGS. 7[0066] a-7 b are longitudinal sectional views of a human heart wherein a blood vessel passageway has been created between the left ventricle and a coronary blood vessel (artery, vein or man-made passageway), and wherein an elastic suture has been positioned, in accordance with the present invention.
  • FIG. 8[0067] a is a longitudinal sectional view showing a protrusive stent apparatus of the present invention implanted within a transmyocardial passageway and extending into a coronary blood vessel (e.g., artery, vein or man-made passageway).
  • FIG. 8[0068] b is a longitudinal sectional view showing an alternative embodiment of the protrusive stent apparatus shown in FIG. 5a.
  • FIG. 8[0069] c is a longitudinal sectional view showing another alternative embodiment of the protrusive stent apparatus shown in FIG. 5a, having an optional tubular covering and/or optional valve(s) incorporated therein.
  • FIG. 9 is a partial sectional view of a portion of a mammalian heart wherein an intravascular valving apparatus has been positioned within a coronary vein to provide pressure-controlled intermittent coronary venous occlusion for enhanced coronary retroperfusion. [0070]
  • FIG. 9[0071] a is a perspective view of the intravascular valving apparatus shown in FIG. 9.
  • FIG. 9[0072] b is a graph of coronary venous pressure vs. time in a coronary vein having an intravascular valving apparatus of the present invention implanted therein.
  • FIG. 9[0073] c is a draft of coronary venous pressure vs. flow in a coronary vein having an intravascular valving apparatus of the present invention implanted therein.
  • FIG. 10 is a partial longitudinal section view through a portion of a mammalian heart showing a passageway-forming catheter device of the present invention being used to form a transmyocardial passageway from a chamber of the heart, into a coronary blood vessel. [0074]
  • FIG. 11[0075] a is a partial section view through a portion of a mammalian heart showing the first stage of a transluminal coronary revascularization procedure wherein a temporary arterio-venous fistula is used to pass a passageway forming catheter into an obstructed coronary artery, downstream of the obstruction.
  • FIG. 11[0076] b is a longitudinal sectional view of a portion of a mammalian heart following completion of the procedure shown in FIG. 11a.
  • FIG. 12[0077] a is a shematic diagram of the flow of blood through the coronary vasculature without full or partial blocking of venous return in accordance with the present invention.
  • FIG. 12[0078] b is a shematic diagram of the flow of blood through the coronary vasculature with full or partial blocking of venous return in accordance with the present invention.
  • FIG. 13[0079] a is an elevational view of one embodiment of a coronay vein blocking device of the present invention having an optional end cap (dotted lines) disposed on the closed end thereof.
  • FIG. 13[0080] b is a cross sectional view through line 13 b-13 b of FIG. 13a.
  • FIG. 13[0081] c is an elevational view of the membrane covering and optional end cap (dotted lines) of the blocker device of FIG. 13a.
  • FIG. 13[0082] d is an elevational view of the radially expandable wire frame of the blocker device of FIG. 13a.
  • FIGS. 14[0083] a-14 c are shematic, staged showings of the operation of a full-occlusion pressure'delay valve of the present invention which utilizes an annular balloon filled w/ viscous fluid as the occluder member.
  • FIGS. 14[0084] a′-14 b′ are shematic, staged showings of the operation of a partial-occlusion pressure delay valve of the present invention which utilizes an annular balloon filled w/ viscous fluid as the occluder member.
  • FIG. 15 is a shematic diagram of an implantable magnetic delay valve of the present invention in its closed position. [0085]
  • FIG. 16 is a shematic diagram of an implantable oxygen sensor delay valve of the present invention. [0086]
  • FIG. 16[0087] a is a cross sectional view through line 16 a-16 a of FIG. 16.
  • FIG. 17 is a graph of valve position vs. capillary pressure for any of the time delayed venous occlusion valves of the present invention. [0088]
  • FIG. 18[0089] a is a schematic showing of a full-occlusion pressure delay valve of the present invention in its closed position.
  • FIG. 18[0090] b is a schematic showing of a full-occlusion pressure delay valve of the present invention in its open position.
  • FIG. 19[0091] a is a schematic showing of a partial-occlusion pressure delay valve of the present invention in its closed position.
  • FIG. 19[0092] b is a schematic showing of a partial-occlusion pressure delay valve of the present invention in its open position.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The following detailed description and the accompanying drawings are provided for purposes of describing and illustrating presently preferred embodiments of the invention only, and are not intended to limit the scope of the invention in any way. [0093]
  • Upon making reference to the accompanying figures, it will be noted that many of the figures include showings of human cardiovascular anatomy. The various anatomical structures shown in the figures are labeled in accordance with the following legend: [0094]
    TMDCR Method Wherein Transmyocardial Passageway is
    Formed Between a Chamber of the Heart and a Coronary
    Vein
    AO Aorta
    CBV Coronary Blood Vessel
    (artery, vein or
    man-made passageway)
    CA Coronary Artery
    CAL Coronary Artery Lumen
    CV Coronary Vein
    CVL Coronary Vein Lumen
    IVC Inferior Vena Cava
    SVC Superior Vena Cava
    LV Left Ventricle
    RV Right Ventricle
    IVS Intraventricular Septum
    M Myocardium
  • With reference to FIGS. [0095] 1-4, the present invention includes methods for improving perfusion of regions of the myocardium M which are ischemic or otherwise affected by the existence of an obstruction OB within a coronary artery CA, by forming a transmyocardial passageway 10 which extends from a chamber of the heart, (e.g., left ventricle LV), to a coronary vein CV.
  • In some embodiments of this method, the [0096] transmyocardial passageway 10 will simply provide a flow of blood from the chamber of the heart and into the coronary vein CV, such that the blood will pass in retrograde fashion through the coronary vein CV to perfuse the ischemic portion of the myocardium through the coronary vein, as sheen in FIG. 1b.
  • In other embodiments of the invention, a [0097] secondary bloodflow passageway 12 may be created between the coronary vein CV into which the transmyocardial passageway 10 extends and the obstructed coronary artery CA, at a location which is downstream of the obstruction OB, as shown in FIG. 1c. The formation of this secondary bloodflow passageway 12 allows blood from the chamber of the heart (e.g., the left ventricle LV) to initially flow through the transmyocardial passageway 10, through a segment of the coronary vein lumen CVL, through the secondary bloodflow passageway 12, and into the coronary artery lumen CAL, at a location downstream of the coronary artery obstruction OB, as shown in FIG. 2b. The secondary bloodflow passageway 12 which extends between the coronary vein CV and the coronary artery CA may optionally be stented or internally supported by a stent, sleeve or coating (e.g., a polymer coating) to maintain patency of the secondary passageway 12.
  • In at least some applications, the coronary vein lumen CVL may be purposely blocked (e.g., ligated, embolized, fused, welded, clamped, etc.) at site(s) upstream and/or downstream of the [0098] transmyocardial passageway 10. As shown in FIG. 1b, when the transmyocardial passageway 10 formed for the purpose of shunting oxygenated blood into the coronary vein lumen CVL, a proximal embolization member 14 a may be positioned within the coronary vein lumen CVL, immediately upstream of transmyocardial passageway 10, to ensure that the shunted blood will flow, in the desired retrograde direction through the coronary vein CV. Similarly, as shown in FIG. 1c, when a secondary bloodflow passageway 12 is formed to carry the oxygenated blood from the coronary vein lumen CVL into the coronary artery lumen CAL, downstream of the obstruction OB, a distal embolization member 14 b may be positioned within the coronary vein lumen CVL immediately downstream of the secondary bloodflow passageway 12, to divert the flow of blood through the secondary bloodflow passageway 12.
  • Examples of methods for forming the optional secondary bloodflow passageway(s) [0099] 12 between the coronary vein CV and coronary artery CA are described in U.S. Provisional Specification Nos. 60/005,164, filed Oct. 13, 1995 and 60/010,614 filed Feb. 2, 1996, the entire disclosures of which are expressly incorporated herein by reference.
  • The proximal embolization member [0100] 14 a and/or distal 14 b embolization member may comprise any suitable type of lumen blocking matter or apparatus, examples of which are the embolization coils described in U.S. Pat. No. 5,382,260 (Dormandy, Jr. et al.), U.S. Pat. No. 5,108,407 (Geremia et al.), and U.S. Pat. No. 5,256,146 (Ensminger, et al.).
  • Alternatively, the coronary vein lumen CVL may be closed off at the sites of the proximal 14a and/or distal 14b embolization members by any suitable alternative means, such as clamping, clipping, ligating, fusing, welding or adhesively conjoining the inner walls of the coronary vein lumen CVL so as to provide the desired blocking of bloodflow therethrough. [0101]
  • FIG. 1[0102] d shows an alternative embodiment of the method of the present invention wherein a secondary bloodflow passageway 12 of the above-described type has been created between the coronary vein CV and coronary artery CA, and wherein the transmyocardial bloodflow passageway 10 a extends from the chamber of the heart (e.g., left ventricle) such secondary bloodflow passageway 12.
  • II. TMDCR Procedures Wherein Temporary A-V Fistula is Used to Facilitate Formation of Transmyocardial Passageway Entering Coronary Artery Downstream of Obstruction or Other Intraluminal Procedure [0103]
  • FIGS. 11[0104] a-11 b show an alternative TMDCR procedure of the present invention wherein a passageway-forming catheter 100 is initially advanced into a coronary vein CV which is situated adjacent a coronary artery CA in which an obstruction OB is present. When the distal end of the passageway-forming catheter 100 has been advanced to a location which is adjacent the segment of the coronary artery CA downstream of the obstruction OB, the passageway forming catheter 100 is oriented appropriately and a tissue-penetrating element 102 is passed out of the catheter 100, through the wall of the coronary vein, through any tissue located between the coronary vein CV and coronary artery CA, through the wall of the coronary artery CA and into the lumen of the coronary artery CA at a site downstream of the obstruction OB. In this manner, an arterio-venous passageway 104 is formed between the coronary vein CV and coronary artery CA.
  • After the distal end of the tissue-penetrating [0105] member 102 is advanced into the lumen of the coronary artery, a guidewire 104 is advanced through a lumen formed in the tissue-penetrating element 102 such that the guidewire enters the lumen of the coronary artery CA. Thereafter, the tissue-penetrating element 102 may be retracted into the catheter 100, and the catheter 100 may be further advanced over the guidewire 104 such that the distal portion of the catheter will pass through the arterio-venous passageway 104 and into the lumen of the coronary artery. Thereafter, the guidewire 104 is once again retracted into the tissue-penetrating element 102 and the catheter 100 is rotationally reoriented, as necessary, to direct the tissue-penetrating element 102 toward the left ventricle LF. Thereafter, the tissue- penetrating element 102 is advanced from the catheter 100, through the wall of the coronary artery CA, through the myocardium M and into the left ventricle LV. This results in the formation of a transmyocardial passageway 10 in accordance with the present invention. If desired, the guidewire 104 may then be once again passed through the lumen of the tissue-penetrating element 102 and into the left ventricle LV such that the tissue-penetrating element 102 may be retracted into the catheter 102 while the guidewire 104 remains extended through the transmyocardial passageway 10 and into the left ventricle LV. In this manner, the guidewire 104 may be used to guide the advancement of one or more passageway-modifying devices, and/or the placement of an internal sleeve, stent, valve or other apparatus within the transmyocardial passageway 10 as known in the prior art, described herein, or described in applicant's earlier filed U.S. patent application Ser. Nos. 08/730,327 and 08/730,496 and the corresponding counterparts thereof filed internationally under the PCT.
  • Thereafter, with the tissue-penetrating [0106] element 102 and guidewire 104 retracted into the catheter 100, the catheter 100 is extracted and removed from the body. The arterio-venous passageway 104 is then closed off (i.e., sealed, fused, cauterized, blocked, occluded, plugged, or otherwise closed) thereby preventing subsequent passage of blood between the coronary vein CV and coronary artery CA. In this manner, as shown in FIG. 11b, this procedure of the present invention results in the formation of a transmyocardial passageway 10 between the left ventricle LV and a coronary artery CA, such that blood may pass from the left ventricle LV, through the transmyocardial passageway 10 and into the lumen of the coronary artery CA, downstream of the obstruction OB. The passage of the tissue-penetrating catheter 100 in the manner described hereabove and shown in FIG. 11a eliminates any necessity for advancing the catheter through the obstruction, and avoids the potential dislodgement of portions or particles of the obstruction OB into the coronary circulation.
  • It will be appreciated that any type of cauterizing, fusing, suturing or blocking apparatus may be used to close off the arterio-[0107] venous passageway 104, including at least some of the blocking devices described in applicant's above cited previously filed applications.
  • III. Other Procedures Which May Be Performed Using the Temporary A-V Passageway [0108]
  • It will be appreciated those skilled in the art that the temporary arterio-[0109] venous passageway 104 described hereabove in Section ii. May also be used for various other therapeutic or interventional procedures wherein it is desirable to gain access to the lumen of a blood vessel, downstream of an occlusion. This temporary arterio-venous passageway 104 is particularly suitable for use in procedures wherein a total or near total occlusion is present in the blood vessel so as to render it difficult or impossible to pass a catheter through the occlusion. The types of therapeutic or interventional procedures which may be performed through the temporary arterio-venous passageway 104 include, but are not necessarily limited to, balloon angioplasty, atherectomy, thrombolysis, placement of apparatus (e.g., a signal emitting target) within the lumen of the blood vessel downstream of the obstruction, or revascularization procedures such as the TMDCR procedure described hereabove.
  • This aspect of the invention may be particularly usable in patients who have previously undergone coronary artery bypass surgery, for bypassing of a total or near total occlusion. In such patients, it is common for new occlusions to occur at sites downstream of the anastomosis which connects the bypass graft to the occluded artery. IN such patients, it may be desirable to access the portion of the artery downstream of the occlusion to pass a balloon angioplasty catheter, atherectomy catheter, or other interventional device so as to treat such occlusions which may occur subsequent to performance of bypass surgery. [0110]
  • IV. TMDCR Procedures Using Unstented Transmyocardial Passageway [0111]
  • The present invention also includes alternative TMDCR methods wherein a [0112] transmyocardial passageway 10 is formed between a chamber of the heart and a coronary vessel (i.e., a) an endogenous coronary vein, b) an endogenous coronary artery, c) a man-made passageway in the heart which connects to an endogenous coronary vein; d) a man-made passageway in the heart which connects to an endogenous coronary or e) a man-made passageway which extends between an endogenous coronary artery and an endogenous coronary vein), and such transmyocardial passageway 10 is allowed to remain non-stented (e.g., devoid of any stent or internal support member positioned therewith).
  • The utilization of a [0113] non-stented transmyocardial passageway 10 in accordance with this embodiment of the present invention eliminates the need for precise measurement, pre-cutting to length and insertion of a stent apparatus within the transmyocardial passageway 10, as is required of the previous TMDCR method described in U.S. Pat. No. 5,287,861 (Wilk), U.S. Pat. No. 5,409,019 (Wilk) and U.S. Pat. No. 5,429,114 (Wilk). When the non-stented transmyocardial passageway 10 of the present invention is intended to provide bloodflow from the chamber of the heart (e.g., left ventricle) into the coronary vessel (e.g., vein, artery or man-made passageway), the non-stented transmyocardial passageway 10 must remain open during systolic contraction of the myocardium. If the non-stented passageway 10 is permitted to substantially occlude or close-off during systolic contraction of the myocardium, such could prevent or deter the desired blood flow from passing through the transmyocardial passageway 10. In this regard, in embodiments of the invention which utilize the non-stented transmyocardial passageway 10, it may be desirable to debulk, core or otherwise enlarge the diameter of the passageway 10 during it's formation so as ensure that the passageway 10 will remain patent and open, even during systolic contraction of the myocardium. Such coring, debulking or other enlargement of the passageway 10 may be accomplished by any suitable means, including the use of a hollow coring needle, laser, electrosurgical probe, or other tissue removing/ablating device capable of debulking and removing tissue so as to create a transmyocardial passageway 10 of the desired diameter.
  • Also, it will be appreciated that the non-stented transmyocardial passageway preferably should not fill-in with granulation tissue or otherwise close-off as a result of any scarring or healing process of the myocardium. In this regard, the coring, de-bulking or other enlargement of the [0114] non-stented passageway 10 and/or the continuing passage of blood, therethrough, may be sufficient to prevent or deter such scarring or natural closing of the non-stented passageway 10. However, in applications wherein scarring or natural closing of the non-stented passageway 10 is a potential problem, it may be desirable to cauterize, heat, chemically treat or coat the walls of the non-stented passageway to prevent or deter blocking of such passageway by scarring or ingrowth of the myocardial tissue.
  • VII. Valving Apparatus Positionable in the Coronary Vessel(s) to Prevent Backflow Into the Transmyocardial Bloodflow Passageway [0115]
  • In many embodiments of the invention, the [0116] transmyocardial passageway 10, 10 a may function in it's intended manner without the inclusion of any valving apparatus, for intermittently blocking the flow of blood therethrough. However, in at least some applications, it may be desired to prevent the backflow of blood through the transmyocardial passageway 10, 10 a during certain phase(s) of the cardiac cycle when the relative hemodynamic pressures would tend to cause such backflow. In this regard, the present invention includes intravascular valving apparatus 20, 30, 31, 33, 40, examples of which are shown in FIGS. 2-4. These intravascular valving apparatus 20, 20, 31, 33, 40 are positionable within the lumen of the coronary blood vessel CBV (e.g., vein, artery or man-made passageway), and operate to prevent backflow of blood into the transmyocardial bloodflow passageway 10, 10 a.
  • In general, each of the [0117] intravascular valving apparatus 20, 30, 31, 33, 40 of the present invention comprise a radially expandable cylindrical or tubular body which is transluminally advanceable into the lumen of the coronary blood vessel CBV (e.g., artery, vein or man-made passageway), and which is then radially expandable so as to become implanted at a location which is adjacent or near to the intersection of that coronary vessel CBV with a transmyocardial bloodflow passageway 10, 10 a. The valving apparatus 20, 30, 31, 33, 40 has an axial bore 24, 34, 42 through which blood may pass as it flows through the lumen of the coronary blood vessel CBV or secondary passageway 12 in which the apparatus 20, 30, 31, 33, 40 is positioned. One or more occluder members 26, 36, 46 are formed within the apparatus 20, 30, 31, 33, 40. Such occluder member(s) 26, 36, 46 are alternately moveable between a first (e.g., open) position whereby blood is permitted to flow from the transmyocardial bloodflow passageway into the coronary blood vessel CBV or secondary passageway 12, and a second (e.g., closed) position whereby blood is prevented or deterred from backflowing or regurgitating from the coronary blood vessel CBV or secondary passageway 12, into the transmyocardial bloodflow passageway.
  • Individual embodiments of the [0118] intravascular valving apparatus 20, 30, 31, 33, 40 are described in more detail herebelow. It will be appreciated, however, that each of the intravascular valving apparatus 20, 30, 31, 33, 40 of the present invention offer advantages over the intramyocardial stenting/valving apparatus described in U.S. Pat. No. 5,248,861 (Wilk), U.S. Pat. No. 5,409,019 (Wilk) and U.S. Pat. No. 5,429,144 (Wilk) in that they are operatively situated entirely within the lumen of the coronary blood vessel CBV of secondary passageway 12 and do not extend into the transmyocardial passage way (e.g., the first passageway 10, 10 a) which emanates from the chamber (e.g., left ventricle) of the heart. In this regard, the valving apparatus 20, 30, 31, 33, 40 of the present invention do not require precise measurement or precise cutting-to-length, as is purportedly required of the intramyocardial stenting/valving apparatus described in U.S. Pat. No. 5,248,861 (Wilk), U.S. Pat. No. 5,409,019 (Wilk) and U.S. Pat. No. 5,429,144 (Wilk).
  • It is desirable that the [0119] valving apparatus 20, 30, 31, 33, 40 of the present invention be initially disposable in a first radially compact diameter which is small enough to be mounted upon or inserted into an intravascular delivery catheter. Such intravascular delivery catheter, having the valving apparatus 20, 30, 31, 33, 40 mounted thereon or therewithin, is transluminally passable through the vasculature and into the lumen of the coronary blood vessel CBV wherein the apparatus 20, 30, 31, 33, 40 is to be implanted. Thereafter, the apparatus 20, 30, 31, 33, 40 is radially expanded (by self-expansion or pressure-expansion) to a second radially expanded diameter, wherein the outer surface of the apparatus 20, 30, 31, 33, 40 frictionally engages the surrounding wall of the coronary blood vessel CBV such that the apparatus 20, 30, 31, 33, 40 is thereby implanted and retained in a stationary position. When the valving apparatus 20, 30, 31, 33, 40 is so implanted within the coronary blood vessel CBV, blood may flow through the axial bore 24, 34, 42 of the apparatus 20, 30, 31, 33, 40, as described in more detail herebelow. It is to be appreciated that the valving apparatus 20, 30, 31, 33, 40 may be either self-expanding or pressure- expandable. In this regard, if the valving apparatus 20, 30, 31, 33, 40 is “self-expanding”, the cylindrical body of the apparatus 20, 30, 31, 33, 40 may be formed of a shape memory alloy or resilient material (e.g., spring metal) which is inherently biased to it's second radially expanded diameter. Alternately, in embodiments wherein the valving apparatus 20, 30, 31, 33, 40 is “pressure- expandable”, the cylindrical body of the apparatus 20, 30, 31, 33, 40 may be formed of plastically deformable material which is initially formed it's first radially compact diameter, and which may be pressure deformed to it's second radially expanded diameter by the exertion of outward force from an internally positioned balloon or other radial expansion device.
  • It is to be further appreciated that the potential useability and applicability of the [0120] intravascular valving apparatus 20, 30, 31, 33, 40, 50 described herebelow is not limited only to uses in connection with the improved TMDCR methods of the present invention, but may also be useable as a modification of the previously described TMDCR methods, such as those of U.S. Pat. No. 5,287,816(Wilk), U.S. Pat. No. 5,409,019(Wilk), and U.S. Pat. No. 5,429,144 (Wilk).
  • a. Intravascular Valving Apparatus—First Embodiment: [0121]
  • FIGS. 2, 2[0122] a and 2 b show a first embodiment of an intravascular valving apparatus 20 which is positioned within the lumen of a coronary-blood vessel CBV (artery, vein or man-made passageway), at a location which is adjacent it's intersection with the transmyocardial passageway 10. This embodiment of the valving apparatus 20 has a cylindrical body having an axial bore 24 which extends longitudinally therethrough, and a side aperture 22 formed in the sidewall thereof. The side aperture 22 is preferably the same size or larger than the diameter of the adjacent end of the transmyocardial passageway 10, such that blood flowing from the cardiac chamber (e.g., left ventricle LV) through the transmyocardial passageway 10 will pass directly through the side aperture 22 and into the bore 24 of the valving apparatus 20. An occluder member 26, such as a hinged obturator or pliable elastomeric leaflet is affixed to the cylindrical body of the valving apparatus 20, and extends over and substantially blocks the side aperture 22 so as to prevent the flow of blood out of the side aperture 22. The occluder member 26 is alternately moveable between a first position wherein it blocks blood from flowing out of the side aperture 22, and a second position wherein it permits blood to flow into the bore 24 through the side aperture 22.
  • This first embodiment of the [0123] valving apparatus 20 may be implanted in the lumen of the coronary blood vessel CBV such that the side aperture 22 is in alignment with the adjacent end of the bloodflow passageway 10. During systolic contraction of the heart the relatively high pressure within the left ventricle will force the occluder member 26 to its second (open) position, allowing blood to flow from the left ventricle, through the transmyocardial passageway 10, through the side aperture 22, through the bore 24 and into the lumen of the coronary blood vessel CBV in the perfusive direction PD, as shown. Thereafter, during systolic relaxation of the heart, the relatively low filling pressure within the left ventricle LV will draw the occluder member 26 to its first (closed) position whereby the occluder member 26 will prevent blood from regurgitating or moving in the backflow direction BD from the lumen of the coronary blood vessel CBV, out of the side aperture 22, and into the bloodflow passageway 10. In this manner the first embodiment of the valving apparatus 20 serves to facilitate efficient pumping of oxygenated blood from the left ventricle and into the lumen of the coronary blood vessel CBV, to improve the flow of oxygenated blood to an ischemic or blood-flow-deprived region of the myocardium M.
  • As shown in FIG. 2[0124] a, a closure member 21, in the nature of an end cap, may be formed on the upstream end of the apparatus 20 so as to completely or substantially block the flow of blood through the coronary blood vessel CBV and into the upstream end of the bore 24 of the apparatus 20. The optional inclusion of the end closure member 21 in the apparatus 20 may serve to obviate any need for the placement of a proximal embolization member 14 a within the lumen of the coronary blood vessel CBV, upstream of the valving apparatus 20.
  • b. Intravascular Valving Apparatus—Second Embodiment [0125]
  • FIG. 3 shows a second embodiment of the [0126] intravascular valving apparatus 30 which comprises a generally cylindrical body having an axial bore 34 extending longitudinally therethrough and a pair of occluder members 46 positioned therewithin, and a side aperture 32 formed in the cylindrical sidewall of the apparatus 30, behind the occluder members 36. Each occluder member 36 is affixed at least one point to the cylindrical body of the apparatus 30, and may comprise any suitable structure or openable and closeable passage, such as a self-sealing slit or hole, or a hinged leaflet or pliable elastomeric member. The occluder members 46 are alternately moveable between first positions wherein the occluder members 36 directly contact one another so as to prevent blood from backflowing in the backflow direction BD through the axial bore 34 of the apparatus 30, and second positions wherein the occluder members 36 move out of contact with one another such that blood may flow through the axial bore 34 of the apparatus 30 in the perfusion direction PD. The side aperture 32 is preferably as large as or larger than the diameter of the bloodflow passageway 10 which extends through the myocardium M from the left ventricle LV to the lumen of the coronary blood vessel CBV. This embodiment of the apparatus 30 is implanted in the lumen of the coronary blood vessel CBV such that its side aperture 32 is directly aligned with the bloodflow passageway 10 so that blood may flow through the bloodflow passageway 10, into the axial bore 34 of the apparatus 30.
  • During systolic contraction of the heart the relatively high pressures created in the left ventricle LV will force blood to flow through the [0127] passageway 10 into the axial bore 34 of the valving apparatus 30. Such systolic bloodflow will move the occluder members 36 to their second (i.e., open) positions, thereby allowing the blood to flow through the lumen of the coronary blood vessel in the perfusion direction PD. Thereafter, when the heart undergoes diastolic relaxation, the relatively low filling pressures created within the left ventricle LV will draw the occluder members 36 to their first (ie. closed) positions, thereby preventing blood from regurgitating or backflowing out of the side aperture 32, in the backflow direction BD. In this manner, this second embodiment of the intravascular valving apparatus 30 serves to facilitate efficient pumping of oxygenated blood from the left ventricle LV and through the lumen of the coronary blood vessel CBV, in order to provide improved bloodflow to an ischemic or blood-flow-deprived region of the myocardium M.
  • Optionally, [0128] secondary occluder members 38 may be formed or mounted within the bore 34 of the apparatus 30, upstream of the side opening 32. These optional secondary occluder members 38 may be of the same type and construction as the above-described downstream occluder members 36. If present, such additional occluder members 38 will assume their first (e.g., closed) position when the pressure of blood within the bore 34 of the apparatus 30 downstream of such secondary occluder members 38 is greater than the pressure of blood within the coronary blood vessel CBV upstream of the such secondary occluder member 38. In this regard, the provision of such secondary occluder members 38 within the apparatus 30 will obviate the need for placement of a proximal occlusion apparatus 14 a within the lumen of the coronary blood vessel CBV upstream of the transmyocardial bloodflow passageway 10. The inclusion of such secondary occluder members 38, or the alternative use of a proximal occlusion member 14 a, will be of particular importance when the coronary blood vessel CBV is a coronary vein CV, due to the substantial difference between endogenous coronary venous blood pressures and those pressures which will be created by systolic arterial bloodflow through the coronary vein, downstream of the transmyocardial bloodflow passageway 10.
  • FIG. 3[0129] a shows one variant of the second embodiment wherein two (2) separate intravascular valving apparatus 31 a, 31 b are respectively positioned upstream and downstream of the transmyocardial bloodflow passageway. The above-described occluder members 36 are formed in the apparatus 31 b which is positioned downstream of the transmyocardial bloodflow passageway 10 and the above-described secondary occluder members 38 are formed within the apparatus 31 a which is positioned upstream of the transmyocardial bloodflow passageway 10. In this manner, these separate intravascular valving apparatus 31 a, 31 b, will function in the same manner as the apparatus 30 shown in FIG. 3, when it is equipped with the optional secondary occluder members 38. However, it will be appreciated that these separate intravascular valving apparatus 31 a, 31 b do not have any side aperture 32, as does the device shown in FIG. 3, and accordingly, will obviate any need for correctly sizing an aligning such side aperture 32 with the transmyocardial bloodflow passageway 10.
  • FIG. 3[0130] b shows another variant of the second embodiment wherein a single intravascular valving apparatus 33, in the nature of a tubular stent or tubular body, is provided with three (3) separate valves 26, 36, 38 at locations which are a) at the junction of the transmyocardial passageway 10 and the coronary blood vessel CBV, b) upstream of the transmyocardial passageway 10 and c) downstream of the transmyocardial passageway 10, respectively. These valves 26, 36, 38 may comprise self-sealing pliable slit openings, elastomeric leaflets, hinged occluder members or any other suitable type of structure or apparatus which will intermittently open and close, to permit bloodflow in the desired direction therethrough. For example, in applications wherein it is desired for the transmyocardial passageway 10 to provide a flow of blood from the cardiac chamber into the coronary blood vessel CBV, the first valve 26 will operate to open during systole to permit blood to flow from the transmyocardial passageway 10 into the coronary blood vessel CBV, but will close during diastole to prevent backflow or regurgitation into the cardiac chamber. Similarly, the second (upstream valve 38 will close during systole to prevent backflow of blood through the proximal end opening of the valving apparatus 33. The third (downstream) valve 36 will open during systole to permit the desired flow of blood entering through the transmyocardial passageway 10, to continue on downstream through the coronary blood vessel CBV in the desired perfusion direction.
  • c. Intravascular Valving Apparatus—Third Embodiment [0131]
  • FIG. 4 shows a third embodiment of the [0132] intravascular valving apparatus 40 which comprises a generally cylindrical body having an axial bore 42 extending longitudinally therethrough and a plurality of occluder members 46 formed therewithin. The cylindrical body and occluder members 46 of this third embodiment of the apparatus 40 are the same as those of the above described second embodiment, except that the cylindrical body of this third embodiment is devoid of any side aperture(s) or openings in the cylindrical sidewall. In contrast to the above described second embodiment 30, this third embodiment of the apparatus 40 is implanted in the lumen of the coronary blood vessel CBV at a location which is downstream of the junction between the coronary blood vessel CBV and the first bloodflow passageway 10.
  • It will be appreciated that the individual features and attributes of each of the above-described embodiments of [0133] valving apparatus 20, 30, 31, 33, 40 may be incorporated into any or all of the other above-described valving apparatus 20, 30, 31, 33, 40 as feasible, to accomplish the desired hemodynamic bloodflow within the coronary vasculature.
  • VI. Intracardiac Valving Apparatus for Controlling Bloodflow through the Transmyocardial Passageway [0134]
  • FIGS. 5 and 5[0135] a show examples of intracardiac valving apparatus 80 which may be utilized to prevent backflow of blood through the transmyocardial passageway 10, or to otherwise control the flow of blood through the transmyocardial passageway 10 in accordance with the systolic/diastolic cardiac cycle.
  • As shown, the [0136] intracardiac valving apparatus 80 is positionable within the cardiac chamber (e.g., left ventricle) immediately adjacent the opening of the transmyocardial passageway 10 thereinto. The intracardiac valving apparatus 80 may comprise any suitable type of hinged, pliable or moveable occlusion member or self-sealing slit which will operate to intermittently block or unblock the flow of blood in at least one direction through the transmyocardial passageway 10. In the embodiment shown in FIGS. 5, 5a, the intracardiac valving apparatus 80 comprises a generally annular body having a central aperture formed therein and an occluder member 81, such as a pliable elastomeric flap, mounted within the aperture. The occluder member 81 will move, in relation to hemodynamic bloodflow and/or contraction of the myocardium M, between an open position whereby blood is permitted to pass in at least one direction through the transmyocardial passageway 10, and a closed position whereby blood is prevented from flowing in at least one direction through the transmyocardial passageway 10.
  • The [0137] intracardiac valving apparatus 80 may be implanted within the cardiac chamber by any suitable surgical or non-surgical technique. Preferably, the intracardiac valving apparatus 80 is initially positioned within or upon a delivery catheter, and the delivery catheter is advanced through the coronary blood vessel CBV, and through the transmyocardial passageway 10. Thereafter, the intracardiac valving apparatus 80 is released or ejected from the delivery catheter, and is caused to radially expand to it's operative configuration. the expanded valving apparatus 80 is then retracted into abutting contact with the myocardial wall, as shown.
  • The [0138] intracardiac valving apparatus 80 may be attached to the myocardial wall by any suitable attachment such as hooks, sutures, adhesives or a retaining assembly which is operative to hold the intracardiac valving apparatus 80 in its desired fixed position upon the myocardial wall. One such retaining apparatus, shown in FIGS. 5 and 5a, comprises an annular retaining ring 82 which is positionable within the coronary blood vessel CBV and a plurality of elastomeric tether members 84 which extend between the retainer ring 82 and the intracardiac valving apparatus 80. In this manner, the elastomeric tethers 84 will resiliently draw the retaining ring 82 and intracardiac valving apparatus 80 toward one another, so as to hold the intracardiac valving apparatus 80 in fixed abutment with the myocardium M as shown.
  • In some embodiments of the [0139] intracardiac valving apparatus 80, the occluder member 81 will be designed to move in response to changes in hemodynamic pressure, such that when the hemodynamic pressure within the cardiac chamber (e.g., left ventricle) exceeds that within the transmyocardial passageway 10, the occluder member 81 will move to it's open position, and when the pressure within the transmyocardial passageway 10 exceeds that within the cardiac chamber (e.g., left ventricle) the occluder member 81 will move to it's closed position.
  • Alternatively, in other embodiments of the [0140] intracardiac valving apparatus 80, the occluder member 81 may be designed to move in relation to contractile changes in the myocardial muscle. In these embodiments, the occluder member 81 will be mechanically linked or coupled to the body of the intracardiac valving apparatus 80 such that, when the myocardium undergoes contraction (e.g., shortening and thickening), the occluder member 81 will be propelled to it's open position, and when the myocardium undergoes relaxation (e.g., lengthening and narrowing) the occluder member 81 will move to it's closed position.
  • In this manner, the [0141] intracardiac valving apparatus 80 of the present invention serves to control the desired bloodflow through the transmyocardial passageway 10, without the need for customizing or precise cutting-to- size of any intramyocardial stent, as has been described in the prior art.
  • VII. Tissue Valve for Preventing Backflow into the Transmyocardial Bloodflow Passageway [0142]
  • An alternative to the use of the above-described [0143] intravascular valving apparatus 20, 30, 31, 33, 40 and/or the intracardiac valving apparatus 80, is an endogenous tissue valve which may be formed within the transmyocardial passageway 10 or at either end thereof. For example, FIGS. 6a-6 b show an endogenous tissue valve 50 which is formed at the junction of the transmyocardial bloodflow passageway 10 and a coronary blood vessel CBV (e.g., artery vein or man-made passageway).
  • With reference to FIG. 6[0144] a-6 b, the endogenous tissue valve 50 may comprise one or more segment(s) 54 of the wall of the coronary blood vessel CBV, along with one or more tapered segment(s) of underlying myocardial tissue 52.
  • This [0145] endogenous tissue valve 50 is formed such that the segment(s) of blood vessel wall 54 and underlying portion(s) of myocardial tissue 52 will receive sufficient blood supply so as not to become necrotic or infarcted. The thickness and mass of 'the tissue valve 50 is preferably defined so that, when the heart undergoes systolic contraction the elevated pressure created within the left ventricle LV and transmyocardial bloodflow passageway 10 will force the tissue valve 50 to an open position, as illustrated in FIG. 5a, thereby creating an opening 56 through which blood may flow into the lumen of the coronary blood vessel CBV, in the profusion direction PD. Thereafter, when the heart .undergoes diastolic relaxation the relatively low filling pressures within the left ventricle LV and transmyocardial bloodflow passageway 10 will allow the tissue valve 50 to return to a second or closed position, as illustrated in FIG. 5b. When in such second or closed position, the tissue valve 50 will substantially or completely close off the transmyocardial bloodflow passageway 10, so as to prevent blood from backflowing or regurgitating in the backflow direction BD, from the lumen of the coronary blood vessel CBV into the transmyocardial bloodflow passageway 10.
  • The [0146] tissue valve 50 may be created by any suitable means, including a procedure whereby the tissue penetrating, cutting or boring device used to create the transmyocardial bloodflow passageway is provided with a tapered distal end having a configuration analogous to that of the inner edge(s) 55 of the wall segment(s) 54 so as to form the desired tissue valve(s) or segment(s) when form the endogenous tissue valve 50, or by another catheter-based device which is equipped to form such tissue valve(s) or segment(s).
  • It will be appreciated that the [0147] tissue valve 50 may be formed in various configuration. For example, although the tissue valve 50 shown in FIGS. 6a and 6 b hereof consists of a single flap, various alternative configurations may be utilized wherein multiple tissue protrusions, multiple tissue flaps, or angularly tapered or funnel shaped tissue flaps are formed to perform the desired valving function. Any and all such configurations of endogenous tissue are intended to be included within the scope of the term “tissue valve” 50 as used herein.
  • VIII. Elastic Closure for Preventing Backflow into the Transmyocardial Bloodflow Passageway [0148]
  • An alternative to the [0149] mechanical valving apparatus 20, 30, 31, 33, 40 or endogenous tissue valve 50 is the elastic closure member 60, shown in FIG. 7a and 7 b.
  • The elastic closure member [0150] 6 d may comprise one or more sutures formed of stretchable or elastic material such as latex or other elastomeric polymer materials. Such elastic closure member(s) 60 are preferably passed through adjacent portions of myocardial tissue next to the opening 66 between the transmyocardial bloodflow passageway 10 and the lumen of the coronary blood vessel CBV (or secondary bloodflow passageway 12).
  • The elastic closure member(s) [0151] 60 is the elastically biased to a retracted state whereby the closure member(s) 60 will draw the adjacent portions of myocardium M together so as to close off the opening 66 between the transmyocardial bloodflow passageway 10 and the lumen of the coronary bloodflow CBV, as shown in FIG. 7b. Upon systolic contraction of the heart the relatively high pressures created within the left ventricle LV and transmyocardial bloodflow passageway 10 will cause the elastic closure member(s) 60 to stretch or expand, thereby forming opening 66 through which blood may flow from the transmyocardial bloodflow passageway 10 into the lumen of the coronary blood vessel CBV (or secondary bloodflow passageway 12) in the perfusion direction PD, as shown in FIG. 7a.
  • Thereafter, when the heart undergoes diastolic relaxation the relatively low filling pressures within the left ventricle Lv and [0152] transmyocardial bloodflow passageway 10 will allow the elastic closure member 60 to retract, thereby closing off the opening 66 and preventing blood from backflowing or regurgitating from the lumen of the coronary blood vessel CBV (or secondary bloodflow passageway 12) into the transmyocardial bloodflow passageway 10, in the backflow direction BD, as shown in FIG. 7b.
  • It will be appreciated that the [0153] elastic closure member 60 may be installed in any suitable method, such as by way of an appropriate suturing or stapling device which operates to attach the elastic closure member 60 at its desired location. Such installation of the elastic closure member 60 may be accomplished by open surgical technique or by way of catheter-based, transluminal methodology. For example, a catheter having a suturing or stapling device positioned therewithin may be advanced to a position adjacent the opening 66. Thereafter, negative pressure or other suitable drawings means may be utilized to draw adjacent segments of the myocardial tissue, from either side of the transmyocardial passageway 10, into the catheter. Thereafter, the desired elastic closure member 60 may be penetrated and threaded through the adjacent sides of the myocardial tissue so as to form the desired elastic closure member 60, as shown.
  • IX. Protrusive Stents and Stented Grafts for Stenting of the Transmyocardial Passageway [0154]
  • In accordance with another aspect of the invention shown in FIGS. 8[0155] a-8 c, protrusive stents or stented grafts may be positioned within the transmyocardial passageway 10, and may extend into one or more adjacent coronary vessels including a) an endogenous coronary vein, b) an endogenous coronary artery, c) a man-made passageway in the heart which connects to an endogenous coronary vein, d) a man-made passageway in the heart which connects to an endogenous coronary artery and/or e) a man-made passageway which extends between an endogenous coronary vein and an endogenous coronary artery. sA described more fully herebelow, the protrusive stent apparatus 90, 90 a, 90 b of the present invention may incorporate one or more valving apparatus to intermittently block or direct bloodflow in accordance with various stages of the systolic/diastolic cardiac cycle. Furthermore, such protrusive stent apparatus may optionally be covered or juxtapositioned to a tubular graft or sheath so as to form a discrete tubular passageway.
  • FIG. 8[0156] a shows a non-valved, non-covered protrusive stent apparatus 90 of the present invention positioned partially within a transmyocardial passageway 10, and extending into the coronary vessel Cv (e.g., artery, vein or man-made passageway) to which such transmyocardial passageway 10 extends. As shown, the protrusive stent apparatus 90 is curved or bent at the junction of the transmyocardial passageway 10 and the coronary vessel CV, and preferably extends into the coronary vessel CV in the desired bloodflow direction.
  • The [0157] protrusive stent apparatus 90 may be formed of any suitable material, such as wire mesh or other metal or polymeric material, and may be self-expanding or pressure-expandable.
  • FIG. 8[0158] b shows a variant of the protrusive stent apparatus 90 a positioned partially within a transmyocardial passageway 10, extending through a coronary vein CV, through a secondary passageway 12, and into a coronary artery CA. As shown the protrusive stent apparatus 90 a is curved or bent at the junction of the secondary passageway 12 and the coronary artery CA and preferably extends into the coronary artery CA in the desired bloodflow direction.
  • FIG. 8[0159] c shows alternative variations of the protrusive stent apparatus 90 b wherein an optional tubular covering 92 is formed on the protrusive stent 90 b. Such optional covering 92 may be any suitable tubular covering such as woven polyester or expanded, sintered polytetrafluoroethylene (PTFt). Additionally, or alternatively, one or more valves such as hinged occluder members or pliable elastomeric leaflets may be located within the protrusive stent apparatus 90 b with or without covering 92, at locations L1 and/or L2 and/or L3 to facilitate control and valving of bloodflow through the transmyocardial passageway 10, coronary vein CV, secondary passageway 12 and/or coronary artery CA. It will be appreciated that embodiments of the protrusive valving apparatus 90 b which incorporates such valves at locations L1 and/or L2 and/or L3 may be provided with appropriate openings or apertures in any covering 92 formed thereon to facilitate the desired inflow or outflow of blood at specific locations thereon.
  • These [0160] protrusive stent apparatus 90, 90 a, 90 b with or without the optional covering 92 and/or without the optional valves at locations L1 and/or L2 and/or L3 offer advantages over previously known intramyocardial stents in that they do not require precise cutting to length or precise positioning within the myocardial passageway 10. Indeed, the protrusive stent apparatus 90, 90 a, 90 b of the present invention are intended to protrude into a coronary blood vessel CBV (e.g., artery, vein and/or man-made passageway) and the length of the portion of the stent apparatus 90, 90 a, 90 b which extends into such coronary blood vessel CBV is typically not critical. In this regard, there will exist no need for custom-fitting or precise pre-cutting of the stent apparatus 90, 90 a, 90 b prior to implantation within the patient.
  • In embodiments where the [0161] stent apparatus 90, 90 a, 90 b is covered by a partial or complete tubular covering, such covering may be formed of any suitable material including but not necessarily limited to polyester, woven polyester, polytetrafluroethylene, expanded polytetraflouroethylene, polyurethane; silicone, polycarbonate, autologous tissue and, xenograft tissue.
  • X. Intravascular Valving Apparatus and Method for Intermittent Coronary Venous Occlusion for Enhanced Coronary Perfusion or Regulation of Coronary Venous Pressure [0162]
  • FIGS. [0163] 9-9 b are illustrative of a method of the present invention wherein a valving device 110 is positioned within the coronary sinus, great cardiac vein or other coronary vein to control coronary venous pressure in a manner which results in increased dwell time of arterial blood within a myocardial capillary bed and/or dilation of the capillary bed and/or other improvement of perfusion of an ischemic region of the myocardium M.
  • The theory underlying the mechanism of total or partial venous occlusion, and various embodiments of valves useable to accomplish such full or partial venous occlusion, are further explained and shown in FIGS. 12[0164] a-19 b.
  • FIGS. 12[0165] a-12 b provide a shematic diagram of the path of blood flow during normal, unrestricted flow (12 a), and valved or blocked flow (12 b). In the case of restricted or blocked venous flow, the outflow from the capillary bed is restricted thereby increasing the dwell time of the blood in the capillary bed, and allowing for the ischemic area to be in contact with oxygenated blood for an increased interval, providing the proposed therapeutic effect.
  • Several devices can be employed to achieve partial, total or intermittent venous occlusion. The range of therapeutic benefits will depend on the 1) placement of the devices in relation to the ischemic tissue, 2) the rate at which the heart's second venous system, the Thebesian system, compensates for the blockage and takes over the function of the venous flow through its capillary network, 3) the device used to create the occlusion, namely, the rate of blockage, and whether or not the blockage is valved, and 4) the extent of the collateralization that may already exist in the circulation. In the event the Thebesian system diverts venous flow and compensates for any flow taken off-line by the placement of a venous block, it may be necessary to valve the blocking device to provide a two-phase effect. In the first phase, Phase I, the valve is in a closed position, restricting the outflow from the capillary bed and providing the desired benefit. In the second phase, Phase II, the valve opens, releasing the flow into the venous system at an interval such that the Thebesian system does not begin compensating for the venous blockage and diminishing the therapeutic effect. In this embodiment the degree to which the flow is restricted is a function of both the magnitude of the restriction and its duration. A description of several embodiments follows that address the variations necessary to achieve desired therapeutic benefits in a given clinical application. [0166]
  • 1. Total Occlusion of the Vein. [0167]
  • In patients with diffuse cardiovascular disease, therapeutic value may be achieved by totally blocking the venous system, e.g. continuously blocking blood flow through the vein. [0168]
  • a) Non-valved—[0169]
  • As shown in FIGS. 13[0170] a-13 e, total or partial occlusion can be achieved by implantation of a particular embodiment of the valaving device 110, such embodiment comprising a non-valved, cylindrical blocker 115. In its preferred construction, this blocker 115 comprises a cylindrical frame structure 118 which is fully or partially encased or covered by a tubular polymer 116 or fabric 117 covering or combination thereof. In a preferred embodiment, a sinusoidal wire frame structure 115 is covered with a silicone film 116. In addition to providing an occlusive surface 116(o), this covering 116 aids in shielding the thin walled vein from any trauma caused by the metal struts of the wire frame structure. It is appreciated that the frame structure of the blocker device 115 may be formed of various materials, including stainless steel, NiTi, platinum, titanium and the like. The structure of said frame can be wound wire, a slotted tube, expanded to a larger configuration, or coiled structure. Preferably, the frame structure will be formed of a material such as NiTi that will exert a constant force on the vessel wall, compensating for any enlargement of the vein due to the changes in pressure. In addition, it is appreciated that the blocker device may be fashioned in the form of a wedge-like geometry (not shown) to further ensure secure placement within the vessel.
  • In some cases, a cap of material is secured to the distal end of the blocking device, to aid in embolization, securement of the device upon placement in a vessel, and ultimately endothelialization (tissue ingrowth). Said cap, [0171] 117, can be formed of various materials including polyester fabric (e.g. Dacron™), PTFE, a high-porosity silicone or polyurethane. (see, PCT International Patent Application No. PCT/US97/01463 for further details, the contents of such application being expressly incorporated herein by reference.
  • b) Single Pressure Valve—As shown, the [0172] valving apparatus 110 of this invention may be positioned within a coronary vein, CV (or within the coronary sinus). The valving apparatus 110 may comprise a cylindrical framework or stent 112 having one or more occluder flaps 114 mounted axially therewithin. The occluder flaps 114 have proximal ends PE and distal ends, DE. The proximal ends PE of the occluder flaps 114 define an inflow opening, and the flaps 114 are alternately moveable between a closed configuration wherein the flaps 114 are in abutment with one another so as to block or prevent blood from flowing in the outflow direction OD, and an open configuration wherein the flaps 114 are sufficiently separated from one another to permit blood to flow through the valving apparatus in the outflow direction OD.
  • In an alternative embodiment, valved structures can be employed that open and allow flow at a certain pressure (P), and close when the pressure goes below P. Certain valves known in the art such as a duckbill valve, slit valve, poppet valve, umbrella valve or like structures can be employed in this manner within an implantable structure for placement into the vein. c) Delayed Action Valve—In contrast to the single pressure valve, embodiments that provide for delayed valving may also be employed, enabling the blockage to be maintained for an extended period of time based on a fixed time delay or a lower closure pressure than that pressure required to open the valve. The length of delay or trigger for release of flow may be timed to the cardiac cycle to maximize the oxygenation phase, or Phase I, and minimize the effect of alternative venous return (such as the Thebesian veins). Examples of such delayed [0173] action valves 119, 122, 125, 123 are shown in FIGS. 14a-18 b.
  • i) Time Delay Mechanism. In FIGS. 14[0174] a-14 c and 14 a′-14 b′, there are shown alternative embodiment of valves 119, 119′ providing for a pressure activated, time-delayed full (119) or partial (119′) venous occlusion. A tubular structure is provided with an outer lumen and an inner lumen, said inner lumen forming a flowable valve flap, 119, 119′ containing a viscous substance, such as silicone gel filled balloon (shown), biased to a closed position CP as shown in FIG. 12a. As depicted in FIGS. 14b-c, one embodiment of the valve 119 is initially fullu closed and, upon being contacted by increasing inflow pressure, move to an open configuration and remain open for a period of time sufficient for the viscous substance to settle back to its original biased position. The time delay is a function of the viscosity of the flowable substance, which can be varied depending on the desired length of delay. A similar embodiment of the valve 119′ shown in FIGS. 14a′ and 14 b′ operates in the sa,e manner as the above-described valve 119, but does not completely occlude venous return even when in its fully closed state (FIG. 14a′).
  • ii) Magnetic Valve. In a further embodiment as shown in FIG. 15 the valving apparatus comprises a tubular structure or [0175] valve body 122, having an inflow direction (IF) and an outflow direction (OF), and further having a valving member comprised of a substantially cylindrical ferrous element 123, detatchably coupled with a fixed magnetic surface 124, located at the inflow IF end of the valve body. In a first or closed position, the valving member 123 and the magnetic surface 124 are coupled thereby blocking flow through the valve body. The magnetic force of the coupling between the valving member 123 and the magnetic surface 124 dictates the opening pressure of the valve. When the pressure exerted by blood flow in the inflow direction is sufficient to overcome the magnetic force of the coupling between the valving member 123 and the magnetic surface 124 (P1 or opening pressure), the valving member 123 is dislodged, allowing flow to travel through the valve body. The time delay function of this embodiment occurs during the interval when the pressure in the inflow direction falls below P1 and the valving member 123 is drawn back into contact with the magnetic surface 124 of the valve body by the magnetic force existing between them.
  • iii) Oxygen sensor valve. With reference to FIGS. 16 and 16[0176] a, the time delay mechanism may also be a function of the level of oxygenation sensed by the valving apparatus. This embodiment of the valving apparatus is triggered to an open or closed position based upon the percent oxygenation it senses at its inlet port. In a further embodiment as shown in FIGS. 16 and 16a, this valving apparatus has an inlet port IP and and outlet port OP and a flowthrough lumen provided therebetween. A septum 125 disposed within the flowthrough lumen, thereby separating the valving apparatus into two chambers, and inflow chamber IFC and an outflow chamber OFC. Said septum 125 being comprised of a valved structure 126 having an oxygen sensor 127 mounted thereon. Said oxygen sensor 127 triggers the valve to be in an open or closed position, depending on the percent oxygenation in the inflowing blood. As blood flow travels into the inflow chamber IFC, it contacts the oxygen sensor 127. Said sensor maintains the valved structure in a closed position until a preset desired oxygen content is reached within the blood in the inflow chamber IFC. Upon sensing the desired, pre- set oxygenation level, the valved structure opens and releases flow into the outflow chamber OFC and the venous system.
  • d) Pressure Delay Mechanism. It may be desirable to have valve structures that open and close along a certain hysteresis curve as shown graphically in FIG. 17. In a first embodiment shown in FIG. 16, a device having a tubular structure with an inflow direction (IF) and outflow direction (OF), having a [0177] piston mechanism 128 that is set to open at a pressure (P1), and remain open until the pressure falls below P2, where P2 is less than P1. The piston 128 is biased towards a closed position with a spring-like member 129, which is secured to strut member on the outflow end of the device. In the closed position, the piston member abuts a ledge 130, provided by the inner contour of the tubular structure. Further defined by the inner contour of the tubular structure is an inlet port (IP) and an outlet port (OP) defining a flow path therethrough. In the closed position, a fluid seal is created between the piston and the ledge, thereby blocking flow between the inlet port IP and the outlet port OP, and defining certain chambers within the tubular structure; an inflow chamber (IFC), and outflow chamber (OFC), a pressure chamber (PC). In operation, the force on the piston in the closed position is equal to the pressure of the fluid at the inlet port IP multiplied by the surface area 1 (SA1). When the force exceeds a certain threshold Ft, the correlating pressure P1 will cause the piston to travel toward the OP, thereby compressing the spring mechanism 129, and allowing flow to travel from IFC to OFC. In the open position, fluid communication is established between the inflow chamber IFC and the pressure chamber PC, thus increasing the force on the piston by an amount equal to the pressure at the inlet port IP multiplied by surface area 2(SA2). The increased surface area allows a lower pressure P2 to generate sufficient force above that of the value of Ft, thereby maintaining the valve in the open position. When pressure decreases below P2, the valve will close and the hysteresis cycle can be repeated (i.e. the valve will not re-open until a pressure P1 is achieved.) In clinical application, this results in an intermittent occlusion of venous flow which may prevent the activation of alternative venous conduits such as the Thebesian veins. The desired crack open pressure and hold open pressure is a function of the spring force of spring member 129, and the values of SA1 and SA2 and can be varied depending on the activity intervals desired.
  • 2. Partial Occlusion of the Vein. [0178]
  • In a similar method to placing a total blocking system, a partial blocker may also be placed in an alternative embodiment, wherein flow through the valve body is never fully blocked, but is restricted to the degree necessary to achieve a therapeutic benefit. [0179]
  • a) Non-valved—In an embodiment similar to that described in FIG. 11, an opening, [0180] 120 can be formed in the distal tip of the blocking device, sufficient to provide for a certain amount of flow therethrough, while still providing a restriction sufficient to achieve a therapeutic effect.
  • b) Single Pressure Valve—Similarly, as shown in FIG. 14[0181] a-c and 14 a′-b′, for example, in the case of the flowable valve, it is appreciated that the flaps of said valve may be positioned such that in the closed or fully biased position, they do not contact each other, thereby affecting a narrowing of flow through the valve body. In operation, the action of the valve in response to the inflow pressure of the blood flow (e.g. viscous biasing) varies the diameter of the narrowing, but does not act to totally occlude the valve lumen.
  • c) Delayed Action Valve—It may be desirable to provide the combined effect of a partial blockage (i.e. reduced by continuous flow) and a hysteresis, or delayed action valve. Toward this end, it is appreciated that the delayed action valve embodiments described above may additionally provide a flow through lumen-positioned within the tubular valving apparatus. For example, in the partial-occlusion embodiment of FIGS. 19[0182] a-19 b, the pressure delay valving apparatus 123′ includes a flow through lumen 120 which allows continuous flow through the valve body even when the occluder 128 is in its closed position (FIG. 19a), while in the full-occlusion embodiment shown in FIGS. 18a-18 b, no flow-through passageway is provided and, when the occluder 128 is in its closed position (FIG. 18a) the flow of blood through the vein will be totally blocked.
  • 3. Method of Implantation [0183]
  • Femoral or jugular vascular access is gained to the venous system via standard sheath and dilator placement in the femoral or jugular vein. A coronary sinus access catheter is placed to cannulate the coronary sinus to assist in the placement of guidewires into the GCV and AIV over which subsequent interventional devices will be placed, including the blocking devices described hereabove. A coronary sinus guide catheter (not shown), with introducer dilator is advanced over the GCV/AIV wire until the tip of the guide is deep seated past the “mouth” of or entrance to the coronary sinus. The introducer dilator is then removed. A blocker delivery catheter, Not shown is advanced over the GCV/AIV guidewire under flouroscopy to a position in the vein approximate the ischemic segment. The GCV/AIV guidewire is then removed, and a blocker is inserted into the proximal end of the delivery catheter. A push rod, (not shown) is then inserted into the blocker delivery catheter, and the blocker device is pushed until it exits the delivery catheter and expands into position in the vein. [0184]
  • The positioning of the blocker varies depending on the location of the ischemic region. Preferably, a blocker is placed in the vein to occlude the specific venous return flow from the region. It is appreciated that it may be necessary to block multiple small veins, or the larger main venous conduits fed by the smaller veins. [0185]
  • A [0186] transmyocardial passageway 10 of the present invention may optionally, but not necessarily, be formed between a chamber of the heart such as the left ventricle LV and the coronary vein CV such that oxygenated blood may enter the lumen of the coronary vein CV to enhance the retroperfusion of the myocardium M.
  • The [0187] flaps 114 of the valving apparatus 110 are constructed so as to be biased to their closed configuration, but so as to separate and move to their open configuration when the pressure of blood exerted against the flaps 114 in the outflow direction OD exceeds a predetermined maximum amount. This causes the pressure of blood within the coronary vein to exceed its normal pressure during a portion of the cardiac cycle. This is illustrated in FIG. 9b wherein the normal pressure of blood within the coronary vein CV is illustrated by the dotted line, and wherein the modified pressure of blood within the coronary vein having the valving apparatus 110 of the present invention positioned therein is illustrated by the solid line. As shown, the valving apparatus 110 of the present invention serves to cause the pressure of blood within the coronary vein CV to raise to a substantially higher level (e.g., 40/hg) before the occluder flaps 114 of the valving apparatus 110 move to their open configuration, thereby allowing the pressure of blood within the coronary vein CV to once again fall.
  • It will be appreciated that the [0188] valving apparatus 110 of the present invention may optionally incorporate one or more of the following additional features:
  • The valving apparatus may be pucturable or traversable so as to permit a catheter to be passed through the valving apparatus in the event that such catheter passage becomes necessary at a later time; [0189]
  • The valving apparatus may be removable such that it may be rescued and removed from the body in the event it is no longer necessary, or if removal becomes desirable for some other reason; [0190]
  • The valving apparatus may be provided with projections, hooks, material for tissue in growth, or other suitable anchoring apparatus to assist in holding the valving apparatus in its desired position within the venus lumen; and [0191]
  • The valving apparatus may be formed of radiologically imagable material, or may be provided with one or more radio dense or radio opaque markers to facilitate visualization of the valving apparatus by x-ray or fluoroscopy. [0192]
  • It is to be further appreciated that any of the transmyocardial passageways between a chamber of the heart and a coronary blood vessel CBV may be formed by any suitable means. In many instances, it will be desirable to pass a passageway-forming [0193] catheter 100 into one of the coronary blood vessels CBV and subsequently orienting the catheter such that the tissue-penetrating element of the catheter will pass from the coronary blood vessel CBV within which it is located into a chamber of the heart, such as the left ventricle. (see FIG. 11a) Alternatively, as shown in FIG. 10, a passageway-forming catheter 100 a may be advanced into a chamber of the heart, such as the left ventricle LV, and will be oriented/positioned such
  • that the tissue-penetrating element [0194] 102 a of the catheter 100 a is directed to the desired coronary blood vessel CBV. Thereafter, the tissue-penetrating element 102 a is passed from the passageway-forming catheter 100 a, through the wall of the myocardium M and into the desired coronary blood vessel CBV. A guidewire 104 a may optionally be advanced through an optional lumen in the tissue-penetrating element 102 a and into the coronary blood vessel CBV such that the tissue-penetrating element 102 a may subsequently be retracted into the catheter 100 a leaving the guidewire 104 a extended through the transmyocardial passageway 10 and into the coronary blood vessel CBV. Thereafter, one or more passageway-modifying apparatus may be advanced over the guidewire 104 a to modify or complete the formation of the desired transmyocardial passageway 10.
  • It will be appreciated that specific passageway-forming [0195] catheter devices 100, 100 a, specific tissue-penetrating elements 102, 102 a, and ancillary apparatus for modifying (e.g., sleeving, cauterizing, enlarging, stenting, valving, etc.) the transmyodardial passageway 10 have been fully described and claimed in earlier-filed applications of which this is a continuation-in-part.
  • The foregoing invention has been described hereabove with reference to certain presently preferred embodiments and examples only. No effort has been made to exhaustively describe all possible embodiments and examples in which the invention may be practiced. Indeed, various additions, deletions, modifications and alterations may be made to the above-described embodiments and examples without departing from the intended spirit and scope of the invention. Accordingly, it is intended that all such additions, deletions and modifications and alterations be included within the scope of the following claims. [0196]

Claims (82)

What is claimed is:
1. A method for transmyocardial coronary revascularization, said method comprising the step of:
a) creating a transmyocardial bloodflow passageway between a chamber of the heart and a coronary vein.
2. The method of claim 1 wherein said passageway is formed such that blood will flow from the chamber of the heart, through the transmyocardial bloodflow passageway, and through the lumen of the coronary vein, in a retrograde direction, so as to perfuse said region of the myocardium.
3. The method of claim 1 wherein said coronary vein is situated next to a coronary artery, and wherein said method further comprises the step of:
b) forming a fistulous connection between said coronary vein and said adjacent coronary artery, at a location which is downstream of said transmyocardial bloodflow passageway, such that blood may flow from the chamber of the heart, through said transmyocardial bloodflow passageway, through said vein, through said fistulous connection, and into the adjacent coronary artery so as to provide enhanced bloodflow through said coronary artery.
4. The method of claim 3 wherein said fistulous connection is a secondary bloodflow passageway which extends from said coronary vein to said coronary artery.
5. The method of claim 1, further comprising the additional step of:
b) blocking the lumen of the coronary vein at a location which is upstream of said transmyocardial bloodflow passageway.
6. The method of claim 3 wherein said method further comprises the steps of:
blocking the lumen of the coronary vein at a location downstream of said fistulous connection.
7. The method of claim 1 further comprising the step of:
b) placing an intraluminal valving apparatus within the lumen of the coronary vein, said intraluminal bloodflow passageway, said tissue valve will move to its closed position.
16. The method of claim 1 further comprising the step of:
connecting an elastic closure member to cardiac tissue on either side of said transmyocardial bloodflow passageway, said elastic closure member being alternately transitionable between:
i) a stretched configuration whereby said transmyocardial bloodflow passageway is opened to permit blood to flow from said transmyocardial bloodflow passageway into said coronary vein; and
ii) a retracted configuration whereby said transmyocardial bloodflow passageway is substantially blocked so as to prevent blood from backflowing from said coronary vein into said transmyocardial bloodflow passageway.
17. The method of claim 16 wherein said elastic closure member comprises a suture which is formed of elastic material, said suture being threaded through said myocardial tissue on opposite sides of said transmyocardial bloodflow passageway.
18. The method of claim 1 further comprising the step of:
b) placing an intracardiac valving apparatus within the chamber of the heart, adjacent one end of said transmyocardial bloodflow passageway, said intracardiac valving apparatus being alternately deployable in:
i) an open position whereby bloodflow is permitted to pass through the transmyocardial bloodflow passageway in a first direction; and,
ii) a closed position whereby blood is prevented from backflowing through the transmyocardial bloodflow passageway, in a second
12. The method of claim 1 further comprising the step of:
c) forming an endogenous tissue valve which is alternately moveable between:
i) an open position whereby bloodflow is permitted to pass from said transmyocardial bloodflow passageway and through the lumen of said coronary vein, in a perfusion direction; and,
ii) a closed position whereby said tissue valve will prevent blood from flowing from the coronary vein into said transmyocardial bloodflow passageway, in a backflow direction.
13. The method of claim 12 wherein said tissue valve is formed at the junction of the transmyocardial bloodflow passageway and the coronary vein.
14. The method of claim 13 wherein the tissue valve comprises at least one segment of the coronary vein in combination with at least one underlying segment of myocardial tissue.
15. The method of claim 14 wherein at least one segment of coronary vein and the at least one segment of underlying tapered segment of myocardial tissue which form said tissue valve are sized and configured such that, when systolic blood pressure is created within said transmyocardial bloodflow passageway, said tissue valve will move to its open position, and thereafter when diastolic blood pressure is present in said transmyocardial bloodflow passageway, said tissue valve will move to its closed position.
16. The method of claim 1 further comprising the step of:
connecting an elastic closure member to cardiac tissue on either side of said transmyocardial bloodflow passageway, said elastic closure member being alternately transitionable between:
i) a stretched configuration whereby said transmyocardial bloodflow passageway is opened to permit blood to flow from said transmyocardial bloodflow passageway into said coronary vein; and
ii) a retracted configuration whereby said transmyocardial bloodflow passageway is substantially blocked so as to prevent blood from backflowing from said coronary vein into said transmyocardial bloodflow passageway.
17. The method of claim 16 wherein said elastic closure member comprises a suture which is formed of elastic material, said suture being threaded through said myocardial tissue on opposite sides of said transmyocardial bloodflow passageway.
18. The method of claim 1 further comprising the step of:
b) placing an intracardiac valving apparatus within the chamber of the heart, adjacent one end of said transmyocardial bloodflow passageway, said intracardiac valving apparatus being alternately deployable in:
i) an open position whereby bloodflow is permitted to pass through the transmyocardial bloodflow passageway in a first direction; and,
ii) a closed position whereby blood is prevented from backflowing through the transmyocardial bloodflow passageway, in a second direction, said second direction being opposite said first direction.
19. The method of claim 18 wherein said transmyocardial bloodflow passageway is intended to provide a flow of blood from the chamber of the heart to the coronary vein, and wherein said first direction is the direction extending from the chamber of the heart to the coronary vein, and said second direction is the direction extending from the coronary vein to the chamber of the heart.
20. The method of claim 18 wherein said transmyocardial bloodflow passageway is intended to drain blood from the coronary vein into the chamber of the heart, and wherein said first direction is the direction extending from the coronary vein to the chamber of the heart, and said second direction is the direction extending from the chamber of the heart to the coronary vein.
21. The method of claim 18 wherein the intracardiac valving apparatus provided in step b is attached to the wall of the chamber of the heart, and is positioned over the opening formed in the chamber of the heart by said transmyocardial bloodflow passageway.
22. The method of claim 21 wherein said intracardiac valving apparatus is sutured to the wall of the chamber of the heart.
23. The method of claim 21 wherein said intracardiac valving apparatus is adhered to the wall of the chamber of the heart.
24. The method of claim 1 further comprising the step of:
b) placing a protrusive stent within said transmyocardial passageway, such that said protrusive stent extends into said coronary vein.
25. The method of claim 24 wherein said protrusive stent is uncovered.
26. The method of claim 24 wherein said protrusive stent is at least partially covered.
27. The method of claim 24 wherein said protrusive stent incorporates at least one valve to intermittently block blood flow, in at least one direction, through said transmyocardial passageway.
28. The method of claim 27 wherein said valve is operative to permit blood to flow from said chamber of the heart through said transmyocardial passageway, and into said coronary vein, but will prevent blood from backflowing from said coronary vein into said transmyocardial passageway.
29. A method for transmyocardial direct coronary revascularization, said method comprising the steps of:
a) forming a transmyocardial bloodflow passageway from a chamber of the heart to a coronary blood vessel;
b) permitting blood to flow from the chamber of the heart, through said transmyocardial bloodflow passageway; and
c) into the coronary blood vessel, while said transmyocardial bloodflow passageway remains devoid of any stent positioned therewithin.
30. The method of claim 29 wherein said blood vessel is selected from the group consisting of:
i) an endogenous coronary artery;
ii) an endogenous coronary vein;
iii) a man-made passageway which has been formed in the heart and which connects to an endogenous coronary vein;
iv) a man-made passageway which has been formed in the heart and which connects to an endogenous coronary artery; and
v) a man-made passageway which extends between an endogenous coronary artery and an endogenous coronary vein.
31. The method of claim 29 wherein said coronary blood vessel is an endogenous coronary vein which is situated next to a coronary artery, and wherein said method further comprises the step of:
d) forming a second bloodflow passageway between said coronary vein and the adjacent coronary artery, at a location which is downstream of said transmyocardial bloodflow passageway.
32. The method of claim 31 wherein said second bloodflow passageway is a fistulous tract which extends between said coronary vein and said coronary artery.
33. The method of claim 29 wherein it is intended for blood to flow in a first flow direction through said coronary blood vessel and wherein said method further comprises the additional step of:
d) blocking the lumen of the coronary blood vessel at a location which is upstream of said transmyocardial bloodflow passageway.
34. The method of claim 31 wherein said method further comprises the step of:
d) blocking the lumen of the coronary vein downstream of said fistulous connection.
35. The method of claim 29 further comprising the step of:
d) placing an intraluminal valving apparatus within the lumen of the coronary blood vessel, said intraluminal valving apparatus comprising at least one occluder member which is alternately deployable in:
i) an open position whereby bloodflow is permitted to pass from said transmyocardial bloodflow passageway and through the lumen of the coronary vein in a perfusion direction; and,
ii) a closed position whereby blood is prevented from flowing from the coronary vein into said transmyocardial bloodflow passageway, in a backflow direction.
36. The method of claim 35 wherein the intravascular valving apparatus of step C is positioned downstream of the transmyocardial bloodflow passageway, and wherein said method further comprises the step of:
e) blocking the lumen of the coronary vein upstream of the transmyocardial bloodflow passageway.
37. The method of claim 29 further comprising the step of:
c) forming an endogenous tissue valve which is alternately moveable between:
i) an open position whereby bloodflow is permitted to pass from said transmyocardial bloodflow passageway and through the lumen of said coronary vessel, in a first direction; and,
ii) a closed position whereby said tissue valve will prevent blood from flowing from the coronary vein into said transmyocardial bloodflow passageway, in a second direction opposite said first direction.
38. The method of claim 37 wherein said tissue valve is formed at the junction of the transmyocardial bloodflow passageway and the coronary blood vessel.
39. The method of claim 38 wherein the tissue valve comprises at least one segment of the coronary blood vessel in combination with at least one underlying segment of myocardial tissue.
40. The method of claim 37 wherein at least one segment of coronary blood vessel and at least one underlying tapered segment of myocardial tissue which form said valving tissue valve are sized and configured such that, when systolic blood pressure is created within said transmyocardial bloodflow passageway said tissue valve will move to its open position, and thereafter when diastolic blood pressure is present in said transmyocardial bloodflow passageway, said tissue valve will move to its closed position.
41. The method of claim 29 further comprising the step of:
connecting an elastic closure member to the myocardial tissue on either side of said transmyocardial bloodflow passageway, said elastic closure member being alternately transitionable between:
i) a stretched configuration whereby an opening is formed to permit blood to flow from said transmyocardial bloodflow passageway into said coronary vein; and
ii) a retracted configuration whereby said opening is substantially closed, thereby preventing blood from backflowing from said coronary vein into said transmyocardial bloodflow passageway.
42. The method of claim 41 wherein said elastic closure member is a suture which is formed of elastic material and passed through said myocardial tissue on opposite sides of said transmyocardial bloodflow passageway.
43. The method of claim 29 further comprising the step of:
b) placing a protrusive stent within said transmyocardial passageway, such that said protrusive stent extends into said coronary vessel.
44. The method of claim 43 wherein said protrusive stent is uncovered.
45. The method of claim 43 wherein said protrusive stent is at least partially covered.
46. The method of claim 43 wherein said protrusive stent incorporates at least one valve to intermittently block blood flow, in at least one direction, through said transmyocardial passageway.
47. The method of claim 46 wherein said valve is operative to permit blood to flow from said chamber of the heart through said transmyocardial passageway, and into said coronary vessel, but will prevent blood from backflowing from said coronary vein into said transmyocardial passageway.
48. An intraluminal valving apparatus which is operative to prevent blood from a backflowing from a coronary blood vessel into a transmyocardial bloodflow passageway which extends from a chamber of the heart to said coronary blood vessel, said apparatus comprising:
a generally cylindrical body having an axial bore which extends longitudinally therethrough; and,
at least one occluder member positioned within said axial bore, said at least one occluder member being alternately moveable between:
i) an open position whereby systolic blood is permitted to pass from said transmyocardial bloodflow passageway, through the lumen of the coronary blood vessel; and,
ii) a closed position whereby blood is prevented from backflowing from the lumen of the coronary blood vessel into the transmyocardial bloodflow passageway.
49. The valving apparatus of claim 48 wherein said generally cylindrical body is initially of a radially compact diameter so as to be transluminally advanceable through the vasculature into said blood vessel, and is subsequently expandable to a second radially expanded diameter wherein said cylindrical body will contact and engage the surrounding wall of said blood vessel.
50. The valving apparatus of claim 49 wherein said cylindrical body is self-expanding.
51. The valving apparatus of claim 49 wherein said cylindrical body is pressure-expandable.
52. The valving apparatus of claim 48 further comprising:
a side aperture formed in the cylindrical body of said apparatus, said side aperture being alienable with said transmyocardial bloodflow passageway such that blood from said transmyocardial bloodflow passageway may flow through said side aperture and into the axial bore of the valving apparatus.
53. The valving apparatus of claim 52 wherein said at least one occluder member is configured to close off said side aperture when in it's closed position, and further such that a subsequent increase in blood pressure within the transmyocardial bloodflow passageway will move said occluder member to said open position, thereby reopening said side aperture.
54. The valving apparatus of claim 53 wherein said at least one occluder member is positioned within the axial bore of the apparatus, at a location downstream of said side aperture, such that systolic bloodflow which passes from the transmyocardial bloodflow passageway into the axial bore of the apparatus will force said occluder member to its open position, thereby causing the bloodflow to continue in the downstream direction, and the subsequent creation of diastolic blood pressure is within the transmyocardial bloodflow passageway will move said occluder member to its closed position thereby preventing blood from backflowing out of said side aperture and into said transmyocardial bloodflow passageway.
55. The valving apparatus of claim 53 further comprising:
a blocking member which closes off the axial bore of the apparatus, upstream of said side aperture.
56. The valving apparatus of claim 48 further comprising:
a secondary occluder member which closes off the axial bore of the apparatus, upstream of said side aperture.
57. The valving apparatus of claim 48 wherein the apparatus is intended to be positioned within said coronary blood vessel at a location downstream of said junction between said blood vessel and said transmyocardial bloodflow passageway, and wherein:
said at least one occluder member which is configured to permit blood to flow in a perfusion direction through said axial bore, when said at least one occluder member is in it's open position, and to prevent blood from backflowing through said axial bore in a backflow direction, when said occluder member is in its closed position.
58. A system comprising two of the valving apparatus of claim 48, one of said valving apparatus being positionable within said coronary blood vessel upstream of said transmyocardial bloodflow passageway, and the other of said valving apparatus being positionable within said coronary blood vessel downstream of said transmyocardial bloodflow passageway.
59. An intracardiac valving apparatus which is operative to control bloodflow through a transmyocardial bloodflow passageway extending from a chamber of the heart to a coronary blood vessel, said intracardiac valving apparatus comprising:
a valve body having an opening formed therethrough, said valve body being positionable in contact with the wall of the heart such that the opening of said valve body is in alignment with said transmyocardial bloodflow passageway;
at least on occluder member positioned within the opening of said valve body, said occluder member being alternately moveable between:
i) an open position whereby blood is permitted to pass through said transmyocardial bloodflow passageway in a first direction; and,
ii) a closed position whereby blood is prevented from flowing through said transmyocardial passageway in at least a second direction opposite said first direction.
60. The intracardiac valving apparatus of claim 59 wherein said apparatus further comprises:
means for holding said intracardiac valving apparatus in substantial fixed position against said wall of the chamber of the heart.
61. The intracardiac valving apparatus of claim 60 wherein said means for holding comprises hooks.
62. The intracardiac valving apparatus of claim 61 wherein said means for holding comprises sutures.
63. The intracardiac valving apparatus of claim 61 wherein said means for holding comprises an adhesive.
64. The intracardiac valving apparatus of claim 61 wherein said means for holding comprises a retainer assembly which engages the heart, and which exerts force upon said intracardiac valving apparatus to hold said intracardiac valving apparatus to hold said intracardiac valving apparatus in substantially fixed position.
65. The intracardiac valving apparatus of claim 64 wherein said retainer assembly comprises:
a generally annular retainer ring having an aperture formed therein, said generally annular retainer ring positionable within the coronary blood vessel such that the aperture formed therein is in alignment with the transmyocardial passageway; and,
at least one elastomeric tether member having a first end connected to said intracardiac valving apparatus and a second end connected to said retainer ring, said elastomeric tether member being of a length and resiliency which is sufficient to exert sufficient inward pressure upon said valving apparatus and said retainer ring to hold said valving apparatus and said retainer ring in substantially fixed positions, with the aperture of the valving apparatus and the aperture of the retainer ring being in alignment with said transmyocardial passageway.
66. A protrusive stent apparatus for stenting a transmyocardial passageway which extends from a chamber of the heart to a coronary blood vessel, said apparatus comprising:
a tubular body which is alternately configureable in:
i) a radially collapsed configuration of a first diameter;
ii) a radially expanded configuration of a second diameter, said second diameter being at least as large as the diameter of the transmyocardial passageway;
said protrusive stenting apparatus having a length which is longer than the length of the transmyocardial passageway, such that said apparatus may be positioned within said transmyocardial passageway from said cardiac chamber to said coronary blood vessel, with a portion of said apparatus protruding into said coronary blood vessel.
67. The protrusive stent apparatus of claim 66 wherein the tubular body of said stent apparatus is self-expanding.
68. The protrusive stent apparatus of claim 66 wherein the tubular body of said stent apparatus is pressure expandable.
69. The protrusive stent apparatus of claim 66 wherein the tubular body of said stent apparatus is formed of material selected from the group of materials consisting of:
metal;
polymeric material.
70. The apparatus of claim 66 wherein said apparatus further comprises:
a tubular covering formed on said stent.
71. The apparatus of claim 70 wherein said tubular covering is formed of a material selected from the group of materials consisting of:
polyester;
woven polyester;
polytetrafluroethylene;
expanded polytetraflouroethylene;
polyurethane;
silicone;
polycarbonate;
autologous tissue; and, xenograft tissue.
72. The apparatus of claim 66 wherein said apparatus further comprises:
at least one valve positioned within said tubular body to control bloodflow therethrough.
73. A method for transmyocardial coronary revascularization of a coronary artery having an occlusion formed therein, said method comprising the steps of:
a) providing a passageway-forming catheter comprising an elongate pliable catheter body having at least one tissue-penetrating element which is passable from the catheter body to form an interstitial passageway through tissue;
b) inserting the passageway-forming catheter into the venous vasculature and advancing the catheter until a distal portion of the catheter is located within a coronary vein adjacent the coronary artery wherein the obstruction is present;
c) orienting the passageway-forming catheter such that the tissue-penetrating element is directed toward the coronary artery at a site downstream of the obstruction;
d) passing the tissue-penetrating element from the passageway-forming catheter, through the wall of the coronary vein wherein the catheter is positioned, through any tissue located between the coronary vein and the coronary artery, through the wall of the coronary artery and into the coronary artery, downstream of the obstruction, thereby forming an arterio-venous passageway between said coronary artery and said coronary vein;
e) advancing the passageway-forming catheter through the arterio-venous passageway and into the coronary artery, downstream of the obstruction;
f) orienting the passageway-forming catheter such that the tissue-penetrating element is directed toward a chamber of the heart;
g) passing the tissue-penetrating element from the passageway-forming catheter, through the wall of the coronary artery, through the myocardium and into a chamber of the heart, thereby forming a transmyocardial passageway through which blood may flow from the chamber of the heart and into the coronary artery, downstream of the obstruction;
h) removing the passageway-forming catheter from the body;
i) closing the arterio-venous passageway which had been formed in step d.
74. The method of claim 73 wherein step i comprises placing an occlusion apparatus within said arterio-venous passageway.
75. The method of claim 73 wherein step i comprises applying energy to the tissue surrounding said arterio-venous passageway to close said arterio-venous passageway.
76. The method of claim 75 wherein the energy utilized to close said arterio-venous passageway is selected from the group of energy types consisting of:
electrocautery, heat, radiofrequency, and light.
77. A method for treating myocardial ischemia, said method comprising the steps of:
a) providing a intravascular valving apparatus, said apparatus comprising a frame which is engageable with a surrounding vascular wall and at least one occluder mounted in said frame, said occluder being alternately moveable between a closed position wherein said occluder will block the flow of blood in an outflow direction through said coronary vein, in an open position wherein said occluder will permit blood to flow in said outflow direction through said coronary vein, said occluder being biased to its closed position but being moveable to its open position when the pressure of blood within the coronary vein exceeds a predetermined maximum pressure;
b) implanting the intervascular valving apparatus at a first location within the coronary venous vasculature such that the occluder member of said valving apparatus will prevent the flow of blood in an outflow direction from at least one coronary vein until such time as the pressure of blood within that coronary vein exceeds said predetermined maximum pressure.
78. The method of claim 77 wherein said method further comprises:
forming a transmyocardial passageway from said coronary vein to a chamber of the heart such that blood may flow from the chamber of the heart, through the transmyocardial passageway, and into the coronary vein.
79. The method of claim 78 wherein said myocardial passageway is formed between the left ventricle of the heart and said coronary vein such that oxygenated blood from the left ventricle will flow through the transmyocardial passageway and into the coronary vein.
80. The method of claim 77 wherein the intravascular valving apparatus is implanted within the coronary sinus.
81. The method of claim 77 wherein the intravascular valving apparatus is implanted within the great cardiac vein.
82. A method for performing an intraluminal medical procedure within the lumen of an obstructed coronary artery, at a site downstream of the obstruction, said method comprising the steps of:
a) providing a passageway-forming catheter comprising an elongate pliable catheter body having at least one tissue-penetrating element which is passable from the catheter body to form an interstitial passageway through tissue;
b) inserting the passageway-forming catheter into the venous vasculature and advancing the catheter until a distal portion of the catheter is located within a coronary vein adjacent the coronary artery wherein the obstruction is present;
c) orienting the passageway-forming catheter such that the tissue-penetrating element is directed toward the coronary artery at a site downstream of the obstruction;
d) passing the tissue-penetrating element from the passageway-forming catheter, through the wall of the coronary vein wherein the catheter is positioned, through any tissue located between the coronary vein and the coronary artery, through the wall of the coronary artery and into the coronary artery, downstream of the obstruction, thereby forming an arterio-venous passageway between said coronary artery and said coronary vein;
e) passing an apparatus through said arterio-venous passageway and into the lumen of the coronary, downstream of the obstruction, and utilizing said apparatus to perform said intraluminal procedure;
f) removing the apparatus from the coronary artery, through said arterio-venous passageway; and
closing the arterio-venous passageway which had been formed in step d.
83. The method of claim 82 wherein said intraluminal procedure is selected from the group of intraluminal procedures consisting of:
an atherectomy procedure wherein a passageway is formed through the occlusion in the coronary;
an ablation procedure wherein the obstruction in the coronary artery is ablated;
a thrombolytic procedure wherein a thrombus within the coronary artery is lysed;
a stenting procedure wherein a stent is placed in the lumen of the coronary artery downstream of the obstruction;
a revascularization procedure wherein a blood flow passageway is formed between said coronary artery at a site downstream of the obstruction to another blood-containing anatomical structure such that blood may flow into said coronary artery at a site downstream of the obstruction; and,
a target apparatus deployment procedure wherein a target apparatus is positioned within the lumen of the coronary artery downstream of the obstruction so as to facilitate targeting of said coronary artery downstream of the obstruction by another device.
US09/994,222 1996-08-26 2001-11-26 Methods and apparatus for transmyocardial direct coronary revascularization Abandoned US20020062146A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/994,222 US20020062146A1 (en) 1996-10-11 2001-11-26 Methods and apparatus for transmyocardial direct coronary revascularization
US10/150,306 US6929009B2 (en) 1996-08-26 2002-05-16 Method and apparatus for transmyocardial direct coronary revascularization

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/730,496 US5830222A (en) 1995-10-13 1996-10-11 Device, system and method for intersititial transvascular intervention
US08/730,327 US6190353B1 (en) 1995-10-13 1996-10-11 Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures
US83729597A 1997-04-11 1997-04-11
US5953198A 1998-04-13 1998-04-13
US09/710,332 US7159592B1 (en) 1995-10-13 2000-11-09 Methods and apparatus for transmyocardial direct coronary revascularization
US09/994,222 US20020062146A1 (en) 1996-10-11 2001-11-26 Methods and apparatus for transmyocardial direct coronary revascularization

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/710,332 Continuation US7159592B1 (en) 1995-10-13 2000-11-09 Methods and apparatus for transmyocardial direct coronary revascularization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/150,306 Continuation US6929009B2 (en) 1996-08-26 2002-05-16 Method and apparatus for transmyocardial direct coronary revascularization

Publications (1)

Publication Number Publication Date
US20020062146A1 true US20020062146A1 (en) 2002-05-23

Family

ID=25274083

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/710,332 Expired - Fee Related US7159592B1 (en) 1995-10-13 2000-11-09 Methods and apparatus for transmyocardial direct coronary revascularization
US09/994,222 Abandoned US20020062146A1 (en) 1996-08-26 2001-11-26 Methods and apparatus for transmyocardial direct coronary revascularization
US10/150,306 Expired - Fee Related US6929009B2 (en) 1996-08-26 2002-05-16 Method and apparatus for transmyocardial direct coronary revascularization
US11/343,936 Expired - Fee Related US7849860B2 (en) 1996-10-11 2006-01-30 Methods and apparatus for transmyocardial direct coronary revascularization

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/710,332 Expired - Fee Related US7159592B1 (en) 1995-10-13 2000-11-09 Methods and apparatus for transmyocardial direct coronary revascularization

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/150,306 Expired - Fee Related US6929009B2 (en) 1996-08-26 2002-05-16 Method and apparatus for transmyocardial direct coronary revascularization
US11/343,936 Expired - Fee Related US7849860B2 (en) 1996-10-11 2006-01-30 Methods and apparatus for transmyocardial direct coronary revascularization

Country Status (7)

Country Link
US (4) US7159592B1 (en)
EP (1) EP0981295A4 (en)
JP (1) JP2001527440A (en)
AU (1) AU744343B2 (en)
CA (1) CA2284720C (en)
IL (1) IL132195A0 (en)
WO (1) WO1998046115A2 (en)

Cited By (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045928A1 (en) * 2000-05-04 2002-04-18 Percardia, Inc. Methods and devices for delivering a ventricular stent
US6582444B2 (en) 1999-08-04 2003-06-24 Percardia, Inc. Blood flow conduit delivery system and method of use
US6605113B2 (en) 1999-08-04 2003-08-12 Percardia Inc. Vascular graft bypass
US6605053B1 (en) 1999-09-10 2003-08-12 Percardia, Inc. Conduit designs and related methods for optimal flow control
US6610100B2 (en) 1998-09-10 2003-08-26 Percardia, Inc. Designs for left ventricular conduit
US6641610B2 (en) 1998-09-10 2003-11-04 Percardia, Inc. Valve designs for left ventricular conduits
US6694983B2 (en) 1998-09-10 2004-02-24 Percardia, Inc. Delivery methods for left ventricular conduit
US20040039452A1 (en) * 2002-08-26 2004-02-26 Marc Bessler Endoscopic gastric bypass
US20040077988A1 (en) * 1998-08-27 2004-04-22 Heartstent Corporation Healing transmyocardial implant
US20040093075A1 (en) * 2000-12-15 2004-05-13 Titus Kuehne Stent with valve and method of use thereof
US20040133154A1 (en) * 1996-10-11 2004-07-08 Flaherty J. Christopher Systems and methods for delivering drugs to selected locations within the body
US20040147868A1 (en) * 2003-01-27 2004-07-29 Earl Bardsley Myocardial implant with collar
US20050228334A1 (en) * 1996-08-13 2005-10-13 Percardia, Inc. Method to deliver blood from a heart chamber to vessel
US20070032802A1 (en) * 2004-05-12 2007-02-08 Modesitt D B Access and closure device and method
US20070255313A1 (en) * 2005-05-12 2007-11-01 Arstasis, Inc. Access and closure device and method
US20080228126A1 (en) * 2006-03-23 2008-09-18 The Trustees Of Columbia University In The City Of New York Method of inhibiting disruption of the healing process in a physically modified stomach
US20090313303A1 (en) * 2008-06-13 2009-12-17 Spence Richard C Method for playing digital media files with a digital media player using a plurality of playlists
US7678133B2 (en) 2004-07-10 2010-03-16 Arstasis, Inc. Biological tissue closure device and method
US7704222B2 (en) 1998-09-10 2010-04-27 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US20110295302A1 (en) * 2010-05-25 2011-12-01 Miracor Medical Systems Gmbh Treating Heart Tissue
US20120316487A1 (en) * 2004-12-15 2012-12-13 Rox Medical, Inc. Method of treating copd with artificial arterio-venous fistula and flow mediating systems
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US20140350669A1 (en) * 2011-12-01 2014-11-27 The Trustees if The University of Pennsylvania Percutaneous valve replacement devices
US20150011843A1 (en) * 2012-01-26 2015-01-08 Tricord Holdings, L.L.C. Controlled sympathectomy and micro-ablation systems and methods
US8939970B2 (en) 2004-09-10 2015-01-27 Vessix Vascular, Inc. Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
US20150039076A1 (en) * 2013-08-05 2015-02-05 Bret J. Park One-Way Heart Assist Valve
US8951251B2 (en) 2011-11-08 2015-02-10 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US8979882B2 (en) 2008-07-21 2015-03-17 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9028472B2 (en) 2011-12-23 2015-05-12 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9079000B2 (en) 2011-10-18 2015-07-14 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9119600B2 (en) 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9125667B2 (en) 2004-09-10 2015-09-08 Vessix Vascular, Inc. System for inducing desirable temperature effects on body tissue
US9125666B2 (en) 2003-09-12 2015-09-08 Vessix Vascular, Inc. Selectable eccentric remodeling and/or ablation of atherosclerotic material
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
US9173696B2 (en) 2012-09-17 2015-11-03 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US9186209B2 (en) 2011-07-22 2015-11-17 Boston Scientific Scimed, Inc. Nerve modulation system having helical guide
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
US9277955B2 (en) 2010-04-09 2016-03-08 Vessix Vascular, Inc. Power generating and control apparatus for the treatment of tissue
US9297845B2 (en) 2013-03-15 2016-03-29 Boston Scientific Scimed, Inc. Medical devices and methods for treatment of hypertension that utilize impedance compensation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9327100B2 (en) 2008-11-14 2016-05-03 Vessix Vascular, Inc. Selective drug delivery in a lumen
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9393133B2 (en) 2011-02-18 2016-07-19 Piolax Medical Devices, Inc. Abdominal cavity-vein shunt stent
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9433760B2 (en) 2011-12-28 2016-09-06 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9486355B2 (en) 2005-05-03 2016-11-08 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
US20160374682A1 (en) * 2014-03-10 2016-12-29 Balatech Limited Surgical procedure and devices for use therein
US9579030B2 (en) 2011-07-20 2017-02-28 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
US9649156B2 (en) 2010-12-15 2017-05-16 Boston Scientific Scimed, Inc. Bipolar off-wall electrode device for renal nerve ablation
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US9693821B2 (en) 2013-03-11 2017-07-04 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US9808300B2 (en) 2006-05-02 2017-11-07 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US9827039B2 (en) 2013-03-15 2017-11-28 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9833283B2 (en) 2013-07-01 2017-12-05 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US9895194B2 (en) 2013-09-04 2018-02-20 Boston Scientific Scimed, Inc. Radio frequency (RF) balloon catheter having flushing and cooling capability
US9907609B2 (en) 2014-02-04 2018-03-06 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
US9943365B2 (en) 2013-06-21 2018-04-17 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9962223B2 (en) 2013-10-15 2018-05-08 Boston Scientific Scimed, Inc. Medical device balloon
US9974607B2 (en) 2006-10-18 2018-05-22 Vessix Vascular, Inc. Inducing desirable temperature effects on body tissue
US10022182B2 (en) 2013-06-21 2018-07-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
US10321946B2 (en) 2012-08-24 2019-06-18 Boston Scientific Scimed, Inc. Renal nerve modulation devices with weeping RF ablation balloons
US10342609B2 (en) 2013-07-22 2019-07-09 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
US10413357B2 (en) 2013-07-11 2019-09-17 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
US10441753B2 (en) 2012-05-25 2019-10-15 Arstasis, Inc. Vascular access configuration
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10660703B2 (en) 2012-05-08 2020-05-26 Boston Scientific Scimed, Inc. Renal nerve modulation devices
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
US10675447B2 (en) 2012-05-25 2020-06-09 Arstasis, Inc. Vascular access configuration
US10695124B2 (en) 2013-07-22 2020-06-30 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
US10722300B2 (en) 2013-08-22 2020-07-28 Boston Scientific Scimed, Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
US10835305B2 (en) 2012-10-10 2020-11-17 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
CN112384170A (en) * 2018-06-29 2021-02-19 频谱医疗有限公司 Blood vessel access tube
US10945786B2 (en) 2013-10-18 2021-03-16 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires and related methods of use and manufacture
US10952790B2 (en) 2013-09-13 2021-03-23 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US11013459B2 (en) 2012-01-26 2021-05-25 Autonomix Medical, Inc. Controlled sympathectomy and micro-ablation systems and methods
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
US11202671B2 (en) 2014-01-06 2021-12-21 Boston Scientific Scimed, Inc. Tear resistant flex circuit assembly
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US11491272B2 (en) 2020-11-09 2022-11-08 Venova Medical, Inc. Endovascular implants and devices and methods for accurate placement
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6283983B1 (en) 1995-10-13 2001-09-04 Transvascular, Inc. Percutaneous in-situ coronary bypass method and apparatus
US6447539B1 (en) 1996-09-16 2002-09-10 Transvascular, Inc. Method and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion
US6102941A (en) * 1997-10-06 2000-08-15 Heartstent Corporation Transmyocardial implant with coronary ingrowth
US6231546B1 (en) 1998-01-13 2001-05-15 Lumend, Inc. Methods and apparatus for crossing total occlusions in blood vessels
US6029672A (en) 1998-04-20 2000-02-29 Heartstent Corporation Transmyocardial implant procedure and tools
US6458092B1 (en) * 1998-09-30 2002-10-01 C. R. Bard, Inc. Vascular inducing implants
US6432126B1 (en) * 1998-09-30 2002-08-13 C.R. Bard, Inc. Flexible vascular inducing implants
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US6409697B2 (en) 1999-05-04 2002-06-25 Heartstent Corporation Transmyocardial implant with forward flow bias
US6406491B1 (en) 1999-05-04 2002-06-18 Heartstent Corporation Compliant transmyocardial implant
US9833167B2 (en) 1999-05-18 2017-12-05 Mediguide Ltd. Method and system for superimposing virtual anatomical landmarks on an image
US9572519B2 (en) 1999-05-18 2017-02-21 Mediguide Ltd. Method and apparatus for invasive device tracking using organ timing signal generated from MPS sensors
US7778688B2 (en) * 1999-05-18 2010-08-17 MediGuide, Ltd. System and method for delivering a stent to a selected position within a lumen
US6719805B1 (en) 1999-06-09 2004-04-13 C. R. Bard, Inc. Devices and methods for treating tissue
US6277082B1 (en) 1999-07-22 2001-08-21 C. R. Bard, Inc. Ischemia detection system
US6629987B1 (en) 1999-07-30 2003-10-07 C. R. Bard, Inc. Catheter positioning systems
US6638237B1 (en) * 1999-08-04 2003-10-28 Percardia, Inc. Left ventricular conduits and methods for delivery
US6113630A (en) * 1999-08-13 2000-09-05 Heartstent Corporation Transmyocardial implant with minimized coronary insertion
US20070265563A1 (en) * 2006-05-11 2007-11-15 Heuser Richard R Device for treating chronic total occlusion
US6953476B1 (en) 2000-03-27 2005-10-11 Neovasc Medical Ltd. Device and method for treating ischemic heart disease
US6464665B1 (en) * 2000-07-05 2002-10-15 Richard R. Heuser Catheter apparatus and method for arterializing a vein
US6602286B1 (en) * 2000-10-26 2003-08-05 Ernst Peter Strecker Implantable valve system
FR2827153A1 (en) * 2001-07-12 2003-01-17 Younes Boudjemline Closure for cardiopathic septal faults has hollow discoid body with central constriction forming tube with one way valve
CA2981561C (en) 2001-10-04 2020-08-25 Neovasc Medical Ltd. Flow reducing implant
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
AU2003275111A1 (en) * 2002-09-23 2004-04-08 Eva Corporation Apparatus and method for reducing fluid loss during a surgical procedure
US7166088B2 (en) * 2003-01-27 2007-01-23 Heuser Richard R Catheter introducer system
US7530995B2 (en) * 2003-04-17 2009-05-12 3F Therapeutics, Inc. Device for reduction of pressure effects of cardiac tricuspid valve regurgitation
WO2004093745A1 (en) * 2003-04-23 2004-11-04 Cook Incorporated Devices kits, and methods for placing multiple intraluminal medical devices in a body vessel
US7402141B2 (en) * 2003-08-27 2008-07-22 Heuser Richard R Catheter guidewire system using concentric wires
US7854761B2 (en) 2003-12-19 2010-12-21 Boston Scientific Scimed, Inc. Methods for venous valve replacement with a catheter
US20050288618A1 (en) * 2004-06-24 2005-12-29 Scimed Life Systems, Inc. Myocardial treatment apparatus and method
US8545418B2 (en) 2004-08-25 2013-10-01 Richard R. Heuser Systems and methods for ablation of occlusions within blood vessels
US20090012429A1 (en) * 2004-08-25 2009-01-08 Heuser Richard R Catheter guidewire system using concentric wires
EP1786367B1 (en) * 2004-08-27 2013-04-03 Cook Medical Technologies LLC Placement of multiple intraluminal medical devices within a body vessel
US7566343B2 (en) 2004-09-02 2009-07-28 Boston Scientific Scimed, Inc. Cardiac valve, system, and method
GB0419954D0 (en) * 2004-09-08 2004-10-13 Advotek Medical Devices Ltd System for directing therapy
WO2006054107A2 (en) * 2004-11-19 2006-05-26 Medtronic Inc. Method and apparatus for treatment of cardiac valves
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
US7867274B2 (en) 2005-02-23 2011-01-11 Boston Scientific Scimed, Inc. Valve apparatus, system and method
US7722666B2 (en) 2005-04-15 2010-05-25 Boston Scientific Scimed, Inc. Valve apparatus, system and method
US8012198B2 (en) 2005-06-10 2011-09-06 Boston Scientific Scimed, Inc. Venous valve, system, and method
AU2006275788B2 (en) * 2005-07-29 2012-07-26 Cvdevices, Llc. Devices and methods for controlling blood perfusion pressure using a retrograde cannula
WO2007033052A2 (en) 2005-09-12 2007-03-22 Bridgepoint Medical, Inc. Endovascular devices and methods for exploiting intramural space
US7918870B2 (en) * 2005-09-12 2011-04-05 Bridgepoint Medical, Inc. Endovascular devices and methods
US8083727B2 (en) 2005-09-12 2011-12-27 Bridgepoint Medical, Inc. Endovascular devices and methods for exploiting intramural space
US11020141B2 (en) 2005-09-12 2021-06-01 Bridgepoint Medical, Inc. Endovascular devices and methods
US8025655B2 (en) 2005-09-12 2011-09-27 Bridgepoint Medical, Inc. Endovascular devices and methods
US7569071B2 (en) 2005-09-21 2009-08-04 Boston Scientific Scimed, Inc. Venous valve, system, and method with sinus pocket
US20070203515A1 (en) * 2006-01-25 2007-08-30 Heuser Richard R Catheter system for connecting adjacent blood vessels
US8062321B2 (en) * 2006-01-25 2011-11-22 Pq Bypass, Inc. Catheter system for connecting adjacent blood vessels
US20070203572A1 (en) * 2006-01-25 2007-08-30 Heuser Richard R Catheter system with stent apparatus for connecting adjacent blood vessels
AU2007240703C1 (en) * 2006-04-19 2012-06-14 Cleveland Clinic Foundation Twin bifurcated stent graft
US20130190676A1 (en) * 2006-04-20 2013-07-25 Limflow Gmbh Devices and methods for fluid flow through body passages
GB0607761D0 (en) 2006-04-20 2006-05-31 Site Specific Therapies Ltd Variable density stent
TW200742251A (en) * 2006-04-28 2007-11-01 Innolux Display Corp Pulse driving circuit
US20080243091A1 (en) * 2006-08-22 2008-10-02 Mitchell R. Humphreys Process and System For Systematic Oxygenation and Renal Preservation During Retrograde Perfusion of the Ischemic Kidney
US8795288B2 (en) * 2006-11-02 2014-08-05 Cook Medical Technologies Llc Access device
US11298511B2 (en) 2006-11-21 2022-04-12 Bridgepoint Medical, Inc. Endovascular devices and methods for exploiting intramural space
US9060802B2 (en) 2006-11-21 2015-06-23 Bridgepoint Medical, Inc. Endovascular devices and methods for exploiting intramural space
US10888354B2 (en) * 2006-11-21 2021-01-12 Bridgepoint Medical, Inc. Endovascular devices and methods for exploiting intramural space
EP2111190B1 (en) 2007-01-19 2013-10-09 Medtronic, Inc. Stented heart valve devices for atrioventricular valve replacement
US20080177249A1 (en) * 2007-01-22 2008-07-24 Heuser Richard R Catheter introducer system
JP5313928B2 (en) 2007-02-05 2013-10-09 ボストン サイエンティフィック リミテッド Percutaneous valves and systems
US20080234813A1 (en) * 2007-03-20 2008-09-25 Heuser Richard R Percutaneous Interventional Cardiology System for Treating Valvular Disease
JP5564416B2 (en) 2007-03-29 2014-07-30 ボストン サイエンティフィック リミテッド Lumen reentry device
GB2448892B (en) * 2007-05-01 2009-04-29 Jotillou Entpr Ltd Catheter
JP5453586B2 (en) * 2007-10-22 2014-03-26 ブリッジポイント、メディカル、インコーポレイテッド Device and method for traversing a chronic total occlusion
US8728141B2 (en) * 2007-12-11 2014-05-20 Cornell University Method and apparatus for sealing an opening in the side wall of a body lumen, and/or for reinforcing a weakness in the side wall of a body lumen, while maintaining substantially normal flow through the body lumen
WO2009099955A2 (en) * 2008-01-31 2009-08-13 Emory University Vascular access to extra-vascular space
US8337425B2 (en) 2008-02-05 2012-12-25 Bridgepoint Medical, Inc. Endovascular device with a tissue piercing distal probe and associated methods
WO2009100129A2 (en) 2008-02-05 2009-08-13 Chad John Kugler Crossing occlusions in blood vessels
US8374680B2 (en) * 2008-04-21 2013-02-12 Medtronic Vascular, Inc. Needleless catheters and methods for true lumen re-entry in treatment of chronic total occlusions and other disorders
US8172863B2 (en) * 2008-04-28 2012-05-08 Bridgepoint Medical, Inc. Methods and apparatus for crossing occlusions in blood vessels
US9005154B2 (en) 2008-09-26 2015-04-14 Covidien Lp Valved hemodialysis catheter
US8197498B2 (en) * 2008-11-06 2012-06-12 Trinitas Ventures Ltd. Gastric bypass devices and procedures
CA2750222C (en) 2009-01-22 2018-02-27 Cornell University Method and apparatus for restricting flow through the wall of a lumen
WO2011025855A2 (en) 2009-08-28 2011-03-03 Si Therapies Ltd. Inverted balloon neck on catheter
ES2656939T3 (en) 2010-03-09 2018-03-01 Solinas Medical Inc. Automatic closing devices
CA2804524C (en) 2010-06-15 2018-04-10 Caymus Medical, Inc. Systems and methods for creating arteriovenous (av) fistulas
US9452015B2 (en) 2010-06-15 2016-09-27 Avenu Medical, Inc. Intravascular arterial to venous anastomosis and tissue welding catheter
US9247942B2 (en) 2010-06-29 2016-02-02 Artventive Medical Group, Inc. Reversible tubal contraceptive device
EP2588042A4 (en) 2010-06-29 2015-03-18 Artventive Medical Group Inc Reducing flow through a tubular structure
WO2012018599A1 (en) 2010-08-03 2012-02-09 Cook Medical Technologies Llc Two valve caval stent for functional replacement of incompetent tricuspid valve
US9149277B2 (en) 2010-10-18 2015-10-06 Artventive Medical Group, Inc. Expandable device delivery
EP4032486A1 (en) 2010-11-16 2022-07-27 TVA Medical, Inc. Devices for forming a fistula
WO2012135859A2 (en) 2011-04-01 2012-10-04 Cornell University Method and apparatus for restricting flow through an opening in the side wall of a body lumen, and/or for reinforcing a weakness in the side wall of a body lumen, while still maintaining substantially normal flow through the body lumen
WO2012161875A1 (en) 2011-04-08 2012-11-29 Tyco Healthcare Group Lp Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery
EP2701623B1 (en) 2011-04-25 2016-08-17 Medtronic Ardian Luxembourg S.à.r.l. Apparatus related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls
US9138230B1 (en) 2011-04-29 2015-09-22 Avenu Medical, Inc. Systems and methods for creating arteriovenous (AV) fistulas
US9668859B2 (en) 2011-08-05 2017-06-06 California Institute Of Technology Percutaneous heart valve delivery systems
WO2013055703A1 (en) 2011-10-07 2013-04-18 Cornell University Method and apparatus for restricting flow through an opening in a body lumen while maintaining normal flow
BR112014009041B1 (en) * 2011-10-18 2021-05-25 William E. Cohn blood vessel occlusion equipment
US8951276B2 (en) 2011-11-04 2015-02-10 Avenu Medical, Inc. Systems and methods for percutaneous intravascular access and guidewire placement
AU2013216809B2 (en) 2012-02-08 2017-05-11 Avenu Medical, Inc. Intravascular arterial to venous anastomosis and tissue welding catheter
WO2013120082A1 (en) 2012-02-10 2013-08-15 Kassab Ghassan S Methods and uses of biological tissues for various stent and other medical applications
US10143822B2 (en) * 2012-07-05 2018-12-04 Covidien Lp Valved tip catheters
WO2014059351A1 (en) 2012-10-11 2014-04-17 Tva Medical, Inc. Devices and methods for fistula formation
CA2891257C (en) 2012-11-14 2020-07-28 Avenu Medical, Inc. Intravascular arterial to venous anastomosis and tissue welding catheter
US9095344B2 (en) 2013-02-05 2015-08-04 Artventive Medical Group, Inc. Methods and apparatuses for blood vessel occlusion
US8984733B2 (en) 2013-02-05 2015-03-24 Artventive Medical Group, Inc. Bodily lumen occlusion
AU2014214700B2 (en) 2013-02-11 2018-01-18 Cook Medical Technologies Llc Expandable support frame and medical device
AU2014226234B2 (en) 2013-03-08 2017-12-07 Limflow Gmbh Methods and systems for providing or maintaining fluid flow through body passages
US10835367B2 (en) 2013-03-08 2020-11-17 Limflow Gmbh Devices for fluid flow through body passages
AU2014236149A1 (en) 2013-03-14 2015-09-17 Tva Medical, Inc. Fistula formation devices and methods therefor
US9744037B2 (en) 2013-03-15 2017-08-29 California Institute Of Technology Handle mechanism and functionality for repositioning and retrieval of transcatheter heart valves
EP2983625B1 (en) 2013-04-13 2024-02-14 Solinas Medical, Inc. Self-closing devices and apparatus and methods for making and delivering them
US9636116B2 (en) 2013-06-14 2017-05-02 Artventive Medical Group, Inc. Implantable luminal devices
US9737306B2 (en) 2013-06-14 2017-08-22 Artventive Medical Group, Inc. Implantable luminal devices
US10149968B2 (en) 2013-06-14 2018-12-11 Artventive Medical Group, Inc. Catheter-assisted tumor treatment
US9737308B2 (en) 2013-06-14 2017-08-22 Artventive Medical Group, Inc. Catheter-assisted tumor treatment
US10070866B1 (en) 2013-08-01 2018-09-11 Avenu Medical, Inc. Percutaneous arterial to venous anastomosis clip application catheter system and methods
US10772672B2 (en) 2014-03-06 2020-09-15 Avenu Medical, Inc. Systems and methods for percutaneous access and formation of arteriovenous fistulas
WO2015138998A1 (en) 2014-03-14 2015-09-17 Tva Medical, Inc. Fistula formation devices and methods therefor
US10363043B2 (en) 2014-05-01 2019-07-30 Artventive Medical Group, Inc. Treatment of incompetent vessels
US10709490B2 (en) 2014-05-07 2020-07-14 Medtronic Ardian Luxembourg S.A.R.L. Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods
US9545263B2 (en) 2014-06-19 2017-01-17 Limflow Gmbh Devices and methods for treating lower extremity vasculature
US10646666B2 (en) 2014-08-27 2020-05-12 Tva Medical, Inc. Cryolipolysis devices and methods therefor
US10603040B1 (en) 2015-02-09 2020-03-31 Tva Medical, Inc. Methods for treating hypertension and reducing blood pressure with formation of fistula
EP3337417B1 (en) 2015-08-21 2023-11-15 Avenu Medical, Inc. Systems and methods for percutaneous access and formation of arteriovenous fistulas
JP6979021B2 (en) 2016-01-15 2021-12-08 ティーブイエー メディカル, インコーポレイテッド Devices and methods for advancing wires
MX2018008565A (en) 2016-01-15 2018-08-23 Tva Medical Inc Devices and methods for forming a fistula.
US10874422B2 (en) 2016-01-15 2020-12-29 Tva Medical, Inc. Systems and methods for increasing blood flow
US10813644B2 (en) 2016-04-01 2020-10-27 Artventive Medical Group, Inc. Occlusive implant and delivery system
JP7222881B2 (en) 2016-04-25 2023-02-15 ソリナス メディカル インコーポレイテッド Self-sealing tubular grafts, patches, methods of making and using same
AU2017331090C1 (en) * 2016-09-25 2023-08-03 Tva Medical, Inc. Vascular stent devices and methods
JP2019533539A (en) 2016-11-11 2019-11-21 アベニュ メディカル インコーポレイテッド System and method for percutaneous endovascular access and wire placement
EP4299086A2 (en) 2017-04-10 2024-01-03 LimFlow GmbH Devices for treating lower extremity vasculature
US11284989B2 (en) * 2018-04-24 2022-03-29 Medtronic Vascular, Inc. Stent-graft prosthesis with pressure relief channels
WO2020076833A1 (en) 2018-10-09 2020-04-16 Limflow Gmbh Devices and methods for catheter alignment
US11096692B2 (en) * 2018-12-13 2021-08-24 Nxt Biomedical, Llc Blood oxygenation treatment methods and devices
CN113891686A (en) 2019-01-23 2022-01-04 内奥瓦斯克医疗有限公司 Flow-altering device with cover
JP2023500067A (en) 2019-11-01 2023-01-04 リムフロウ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Devices and methods for increasing blood perfusion to distal limbs

Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995617A (en) * 1972-05-31 1976-12-07 Watkins David H Heart assist method and catheter
US4546499A (en) * 1982-12-13 1985-10-15 Possis Medical, Inc. Method of supplying blood to blood receiving vessels
US4580568A (en) * 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US4769031A (en) * 1986-06-25 1988-09-06 Mcgough Edwin C Ventricular access device and method
US4850969A (en) * 1987-10-01 1989-07-25 Retroperfusion Systems, Inc. Retroperfusion catheter and tip construction for use therewith
US4865581A (en) * 1987-05-29 1989-09-12 Retroperfusion Systems, Inc. Retroperfusion control apparatus, system and method
US4887608A (en) * 1986-01-31 1989-12-19 Boston Scientific Corporation Method and apparatus for estimating tissue damage
US4917667A (en) * 1988-02-11 1990-04-17 Retroperfusion Systems, Inc. Retroperfusion balloon catheter and method
US4927412A (en) * 1988-12-08 1990-05-22 Retroperfusion Systems, Inc. Coronary sinus catheter
US4934996A (en) * 1984-02-27 1990-06-19 Boston Scientific Corporation Pressure-controlled intermittent coronary sinus occlusion apparatus and method
US4969470A (en) * 1984-02-27 1990-11-13 Boston Scientific Corporation Heart analysis using pressure-controlled intermittent coronary sinus occlusion
US5011468A (en) * 1987-05-29 1991-04-30 Retroperfusion Systems, Inc. Retroperfusion and retroinfusion control apparatus, system and method
US5024668A (en) * 1987-01-20 1991-06-18 Rocky Mountain Research, Inc. Retrograde perfusion system, components and method
US5033998A (en) * 1984-01-20 1991-07-23 Eliot Corday Retrograde delivery of pharmacologic and diagnostic agents via venous circulation
US5059167A (en) * 1987-05-29 1991-10-22 Retroperfusion Systems, Inc. Retroperfusion and retroinfusion control apparatus, system and method
US5106386A (en) * 1989-08-30 1992-04-21 Angelase, Inc. Catheter
US5287861A (en) * 1992-10-30 1994-02-22 Wilk Peter J Coronary artery by-pass method and associated catheter
US5382261A (en) * 1992-09-01 1995-01-17 Expandable Grafts Partnership Method and apparatus for occluding vessels
US5389096A (en) * 1990-12-18 1995-02-14 Advanced Cardiovascular Systems System and method for percutaneous myocardial revascularization
US5409019A (en) * 1992-10-30 1995-04-25 Wilk; Peter J. Coronary artery by-pass method
US5411552A (en) * 1990-05-18 1995-05-02 Andersen; Henning R. Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis
US5429144A (en) * 1992-10-30 1995-07-04 Wilk; Peter J. Coronary artery by-pass method
US5443497A (en) * 1993-11-22 1995-08-22 The Johns Hopkins University Percutaneous prosthetic by-pass graft and method of use
US5500014A (en) * 1989-05-31 1996-03-19 Baxter International Inc. Biological valvular prothesis
US5499995A (en) * 1994-05-25 1996-03-19 Teirstein; Paul S. Body passageway closure apparatus and method of use
US5533957A (en) * 1994-05-06 1996-07-09 Trustees Of Boston University Method of tissue retroperfusion
US5604465A (en) * 1995-06-07 1997-02-18 International Business Machines Corporation Adaptive self-calibration for fast tuning phaselock loops
US5607418A (en) * 1995-08-22 1997-03-04 Illinois Institute Of Technology Implantable drug delivery apparatus
US5618270A (en) * 1995-05-26 1997-04-08 Orejola; Wilmo C. Transthoracic aortic sleeve
US5626599A (en) * 1992-01-22 1997-05-06 C. R. Bard Method for the percutaneous transluminal front-end loading delivery of a prosthetic occluder
US5643195A (en) * 1992-11-30 1997-07-01 Drevet; Jean-Baptiste Device for regulating the flow of cerebrospinal fluid in a drainage circuit
US5655548A (en) * 1996-09-16 1997-08-12 Circulation, Inc. Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion
US5662124A (en) * 1996-06-19 1997-09-02 Wilk Patent Development Corp. Coronary artery by-pass method
US5662711A (en) * 1995-06-07 1997-09-02 Douglas; William Flow adjustable artery shunt
US5674277A (en) * 1994-12-23 1997-10-07 Willy Rusch Ag Stent for placement in a body tube
US5693085A (en) * 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen
US5702421A (en) * 1995-01-11 1997-12-30 Schneidt; Bernhard Closure device for closing a vascular opening, such as patent ductus arteriosus
US5755779A (en) * 1995-12-07 1998-05-26 Horiguchi; Sachio Blood stream adjuster
US5755682A (en) * 1996-08-13 1998-05-26 Heartstent Corporation Method and apparatus for performing coronary artery bypass surgery
US5800525A (en) * 1997-06-04 1998-09-01 Vascular Science, Inc. Blood filter
US5810836A (en) * 1996-03-04 1998-09-22 Myocardial Stents, Inc. Device and method for trans myocardial revascularization (TMR)
US5827315A (en) * 1994-01-04 1998-10-27 Yoon; Inbae Safety penetrating instrument with penetrating member protected after penetration to predetermined depth
US5851232A (en) * 1997-03-15 1998-12-22 Lois; William A. Venous stent
US5860951A (en) * 1992-01-07 1999-01-19 Arthrocare Corporation Systems and methods for electrosurgical myocardial revascularization
US5980552A (en) * 1994-03-17 1999-11-09 Medinol Ltd. Articulated stent
US6010530A (en) * 1995-06-07 2000-01-04 Boston Scientific Technology, Inc. Self-expanding endoluminal prosthesis
US6027525A (en) * 1996-05-23 2000-02-22 Samsung Electronics., Ltd. Flexible self-expandable stent and method for making the same
US6254564B1 (en) * 1998-09-10 2001-07-03 Percardia, Inc. Left ventricular conduit with blood vessel graft
US6287334B1 (en) * 1996-12-18 2001-09-11 Venpro Corporation Device for regulating the flow of blood through the blood system

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1159433B (en) * 1983-07-25 1987-02-25 Sorin Biomedica Spa PROCEDURE AND EQUIPMENT FOR THE MANUFACTURE OF VALVE FLAPS FOR CARDIAC VALVE PROSTHESIS AND CARDIAC VALVE PROSTHESIS PROVIDED WITH SUCH FLAPS
EP0335205A1 (en) 1984-01-20 1989-10-04 Corday, Eliot, Dr. Catheter for retroinfusion of pharmalogical agents
US5380316A (en) * 1990-12-18 1995-01-10 Advanced Cardiovascular Systems, Inc. Method for intra-operative myocardial device revascularization
US5304220A (en) * 1991-07-03 1994-04-19 Maginot Thomas J Method and apparatus for implanting a graft prosthesis in the body of a patient
US5222980A (en) * 1991-09-27 1993-06-29 Medtronic, Inc. Implantable heart-assist device
EP0667133B1 (en) 1993-12-14 2001-03-07 Sante Camilli A percutaneous implantable valve for the use in blood vessels
CA2181045C (en) 1993-12-17 2004-08-31 John H. Stevens System for cardiac procedures
US5545215A (en) * 1994-09-14 1996-08-13 Duran; Carlos G. External sigmoid valve complex frame and valved conduit supported by the same
US6124523A (en) * 1995-03-10 2000-09-26 Impra, Inc. Encapsulated stent
WO1996032153A1 (en) 1995-04-14 1996-10-17 Interventional Therapeutics Corporation Dual valve detachable occlusion balloon and over-the-wire delivery apparatus and method for use therewith
FR2733143B1 (en) 1995-04-21 1997-11-07 Nycomed Lab Sa DEVICE FOR TEMPORARILY SHUTTERING A BODY CHANNEL, ESPECIALLY USEFUL FOR PRESSURE HEART ASSISTANCE
US5620439A (en) * 1995-06-06 1997-04-15 George S. Abela Catheter and technique for endovascular myocardial revascularization
US6726677B1 (en) * 1995-10-13 2004-04-27 Transvascular, Inc. Stabilized tissue penetrating catheters
FR2739783B1 (en) * 1995-10-13 1998-01-23 Ela Medical Sa DEFIBRILLATOR / ACTIVE IMPLANTABLE CARDIOVERVER MEDICAL DEVICE WITH HEADSET DEFIBRILLATION
US6638293B1 (en) * 1996-02-02 2003-10-28 Transvascular, Inc. Methods and apparatus for blocking flow through blood vessels
US5769843A (en) 1996-02-20 1998-06-23 Cormedica Percutaneous endomyocardial revascularization
US5891133A (en) * 1996-03-29 1999-04-06 Eclipse Surgical Technologies, Inc. Apparatus for laser-assisted intra-coronary transmyocardial revascularization and other applications
US5766164A (en) * 1996-07-03 1998-06-16 Eclipse Surgical Technologies, Inc. Contiguous, branched transmyocardial revascularization (TMR) channel, method and device
CA2263672A1 (en) * 1996-08-26 1998-03-05 Transvascular, Inc. Methods and apparatus for transmyocardial direct coronary revascularization
US6447539B1 (en) * 1996-09-16 2002-09-10 Transvascular, Inc. Method and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion
AU721415B2 (en) 1996-11-08 2000-07-06 Converge Medical, Inc. Percutaneous bypass graft and securing system
US6155264A (en) 1997-03-06 2000-12-05 Scimed Life Systems, Inc. Percutaneous bypass by tunneling through vessel wall
US6035856A (en) 1997-03-06 2000-03-14 Scimed Life Systems Percutaneous bypass with branching vessel
US6026814A (en) 1997-03-06 2000-02-22 Scimed Life Systems, Inc. System and method for percutaneous coronary artery bypass
US6196230B1 (en) * 1998-09-10 2001-03-06 Percardia, Inc. Stent delivery system and method of use
US6290728B1 (en) * 1998-09-10 2001-09-18 Percardia, Inc. Designs for left ventricular conduit

Patent Citations (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995617A (en) * 1972-05-31 1976-12-07 Watkins David H Heart assist method and catheter
US4546499A (en) * 1982-12-13 1985-10-15 Possis Medical, Inc. Method of supplying blood to blood receiving vessels
US5033998A (en) * 1984-01-20 1991-07-23 Eliot Corday Retrograde delivery of pharmacologic and diagnostic agents via venous circulation
US4969470A (en) * 1984-02-27 1990-11-13 Boston Scientific Corporation Heart analysis using pressure-controlled intermittent coronary sinus occlusion
US4934996A (en) * 1984-02-27 1990-06-19 Boston Scientific Corporation Pressure-controlled intermittent coronary sinus occlusion apparatus and method
US4580568A (en) * 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US4887608A (en) * 1986-01-31 1989-12-19 Boston Scientific Corporation Method and apparatus for estimating tissue damage
US4769031A (en) * 1986-06-25 1988-09-06 Mcgough Edwin C Ventricular access device and method
US5024668A (en) * 1987-01-20 1991-06-18 Rocky Mountain Research, Inc. Retrograde perfusion system, components and method
US4865581A (en) * 1987-05-29 1989-09-12 Retroperfusion Systems, Inc. Retroperfusion control apparatus, system and method
US5059167A (en) * 1987-05-29 1991-10-22 Retroperfusion Systems, Inc. Retroperfusion and retroinfusion control apparatus, system and method
US5011468A (en) * 1987-05-29 1991-04-30 Retroperfusion Systems, Inc. Retroperfusion and retroinfusion control apparatus, system and method
US4850969A (en) * 1987-10-01 1989-07-25 Retroperfusion Systems, Inc. Retroperfusion catheter and tip construction for use therewith
US4917667A (en) * 1988-02-11 1990-04-17 Retroperfusion Systems, Inc. Retroperfusion balloon catheter and method
US4927412A (en) * 1988-12-08 1990-05-22 Retroperfusion Systems, Inc. Coronary sinus catheter
US5500014A (en) * 1989-05-31 1996-03-19 Baxter International Inc. Biological valvular prothesis
US5106386A (en) * 1989-08-30 1992-04-21 Angelase, Inc. Catheter
US5411552A (en) * 1990-05-18 1995-05-02 Andersen; Henning R. Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis
US5389096A (en) * 1990-12-18 1995-02-14 Advanced Cardiovascular Systems System and method for percutaneous myocardial revascularization
US5860951A (en) * 1992-01-07 1999-01-19 Arthrocare Corporation Systems and methods for electrosurgical myocardial revascularization
US5626599A (en) * 1992-01-22 1997-05-06 C. R. Bard Method for the percutaneous transluminal front-end loading delivery of a prosthetic occluder
US5382261A (en) * 1992-09-01 1995-01-17 Expandable Grafts Partnership Method and apparatus for occluding vessels
US5429144A (en) * 1992-10-30 1995-07-04 Wilk; Peter J. Coronary artery by-pass method
US5409019A (en) * 1992-10-30 1995-04-25 Wilk; Peter J. Coronary artery by-pass method
US5287861A (en) * 1992-10-30 1994-02-22 Wilk Peter J Coronary artery by-pass method and associated catheter
US5643195A (en) * 1992-11-30 1997-07-01 Drevet; Jean-Baptiste Device for regulating the flow of cerebrospinal fluid in a drainage circuit
US5443497A (en) * 1993-11-22 1995-08-22 The Johns Hopkins University Percutaneous prosthetic by-pass graft and method of use
US5827315A (en) * 1994-01-04 1998-10-27 Yoon; Inbae Safety penetrating instrument with penetrating member protected after penetration to predetermined depth
US5980552A (en) * 1994-03-17 1999-11-09 Medinol Ltd. Articulated stent
US5693085A (en) * 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen
US5597377A (en) * 1994-05-06 1997-01-28 Trustees Of Boston University Coronary sinus reperfusion catheter
US5533957A (en) * 1994-05-06 1996-07-09 Trustees Of Boston University Method of tissue retroperfusion
US5499995C1 (en) * 1994-05-25 2002-03-12 Paul S Teirstein Body passageway closure apparatus and method of use
US5499995A (en) * 1994-05-25 1996-03-19 Teirstein; Paul S. Body passageway closure apparatus and method of use
US5674277A (en) * 1994-12-23 1997-10-07 Willy Rusch Ag Stent for placement in a body tube
US5702421A (en) * 1995-01-11 1997-12-30 Schneidt; Bernhard Closure device for closing a vascular opening, such as patent ductus arteriosus
US5618270A (en) * 1995-05-26 1997-04-08 Orejola; Wilmo C. Transthoracic aortic sleeve
US5604465A (en) * 1995-06-07 1997-02-18 International Business Machines Corporation Adaptive self-calibration for fast tuning phaselock loops
US6010530A (en) * 1995-06-07 2000-01-04 Boston Scientific Technology, Inc. Self-expanding endoluminal prosthesis
US5662711A (en) * 1995-06-07 1997-09-02 Douglas; William Flow adjustable artery shunt
US5607418A (en) * 1995-08-22 1997-03-04 Illinois Institute Of Technology Implantable drug delivery apparatus
US5755779A (en) * 1995-12-07 1998-05-26 Horiguchi; Sachio Blood stream adjuster
US5810836A (en) * 1996-03-04 1998-09-22 Myocardial Stents, Inc. Device and method for trans myocardial revascularization (TMR)
US6027525A (en) * 1996-05-23 2000-02-22 Samsung Electronics., Ltd. Flexible self-expandable stent and method for making the same
US5662124A (en) * 1996-06-19 1997-09-02 Wilk Patent Development Corp. Coronary artery by-pass method
US6361519B1 (en) * 1996-08-13 2002-03-26 Heartstent Corporation Mesh tip myocardial implant
US5755682A (en) * 1996-08-13 1998-05-26 Heartstent Corporation Method and apparatus for performing coronary artery bypass surgery
US5824071A (en) * 1996-09-16 1998-10-20 Circulation, Inc. Apparatus for treatment of ischemic heart disease by providing transvenous myocardial perfusion
US5655548A (en) * 1996-09-16 1997-08-12 Circulation, Inc. Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion
US6287334B1 (en) * 1996-12-18 2001-09-11 Venpro Corporation Device for regulating the flow of blood through the blood system
US6605112B1 (en) * 1996-12-18 2003-08-12 Venpro Corporation Device for regulating the flow of blood through the blood system
US5851232A (en) * 1997-03-15 1998-12-22 Lois; William A. Venous stent
US5800525A (en) * 1997-06-04 1998-09-01 Vascular Science, Inc. Blood filter
US6254564B1 (en) * 1998-09-10 2001-07-03 Percardia, Inc. Left ventricular conduit with blood vessel graft

Cited By (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100324471A1 (en) * 1995-10-13 2010-12-23 Medtronic Vascular, Inc. Systems and Methods for Delivering Drugs to Selected Locations Within the Body
US8083708B2 (en) 1995-10-13 2011-12-27 Medtronic Vascular, Inc. Systems and methods for delivering drugs to selected locations within the body
US7670329B2 (en) 1995-10-13 2010-03-02 Medtronic Vascular, Inc. Systems and methods for delivering drugs to selected locations within the body
US20070021730A1 (en) * 1995-10-13 2007-01-25 Medtronic Vascular, Inc. Systems and Methods for Delivering Drugs to Selected Locations Within the Body
US20060155239A1 (en) * 1996-08-13 2006-07-13 Percardia, Inc. Method to deliver blood from a heart chamber to vessel
US20050228334A1 (en) * 1996-08-13 2005-10-13 Percardia, Inc. Method to deliver blood from a heart chamber to vessel
US20040133154A1 (en) * 1996-10-11 2004-07-08 Flaherty J. Christopher Systems and methods for delivering drugs to selected locations within the body
US7094230B2 (en) * 1996-10-11 2006-08-22 Medtronic Vascular, Inc. Systems and methods for delivering drugs to selected locations within the body
US8540694B2 (en) 1998-03-25 2013-09-24 Medtronic Vascular, Inc. Systems and methods for delivering drugs to selected locations within the body
US20040077988A1 (en) * 1998-08-27 2004-04-22 Heartstent Corporation Healing transmyocardial implant
US7704222B2 (en) 1998-09-10 2010-04-27 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US8597226B2 (en) 1998-09-10 2013-12-03 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US7736327B2 (en) 1998-09-10 2010-06-15 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US6610100B2 (en) 1998-09-10 2003-08-26 Percardia, Inc. Designs for left ventricular conduit
US6694983B2 (en) 1998-09-10 2004-02-24 Percardia, Inc. Delivery methods for left ventricular conduit
US6641610B2 (en) 1998-09-10 2003-11-04 Percardia, Inc. Valve designs for left ventricular conduits
US8216174B2 (en) 1998-09-10 2012-07-10 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US6605113B2 (en) 1999-08-04 2003-08-12 Percardia Inc. Vascular graft bypass
US6582444B2 (en) 1999-08-04 2003-06-24 Percardia, Inc. Blood flow conduit delivery system and method of use
US6605053B1 (en) 1999-09-10 2003-08-12 Percardia, Inc. Conduit designs and related methods for optimal flow control
US20020045928A1 (en) * 2000-05-04 2002-04-18 Percardia, Inc. Methods and devices for delivering a ventricular stent
US20040093075A1 (en) * 2000-12-15 2004-05-13 Titus Kuehne Stent with valve and method of use thereof
US7837645B2 (en) 2002-08-26 2010-11-23 The Trustees Of Columbia University In The City Of New York Endoscopic gastric bypass
US7211114B2 (en) * 2002-08-26 2007-05-01 The Trustees Of Columbia University In The City Of New York Endoscopic gastric bypass
US20040039452A1 (en) * 2002-08-26 2004-02-26 Marc Bessler Endoscopic gastric bypass
US20040147868A1 (en) * 2003-01-27 2004-07-29 Earl Bardsley Myocardial implant with collar
US9510901B2 (en) 2003-09-12 2016-12-06 Vessix Vascular, Inc. Selectable eccentric remodeling and/or ablation
US9125666B2 (en) 2003-09-12 2015-09-08 Vessix Vascular, Inc. Selectable eccentric remodeling and/or ablation of atherosclerotic material
US10188457B2 (en) 2003-09-12 2019-01-29 Vessix Vascular, Inc. Selectable eccentric remodeling and/or ablation
US7998169B2 (en) 2004-05-12 2011-08-16 Arstasis, Inc. Access and closure device and method
US8002793B2 (en) 2004-05-12 2011-08-23 Arstasis, Inc. Access and closure device and method
US8002792B2 (en) 2004-05-12 2011-08-23 Arstasis, Inc. Access and closure device and method
US8002791B2 (en) 2004-05-12 2011-08-23 Arstasis, Inc. Access and closure device and method
US8012168B2 (en) 2004-05-12 2011-09-06 Arstasis, Inc. Access and closure device and method
US20070032802A1 (en) * 2004-05-12 2007-02-08 Modesitt D B Access and closure device and method
US7678133B2 (en) 2004-07-10 2010-03-16 Arstasis, Inc. Biological tissue closure device and method
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US9125667B2 (en) 2004-09-10 2015-09-08 Vessix Vascular, Inc. System for inducing desirable temperature effects on body tissue
US8939970B2 (en) 2004-09-10 2015-01-27 Vessix Vascular, Inc. Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
US9011362B2 (en) * 2004-12-15 2015-04-21 Rox Medical, Inc. Method of treating COPD with artificial arterio-venous fistula and flow mediating systems
US20120316487A1 (en) * 2004-12-15 2012-12-13 Rox Medical, Inc. Method of treating copd with artificial arterio-venous fistula and flow mediating systems
US9669148B2 (en) 2004-12-15 2017-06-06 Rox Medical, Inc. Method of treating COPD with artificial arterio-venous fistula and flow mediating systems
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US9486355B2 (en) 2005-05-03 2016-11-08 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
US8083767B2 (en) 2005-05-12 2011-12-27 Arstasis, Inc. Access and closure device and method
US8002794B2 (en) 2005-05-12 2011-08-23 Arstasis, Inc. Access and closure device and method
US20090318889A1 (en) * 2005-05-12 2009-12-24 Arstasis, Inc. Access and closure device and method
US8241325B2 (en) 2005-05-12 2012-08-14 Arstasis, Inc. Access and closure device and method
US20070255313A1 (en) * 2005-05-12 2007-11-01 Arstasis, Inc. Access and closure device and method
US20080228126A1 (en) * 2006-03-23 2008-09-18 The Trustees Of Columbia University In The City Of New York Method of inhibiting disruption of the healing process in a physically modified stomach
US9808300B2 (en) 2006-05-02 2017-11-07 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US9974607B2 (en) 2006-10-18 2018-05-22 Vessix Vascular, Inc. Inducing desirable temperature effects on body tissue
US10213252B2 (en) 2006-10-18 2019-02-26 Vessix, Inc. Inducing desirable temperature effects on body tissue
US10413356B2 (en) 2006-10-18 2019-09-17 Boston Scientific Scimed, Inc. System for inducing desirable temperature effects on body tissue
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11154398B2 (en) 2008-02-26 2021-10-26 JenaValve Technology. Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US20090313303A1 (en) * 2008-06-13 2009-12-17 Spence Richard C Method for playing digital media files with a digital media player using a plurality of playlists
US8979882B2 (en) 2008-07-21 2015-03-17 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
US9327100B2 (en) 2008-11-14 2016-05-03 Vessix Vascular, Inc. Selective drug delivery in a lumen
US9277955B2 (en) 2010-04-09 2016-03-08 Vessix Vascular, Inc. Power generating and control apparatus for the treatment of tissue
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US11337707B2 (en) * 2010-05-25 2022-05-24 Miracor Medical Sa Treating heart tissue
US11291455B2 (en) 2010-05-25 2022-04-05 Miracor Medical Sa Treating heart tissue
US20110295302A1 (en) * 2010-05-25 2011-12-01 Miracor Medical Systems Gmbh Treating Heart Tissue
US11241238B2 (en) 2010-05-25 2022-02-08 Miracor Medical Sa Treating heart tissue
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US8880185B2 (en) 2010-06-11 2014-11-04 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9848946B2 (en) 2010-11-15 2017-12-26 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9649156B2 (en) 2010-12-15 2017-05-16 Boston Scientific Scimed, Inc. Bipolar off-wall electrode device for renal nerve ablation
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US9393133B2 (en) 2011-02-18 2016-07-19 Piolax Medical Devices, Inc. Abdominal cavity-vein shunt stent
US9579030B2 (en) 2011-07-20 2017-02-28 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
US9186209B2 (en) 2011-07-22 2015-11-17 Boston Scientific Scimed, Inc. Nerve modulation system having helical guide
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
US9079000B2 (en) 2011-10-18 2015-07-14 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
US8951251B2 (en) 2011-11-08 2015-02-10 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
US9119600B2 (en) 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US20140350669A1 (en) * 2011-12-01 2014-11-27 The Trustees if The University of Pennsylvania Percutaneous valve replacement devices
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
US9402684B2 (en) 2011-12-23 2016-08-02 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9037259B2 (en) 2011-12-23 2015-05-19 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9592386B2 (en) 2011-12-23 2017-03-14 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9174050B2 (en) 2011-12-23 2015-11-03 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9072902B2 (en) 2011-12-23 2015-07-07 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9028472B2 (en) 2011-12-23 2015-05-12 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9186211B2 (en) 2011-12-23 2015-11-17 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9433760B2 (en) 2011-12-28 2016-09-06 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US10470684B2 (en) * 2012-01-26 2019-11-12 Autonomix Medical, Inc. Controlled sympathectomy and micro-ablation systems and methods
US20150011843A1 (en) * 2012-01-26 2015-01-08 Tricord Holdings, L.L.C. Controlled sympathectomy and micro-ablation systems and methods
US11013459B2 (en) 2012-01-26 2021-05-25 Autonomix Medical, Inc. Controlled sympathectomy and micro-ablation systems and methods
US10660703B2 (en) 2012-05-08 2020-05-26 Boston Scientific Scimed, Inc. Renal nerve modulation devices
US10441753B2 (en) 2012-05-25 2019-10-15 Arstasis, Inc. Vascular access configuration
US10675447B2 (en) 2012-05-25 2020-06-09 Arstasis, Inc. Vascular access configuration
US10321946B2 (en) 2012-08-24 2019-06-18 Boston Scientific Scimed, Inc. Renal nerve modulation devices with weeping RF ablation balloons
US9173696B2 (en) 2012-09-17 2015-11-03 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10835305B2 (en) 2012-10-10 2020-11-17 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
US9693821B2 (en) 2013-03-11 2017-07-04 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US9297845B2 (en) 2013-03-15 2016-03-29 Boston Scientific Scimed, Inc. Medical devices and methods for treatment of hypertension that utilize impedance compensation
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
US9827039B2 (en) 2013-03-15 2017-11-28 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US10022182B2 (en) 2013-06-21 2018-07-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
US9943365B2 (en) 2013-06-21 2018-04-17 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
US9833283B2 (en) 2013-07-01 2017-12-05 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10413357B2 (en) 2013-07-11 2019-09-17 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
US10695124B2 (en) 2013-07-22 2020-06-30 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
US10342609B2 (en) 2013-07-22 2019-07-09 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US9655723B2 (en) * 2013-08-05 2017-05-23 Savant Holdings LLC One-way heart assist valve
US20150039076A1 (en) * 2013-08-05 2015-02-05 Bret J. Park One-Way Heart Assist Valve
US10722300B2 (en) 2013-08-22 2020-07-28 Boston Scientific Scimed, Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US9895194B2 (en) 2013-09-04 2018-02-20 Boston Scientific Scimed, Inc. Radio frequency (RF) balloon catheter having flushing and cooling capability
US10952790B2 (en) 2013-09-13 2021-03-23 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
US9962223B2 (en) 2013-10-15 2018-05-08 Boston Scientific Scimed, Inc. Medical device balloon
US10945786B2 (en) 2013-10-18 2021-03-16 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires and related methods of use and manufacture
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
US11202671B2 (en) 2014-01-06 2021-12-21 Boston Scientific Scimed, Inc. Tear resistant flex circuit assembly
US9907609B2 (en) 2014-02-04 2018-03-06 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US20160374682A1 (en) * 2014-03-10 2016-12-29 Balatech Limited Surgical procedure and devices for use therein
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
CN112384170A (en) * 2018-06-29 2021-02-19 频谱医疗有限公司 Blood vessel access tube
US11491272B2 (en) 2020-11-09 2022-11-08 Venova Medical, Inc. Endovascular implants and devices and methods for accurate placement
US11878100B2 (en) 2020-11-09 2024-01-23 Venova Medical, Inc. Endovascular implants and devices and methods for accurate placement

Also Published As

Publication number Publication date
US7159592B1 (en) 2007-01-09
AU744343B2 (en) 2002-02-21
US20060184089A1 (en) 2006-08-17
US20020179098A1 (en) 2002-12-05
EP0981295A4 (en) 2005-02-02
CA2284720A1 (en) 1998-10-22
WO1998046115A3 (en) 1999-01-21
AU6968698A (en) 1998-11-11
CA2284720C (en) 2006-09-12
IL132195A0 (en) 2001-03-19
US6929009B2 (en) 2005-08-16
JP2001527440A (en) 2001-12-25
US7849860B2 (en) 2010-12-14
WO1998046115A2 (en) 1998-10-22
EP0981295A2 (en) 2000-03-01

Similar Documents

Publication Publication Date Title
US7849860B2 (en) Methods and apparatus for transmyocardial direct coronary revascularization
AU743142B2 (en) Methods and apparatus for transmyocardial direct coronary revascularization
US8187217B2 (en) TMR shunt
US7101402B2 (en) Designs for left ventricular conduit
EP1112044B1 (en) Tmr shunt with valve for left ventricular revascularization
US6746426B1 (en) Transluminally deliverable vascular blockers and methods for facilitating retrograde flow of arterial blood through veins
JP2008514345A (en) Device for treating or replacing a heart valve or surrounding tissue without requiring full cardiopulmonary support
WO2004112585A2 (en) Valve annulus reduction system
US20070010781A1 (en) Implantable aorto-coronary sinus shunt for myocardial revascularization
US20020033180A1 (en) Device, an introducer and a method for providing a supplemental flow of blood
JP2003510143A (en) Direct coronary revascularization method and apparatus
AU4237102A (en) Method and apparatus for transmyocardial direct coronary revascularization
AU3440302A (en) Methods and apparatus for transmyocardial direct coronary revascularization
US20070010780A1 (en) Methods of implanting an aorto-coronary sinus shunt for myocardial revascularization
MXPA99001847A (en) Methods and apparatus for transmyocardial direct coronary revascularization
WO2007002616A2 (en) Implantable aorto-coronary sinus shunt for myocardial revascularization and method of usng the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDTRONIC VASCULAR, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSVASCULAR, INC.;REEL/FRAME:015000/0001

Effective date: 20030909

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION